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ABSTRACT 
Prostate cancer is the most common male cancer in Western countries. The genetic 
mechanism underlying its initiation and progression is still unclear. The aim of this 
project was to identify novel genomic changes in prostate cancer and the underlying 
genetic mechanisms of prostate carcinogenesis using a high-resolution genome-wide 
analysis approach.  
 
Firstly, three prostate cancer cell lines, thirty-two UK and thirty-nine Chinese prostate 
cancer clinical samples were analysed using Affymetrix’s SNP microarrays (500K and 
array 6.0).  Most of the common genomic changes observed in these samples are the 
same as those found in previous studies. Among the common genomic alterations, ERG 
rearrangements were also detected in 6/10 circulating tumour cell samples by 
flouroscence in situ hybridisation (FISH). Interestingly, loss of 21q22 and PTEN deletion, 
which were commonly found in Western prostate cancer, were rarely detected in the 
Chinese samples. This was further evaluated and comfirmed by FISH and 
immunohistochemistry analyses on UK and Chinese prostate cancer tissue microarrays 
and reverse transcript polymerase chain reaction (RT-PCR) analysis of TMPRSS2:ERG 
fusion transcripts in 48 UK and 66 Chinese fresh frozen cases (p<0.001). Subsequently, I 
identified a difference in the AR CAG repeat length polymorphism between UK and 
Chinese samples. This genetic disparity indicates differential distribution of 
causative/protective factors in these two populations.  
 
To study chromosome rearrangements and fusion genes, I developed a high-resolution 
karyotype approach to fully karyotype three cell lines, and identified five potential 
genomic fusions. Genomic fusion sequence of MAMDC1:SCL25A21 was identified, but 
the expected fusion transcript could not be detected by RT-PCR. As metaphase spreads 
are difficult to make in prostate cancer clinical samples, I used a common breakpoint 
identification approach and identified many frequently truncated genes. 
 
During this study, I observed extensive intratumour heterogeneity, which reflects 
genomic instability in prostate cancer. Therefore, I investigated the involvement of 
genomic instability in human cancers through genomic analysis of four 2N cancer cell 
lines.  
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CHAPTER I INTRODUCTION 
 
1.1 Cancer 
 
1.1.1 The definition of cancer 
Cancer is a class of diseases caused by uncontrolled growth of cells. The term cancer 
drives from the Greek term “carcinos”, which means crab or crayfish in Greek. The 
first surgical treatment of cancer was documented to have occurred in Egypt in 1600 
B.C. and this involved the use of cauterisation. It is now clear that cancer is a complex 
disease with multiple genetic defects, biological alterations and physiological 
changes. While normal cells can control their proliferation and apoptosis, genetic 
alterations in tumour cells can lead to uncontrolled cell growth. Briefly, in epithelial 
tumour formation, normal cells proliferate uncontrollably, followed by the 
development of hyperplasia, carcinoma in situ and invasion of surrounding stroma. 
When the cancer cells spread to a non-adjacent organ through blood or lymphocyte 
circle, metastasis is formed (1). In the 1870’s, the concept of metastasis was described 
by English surgeon Campbell De Morgan (2). 
 
In 2000, Hanahan and Weinberg summarised six hallmarks of cancer: self-sufficiency 
in growth signals, insensitivity to antigrowth signals, evading apoptosis, limitless 
replicative potential, sustained angiogenesis, invasion and metastasis (3).  
 
1.1.2 Classification of tumour 
Tumours can be divided into benign and malignant tumours based on their behaviour. 
Benign tumours do not grow unlimitedly and do not invade or metastasise. Most 
benign tumours are harmless for health. Malignant tumours, as defined by Hanahan 
and Weinberg (3), growth unlimitedly and in an uncontrolled manner, killing the 
patients if not well-treated. Malignant tumour can be further grouped according to the 
type of cellular constituents of the tumour. For instance, carcinoma arises from 
epithelial cells, sarcoma from mesenchymal cells, lymphoma and leukemia from 
hematopoietic cells, germ cell tumour from germline cells and neuroectodermal 
tumours from neuronal cells.   
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1.1.3 Aetiology of cancer 
The causes of cancer could be divided into internal and external factors. Internal 
factors associated with cancer include hormones, regulators of the immune system 
and heredity. External factors include environmental exposure to particular chemicals, 
radiation, infection, as well as diet patterns.  
 
1.1.3.1 Internal factors  
Age: Cancer affects the people at all ages. However, the risk of most cancers increases 
with age. The majority of cancer cases are diagnosed in patients over the age of 65 (4). 
The increasing incidence may be explained by the accumulation of the genomic 
alterations associated with cancer. The major cancers among young people are 
leukemia, lymphomas, soft tissue sarcomas and bone sarcomas. 
 
Heredity: Cancer risk can be inherited. 40% of childhood retinoblastomas are familial. 
The risk of breast cancer is higher for individuals whose family members have breast 
cancer. BRCA1 and BRCA2 are known susceptibility genes in breast and ovarian 
cancers (5). APC mutations, associated with colon carcinomas, can also be hereditary 
(6, 7). 
 
Hormone: The development of certain cancers can be effected by hormone level. 
Breast and prostate cancers are typical hormone-dependent cancers, and oestrogens 
and androgens are crucial for breast and prostate cancers. Hormone blocking therapies 
are widely used to treat these two cancers (8).  
 
1.1.3.2 External factors 
Chemical carcinogens: It is clear that chemical carcinogens can cause DNA mutation, 
resulting in uncontrolled cell growth or metastasis. The first study linking chemical 
carcinogens to cancer was reported in 1775. Percivall Pott correlated the high 
incidence of scrotal cancer in chimney sweepers due to the carcinogen in soot, which 
later was confirmed as containing polycyclic aromatic hydrocarbons (9). Tobacco 
contains at least five known chemical carcinogens. Smoking tobacco is the cause of 
90% of lung cancers as well as being associated with a number of other cancers (10, 
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11). Other chemical carcinogens include benzene, asbestos, ethylene oxide, vinyl 
chloride, etc. 
 
Radiation: The cumulative exposure of ultraviolet (UV) radiation is a common 
radiation rescource associated with melanoma and other skin malignances. UV can 
cause DNA damage and severe sunburns increase the risk of the melanoma (12). 
 
Virus: Virus is the main infectious agent, which is responsible for up to 20% of 
cancer (13). For example, hepatitis B and C infections are implicated in the 
occurrence of hepatocellular carcinoma, Human papillomavirus (HPV) can cause 
cervical cancer and Epstein-Barr virus (EBV) initiates B-cell lymphoproliferative 
disease and nasopharyngeal carcinoma (13). There is a wide range of cancers with 
increased risk in HIV positive patients, such as Kaposi’s sarcoma, non-Hodgkin’s 
lymphoma, cervical cancer, anal cancer and Hodgkin’s lymphoma (14). 
 
1.1.4 Epidemiology 
Systematically conducted epidemiological studies started in early 20th century with 
Janet Lane-Claypon first reporting on the relationship between smoking and lung 
cancer in 1926 (15). In 2000, approximately 10 million people were diagnosed with 
cancer and 6.2 million people succumbed the disease (16). Of concern, the incidence 
and mortality rates have dramatically increased during the last ten years. 
GLOBOCAN 2008 estimated that about 12.7 million cancer cases (excluding non-
melanoma skin cancer) 
(http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900). Figure 1.1 
summarises the number and age-world-standardised incidence rate (ASR (W)) for 
incidence and mortality of the main cancer types. 
 27 
 
Figure 1.1 The incidence and mortality rates of cancers. 
(Adapted from http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900 )  
 
Globally, lung cancer is the most common cancer, followed by breast, colorectal, 
stomach and prostate cancers (see Figure 1.1). The incidence of many human cancers 
varies dramatically between different geographical regions. For example, cervical and 
liver cancers have the highest incidence in Asia, while breast and prostate cancers 
have the highest incidence in Europe and America (17). The different incidence may 
be associated with specific oncogenic agents, which have distinct geographic 
distribution. For example, EBV is associated with Burkitt’s lymphoma and 
nasopharyngeal cancer, and aflatoxins are associated with hepatocellular carcinoma 
(13, 18). However, for many cancers, the factors underlying the differential 
geographical distribution are still not clear. 
 
1.1.5 Cancer associated genes 
The genetic study of cancer mainly started in early 20th century. Epidemiological and 
molecular evidence indicated the tumourigenesis to be a multi-step process driven by 
genetic alterations resulting in aberrant cellular physiology that collectively lead to 
malignant growth (3). The genes involved in cancer initiation and progression can be 
broadly divided into oncogenes and tumour suppressor genes (TSGs). 
 
 28 
1.1.5.1 Oncogenes 
The concept of oncogenes first arose in the 1960’s (19). An oncogene is a type of 
modified gene, which contributes to tumourigenesis through gain-of-function of the 
gene. Proto-oncogene, its counterpart in normal cells, regulates the normal process of 
cell growth and differentiation. Mutation, amplification and over-expression of the 
oncogene leads to uncontrolled cell growth and proliferation, and consequently 
tumour development, usually in the presence of other genetic alterations (19).  
 
In the late 1970’s, Ha-ras was discovered as the first proto-oncogene through a cell 
transformation study in animal models (19). Wild type Ha-ras has low intrinsic 
GTPase activity. When mutated, this proto-oncogene turns to an over-expressed 
activated form and has the potential to turn normal cells to cancerous (20). With the 
development of chromosome banding technology in the 1970’s, many recurrent 
chromosome rearrangements were discovered in human cancers. Some chromosome 
rearrangements, predominantly translocations, can activate oncogenes if the 
breakpoints are in close proximity, an example being C-Myc activation in Burkitts 
lymphoma (21). Alternatively, novel genes can be generated through gene fusion, 
such as the BCR:ABL fusion gene in chronic myelogenous leukaemia (CML) (22, 23). 
Another common form of chromosome alteration, chromosomal amplification, also 
activates oncogenes, such as the amplification and over-expression of N-Myc in 
neuroblastoma and ERBB2 in breast cancer (24, 25). 
 
1.1.5.2 TSGs 
When present, TSGs reduce the probability of malignant transformation. Hence, 
neoplasia are characterised by loss of TSGs. In normal cells, TSGs control regulation 
of cell cycle, surveillance and maintenance of genomic integrity, as well as promoting 
apoptosis (19). Broadly speaking, these genes can be divided into two major classes, 
i.e. ‘gatekeepers’ and ‘caretakers’. While ‘gatekeeper’ genes limit cancer 
development, loss-of-function of the ‘caretaker’ genes can accelerate tumourigenesis, 
although the latter is not essential. TSGs are usually inactivated in cancer cells by 
three main mechanisms: mutation, deletion and promoter hypermethylation.  
 
In 1971, Knudson proposed the ‘two-hit hypothesis’ of tumourigenesis (26). Based on 
the observation of the onset time of hereditary and sporadic forms of retinoblastoma, 
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Kundson suggested that two rate-limiting events are required for cancer formation. 
Based on this hypothesis and the observed deletion on 13q in retinoblastoma, RB was 
found as the first TSG in 1986 (26). Due to the presence of an underlying germline 
mutation of RB, inherited retinoblastoma occurs early in childhood and usually 
bilateral because only one somatic event is required (27). In sporadic cancer, 
mutations for both alleles of Rb have to be acquired; therefore the cancer is generated 
later and usually only affects one eye.  Most of TSGs are recessive genes and fit in 
this hypothesis.  Later, it was also found that haploinsufficiency for TSGs, in which 
one hit can affect the tumour suppressor role of certain TSGs (28). For example, 
mutation of a single allele of the commonly inactivated TSG TP53 can lead to cancer 
development. 
 
Loss of TSGs, through chromosome deletion, is a common somatic event in tumour 
development and this can be frequently detected as loss of heterozygosity (LOH), 
resulting from the loss of one allele of the genomic sequences located at these deleted 
chromosome regions. Thus, LOH usually points to the existence of a TSG. Promoter 
hypermethylation can also silence TGSs. The details will be discussed in section 
1.1.7. 
 
The germline mutation of a TSG can increase the risk of cancer development in the 
affected individuals.  The CDKN2A germline mutations affecting p16INK4a is linked to 
high risk of familial pancreatic cancer (29). Germline mutation in BRCA1 is 
associated with high risk of breast and ovarian cancers (30-32). Germline mutation of 
BRCA2 is also associated with increased risks of breast, pancreatic and gastric cancers 
and melanoma (33). In familial breast cancer, associated germline mutations include 
BRCA1, BRCA2, p53, PTEN, ATM, NBS1, CHEK2, RAD50, BRIP and PALB2 (30-
32).  
 
1.1.6 Genetic alterations in cancer 
Genetic alterations occur as single nucleotide changes, rearrangements of a genomic 
fragments or gains or losses of whole chromosomes. 
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1.1.6.1 Mutation 
Although all alterations to the DNA sequence can be described as mutations, the term 
‘mutation’ most commonly refers to point mutations where the mutation is caused by 
single nucleotide exchange, including transition and transversion. Transition is the 
most common type and refers to the change between adenosine triphosphate (A) and 
thymidine triphosphate (T) or guanosine triphosphate (G) and cytidine triphosphate 
(C). Transversion occurs between A/T and C/G. Mutations, which occur in protein 
coding regions, can be classified into three types: silent mutations (coding for the 
same amino acid), nonsense mutations (coding for a stop codon) and missense 
mutation (coding for a different amino acid). Missense mutations are thought to be 
related to cancer risk. For example, a common missense mutation GCC→ACC of 
SRD5A2 is associated with high risk of prostate cancer (34). Missense mutations in 
EGFR were found in 70% of non-small-cell lung cancer, which are correlated with 
response to single agent tyrosine kinase inhibitors (TKIs) (35, 36).  
 
1.1.6.2 Genomic rearrangement 
Chromosome rearrangements, including amplifications, deletions, translocations, 
insertions and reversions are widely found in human cancers. Since the introduction 
of chromosome banding technology in the 1970s for cytogenetic analysis (37), many 
recurrent large chromosome rearrangements have been identified in a range of tumour 
types (38).  
 
1.1.6.2.1 Amplification 
Amplification is the replication of genomic fragments, thus increasing gene dosage 
(Figure 1.2). It can be in the same chromosome the form of homogeneous staining 
region or as free chromsome fragments in the form of double minutes. Many 
oncogenes are located at the region of genomic amplification. For example, the 
amplification of HER2 occurs in 15-20% of breast cancers and confers a worse 
prognosis. At the same time, it is used to guide the use of anti-Her2 targeting 
therapies, including Trastuzumab and Lapatinib (39). 
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Figure 1.2 Illustration of chromosome amplification. 
 
1.1.6.2.2 Deletion 
Deletion is defined as the loss of genomic fragments, thus, decreasing the gene dosage 
(Figure 1.3). Some TSGs lose their functions due to deletion events. The well-known 
TSGs, PTEN and P53 are both located at regions that are commonly deleted in 
cancers. Deletion events can also lead to the formation of fusion genes. A 
chromosome 21q internal deletion results in the fusion of ERG to TMPRSS2 in 
prostate cancer (40-42). With technological advances allowing improved sensitivity, 
many sub-chromosome deletions have recently been identified (43).  
 
Figure 1.3 Illustration of chromosome deletion. 
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1.1.6.2.3 Chromosome translocation 
Chromosome translocation is the exchange of genetic material between 
nonhomologous chromosomes. Chromosome translocation can be classified as 
‘balanced translocations’, with no loss of chromosome material, or ‘unbalanced’ 
translocations, which incur the loss of chromosome fragments (Figure 1.4). 
Chromosome translocation can create chimeric genes with novel functions that 
contribute to tumourigenesis. In 1960, the first recurrent chromosome translocation, 
the Philadelphia chromosome, was discovered. This translocation between 
chromosome 9 and 22 leads to the fusion of BCR and ABL genes to generate a novel 
form of protein, which is associated with CML (38, 44). Besides fusion genes, 
chromosome translocation can also lead to the disregulation of oncogenes. For 
example, in Burkitts lymphoma, C-Myc is placed down-stream of the IgH promoter in 
about 80% of t(8;14) cases. In the majority of the remaining 20% of t(8;14) genative 
cases, C-Myc is placed under the control of immunoglobulin light chains ? or ? 
enhancer elements (21). Although chromosome translocation generally results in 
gain-of-functions, as described above, a few translocations lead to loss-of-function 
have also been reported in recent years (38).  
 
 
Figure 1.4 Illustration of chromosome translocation. 
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1.1.6.2.4 Insertion 
Insertion is defined as the addition of a genomic fragment (from few base pairs to 
large fragments) into another chromosome region (Figure 1.5). Genomic insertions 
can occur during meiosis or in cancer cells during mitosis. Insertion can have the 
same consequence as chromosome translocation leading to gene fusion, truncation or 
disregulation. If a small DNA sequence is inserted into an exon, the normal reading 
frame can be altered to generate a protein with abnormal function. In the case of 
insertion of a stop codon, the translation of protein will be prematurely stopped. 
Notably, even if the insertion is small and in-frame, the normal coding sequence can 
be changed, resulting in a protein with altered function.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Illustration of chromosome insertion. 
 
1.1.6.2.5 Inversion 
Inversion is a chromosome rearrangement event in which a chromosome fragment is 
flipped over and reunited to the same chromosome. Inversion can be classified as 
paracentric (without centromere, Figure 1.6A) or pericentric (with centromere, 
Figure 1.6B). As well as deletions, translocations and insertion, inversion events can 
lead to the formation of a fusion gene. A small inversion within chromosome 2p 
results in a recurrent fusion gene, EML4:ALK, in 9% of non-small-cell lung cancer 
cells (45). Detection of RML4:ALK cDNA can be a sensitive diagnosis for fusion 
positive cases (46). EML4:ALK is also a potential therapeutic target. The chemical 
compound, WHI-P154, suppressing the growth of cell through inhibiting the kinase 
activity of ALK, was proved inhibiting the growth of the cells expressing EML4:ALK 
(45). 
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Figure 1.6 Illustration of paracentric (A) and pericentric (B) chromosome 
inversions. 
 
1.1.6.3 Whole chromosome gain or loss 
Aneuploidy refers to cancer cells with aberrant chromosome copy number, which is 
common in cancers. This occurs during cell division due to improper chromosome 
separation into the daughter cells. Some of the proposed mechanisms driving this 
include the inactivation or down-regulation of mitotic checkpoint genes (Bub1) or 
over-expression of some genes (MDA2 and HEC1) (47, 48).  
 
1.1.7 Epigenetic alterations 
Epigenetics plays important roles in the regulation of cell differentiation during 
embryogenesis. Epigenetics implicates the modification of DNA chains (methylation) 
and histones involved in DNA packaging into chromatin (acetylation, methylation, 
ubiquitylation, phosphorylation and sumoylation). DNA methylation is mainly found 
in genomic regions rich in cytosine-guanine doublets (CpG) islands, which are 
predominantly located in the promoter region of genes. Although epigenetic 
modifications do not change the primary DNA sequence, they regulate gene 
expression. In human cancers, an overall hypomethylated genome can activate 
oncogenes (49). In contrast, local hypermethylation is a common mechanism in 
various cancers, leading to the silencing of TSGs, such as VHL, MLH1, p16 and 
BRCA1 (50). Hypermethylation of different genes is associated with various cancer 
A B 
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types (49). Although histone modifications are common in human cancers, they are 
not well studied compared with DNA methylation. In eukaryotic cells, genomic DNA 
is packaged into chromatin by DNA-histone complexes. Histone modification can 
change the structure and regulate transcription. In cancer cells, CpG island 
methylation is associated with a certain combination of histone modification, 
including deacetylation of histones H3 and H4, loss of histone H3 lysine K4 (H3K4) 
trimethylation, and gain of H3K9 methylation and H3K27 trimethylation. Histone 
modification can silence certain tumour suppressor-like gene, such as p21. Post-
translational modification of histone H4 is widely found in human normal tissue and 
tumors. Histone modification on some genes, such as EZH2 and NSD1, leads to 
deletion, amplification, mutation, translocation and abnormal expression (51). 
 
1.1.8 Genomic instability 
Genomic instability is a characteristic observed almost ubiquitously in solid tumours 
and adult-onset leukaemias. Genomic instability is considered to be associated with 
defects in DNA repair and genomic surveillance genes (52). Genomic instability 
underlying cancer initiation and progression can be broadly classified into 
chromosome instability (CIN) and microsatellite instability (MIN).  
 
1.1.8.1 CIN   
CIN is the major form of genomic instability and is found in most cancers. CIN refers 
to the high rate of abnormal chromosome structure and copy number changes in 
cancer cells compared to normal cells. Gain or loss of the whole chromosome through 
CIN may be the most common pathway to aneuploidy (section 1.1.6.3). CIN was first 
proposed over one hundred years ago (52). It is widely observed in human cancers. 
CIN normally happened during the chromosome segregation in mitosis. The defects 
of chromosome cohesion, the spindle assembly checkpoint, centrosome copy number, 
kinetochore-microtubule attachment dynamics and cell cycle regulation are the main 
mechanisms to induce CIN (53). In addition to the protein directly associated with 
chromosome segregation, some cell-cycle regulators are associated with CIN, such as 
BRCA1, BRCA2, Rb, cyclin E and p53 (53). Telomere dysfunction is also considered 
to be associated with CIN. Shorter telomeres and increased telomerase activity were 
reported in colorectal tumours with CIN (54, 55). Finally, the inactivating mutations 
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in genes involved in DNA repair and surveillance, such as TP53, ATM and H2AX, 
may play a role in development of CIN (56).  
 
CIN is also reported to be associated with poor patient prognosis, tumour metastatics 
and drug resistance (57, 58). Some of the factors causing CIN are potential 
therapeutic targets for novel forms of treatment. 
 
1.1.8.2 MIN 
MIN is another form of genomic instability characterised by increasing alterations of 
polymorphic microsatellite repeats. MIN results from mutations in DNA mismatch 
repair genes. Loss of DNA mismatch repair activities enhanced MIN leading to 
cancer progression (59). For example, mutations in DNA mismatch repair genes lead 
to MIN in hereditary non-polyposis colon cancer (60, 61). In sporadic cancers, MIN is 
mainly found in colon cancer. Approximately 12% sporadic colon cancers are 
identified with MIN (62).  
 
In summary, it is generally acknowledged that cancer is a genetic disease. Many 
notable genetic changes were identified associated with cancer initiation and 
progession. More important, genetic alterations can be used for cancer diagnosis, 
subgrouping, prognosis and treatment stratification. Many drugs were invented to 
target crucial genes, such as HER2, BRCAs, ABL, KIT and ALK. With the 
development of the new techniques, more genetic alterations are being and will be 
revealed and will contribute to prevention and treatment of cancer.  
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1.2 Prostate cancer 
 
1.2.1 The prostate gland 
The prostate gland was first described by a Venetian anatomist, Niccolò Massa, in 
1536, and illustrated by Flemish anatomist Andreas Vesalius in 1538. The prostate is 
an acorn-shaped tubuloalveolar exocrine gland of the male mammalian reproductive 
system. It is located in the pelvis, inferior to the bladder, surrounds part of the urethra 
and is anterior to the rectum (Figure 1.7). The main known functions of the prostate 
are the secretion and storage of seminal fluid. The prostate includes three distinct 
zones, including the peripheral zone, the transition zone, and the central zone (63). 
Notably, most prostate cancers originated in the peripheral zone.  
 
Figure 1.7 Location of the prostate gland 
(Adapted from http://www.psa-rising.com/detection/prostate-location.htm) 
 
1.2.2 Prostate cancer 
Since its initial description by Adams in 1853 (64), prostate cancer is currently the 
second most common male cancer world-wide 
(http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900). With an 
increased understanding of prostate cancer, new diagnosis and treatments are being 
applied to control this disease.  
 
1.2.2.1 Epidemiology of prostate cancer 
The incidence of prostate cancer is dramatically different in different countries 
(Figure 1.8). It is the most common male cancer in Western countries, including 
Europe, North America and parts of Africa (65). The highest incidence is in Northern 
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American and Scandinavia, affecting 1 in 6 men, which is 90 times higher than the 
incidence in Asia, which has the lowest risk (65). In America, the incidence of 
prostate cancer amongst African-American is 2.5 times higher compared to that of the 
Caucasian population. Recently, the incidence of prostate cancer has been reported to 
be increasing in developing countries, but it is still much less than that in the Western 
countries (66). Many factors contribute to this variable incidence in different 
countries, including age, diet, hormone level, genetic polymorphism and environment.  
 
 
Figure 1.8 Prostate cancer incidence and mortality world-wide in 2002. 
(Adopted from http://info.cancerresearchuk.org/cancerstats/types/prostate/mortality/) 
 
According to the latest summary from CR-UK, prostate cancer was the most common 
male cancer in 2007 with 36,101 new diagnosed cases and the second most common 
cause of cancer related male deaths in 2008 in the UK (Figure 1.9).  
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Figure 1.9 The incidence (2007) and mortality (2008) of the twelve most common 
cancers in male in the UK.  
(Data from http://info.cancerresearchuk.org/cancerstats/incidence/) 
 
1.2.2.1.1 Age 
The mean age of prostate cancer diagnosis ranges between 72 and 74 years. Prostate 
cancer patients under 50 years of age are rarely diagnosed while 85% of prostate 
cancer patients are over the age of 65 (65). Figure 1.10 indicates the relationship 
between age and incidence. 
 
 
Figure 1.10 Numbers of new prostate cancer cases and age specific incidence 
rates in UK in 2006. 
(Adapted from http://info.cancerresearchuk.org/cancerstats/types/prostate/mortality/) 
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1.2.2.1.2 Diet 
Many studies have investigated the possible link between potential dietary factors and 
the risk of prostate cancer. The dietary factor may affect the level of circulating 
androgens or oestrogens or protect cells against mitogens.  
 
Selenium is believed to reduce about 50% risk of prostate cancer (67). However, The 
Selenium and Vitamin E Cancer Prevention Trial (SELECT) including 35,533 men 
from USA, Canada and Puerto Rico didn’t find any relationship between selenium 
and developing prostate cancer (68). Several large randomized clinical trials studying 
the utility of vitamin E and selenium in prostate cancer prevention are underway.  
 
Soybean and related products are commonly found in Chinese and Japanese diets. 
Isoflavonoids from soybean were found to suppress DNA synthesis and inhibit 
apoptosis in the LNCaP cell line and decrease the circulating oestrone concentrations 
and plasma DHT levels in human and rat models (69, 70).  
 
Green tea is considered to be protective for prostate cancer. Polypenol in green tea 
can reduce the risk of prostate cancer via effects on the P53 and NF-кB pathway and 
shifting the balance between pro- and anti-apoptotic proteins (71, 72). However, some 
clinical studies haven’t find association between green tea and the risk of prostate 
cancer (73). 
 
Studies have also revealed a relationship between dietary fat and prostate cancer. 
Oleic acid and saturated fat is thought to be associated with higher risk, and the farine 
fatty acids, especially the long-chain eicosapentaenoic (74, 75) and docosahexaenoic 
acids, are associated with reduced risk of prostate cancer (76). Another study 
published in 2007 found that the risk of prostate cancer reduces 40% if eating 
cruciferous vegetables, like cauliflower and broccoli, at least once a week (77). 
 
1.2.2.1.3 Hormonal factors 
High levels of circulating serum androgens, including DHT, testosterone, 3α-
androstanediol glucuronide (AAG), androsterone glucuronide (ADG) and oestradiol, 
as well as sex-hormone binding globulin (SHBG) and 5α-reductase, increase the risk 
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of prostate cancer. Ross et al found African American men have a 15% higher total 
testosterone level and 13% higher free testosterone level than whites (78). Wu et al 
reported that the ratio of DHT:testosterone was highest in African-Americans, 
intermediate in whites and lowest in Asian-Americans (79).  
 
1.2.2.1.4 Inheritance 
The risk of prostate cancer in men with a first-degree relative with prostate cancer is 
two or three times higher than that of a person without a family history (80). Some 
predisposation loci have been identified (81). However, it is now generally accepted 
that the risk of prostate cancer is mainly caused by low-penetrance susceptibility loci 
rather than high-penetrance susceptibility genes (82). In addition to previous linkage 
analysis, the recent genome-wide association study (GWAS) analyses have identified 
many predisposition SNPs (82-85) (more details about susceptibility will be discussed 
in sections 1.3.1 and 1.4.3.2). 
 
1.2.2.1.5 Environment 
Although the incidence rates for Asians born in the USA is still lower than blacks and 
whites Americans, it is more than double compared to the incidence rates of native 
Asian men (86). This suggests that the change of environment and lifestyle can 
impact on prostate cancer risk.  
 
1.2.2.2 Pathology of prostate cancer 
The most commonly used pathology grading system for prostate cancer is the Gleason 
scoring system. The Gleason score scale ranges from grade 2 to 10, which is a 
composite of scores derived from the two most prevalent histopathological patterns 
from grade 1 to 5 (Figure 1.11). The higher the Gleason score, the poorer the cell 
differentiation. Within this framework, it is generally accepted that high-grade 
prostatic intraepithelial neoplasia (HGPIN) and atypical small acinar proliferation are 
putative precursor lesions of prostate cancer (80). Benign prostatic hyperplasia (BPH) 
is not considered a pre-neoplastic lesion. 
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Figure 1.11 Gleason score system. 
(Adopted from http://www.prostate-cancer.org/education/staging/Dowd_GleasonScore.html)  
 
1.2.2.3 Clinical stage 
Clinical staging can be described by the TNM system. “T” represents the size of 
tumour; “N” represents the regional lymph nodes involved; and “M” represents the 
distant metastasis. TNM system is based on digital rectal examination (DRE), 
transrectal ultrasound, CT or MRI. To improve the diagnosis precision, the 
combination of Gleason score, prostate-specific antigen (PSA) level and clinical stage 
is used to guide diagnosis and treatment.  
 
1.2.2.4 Diagnosis 
Commonly used diagnostic investigations for prostate cancer include DRE, 
Transrectal ultrasound, serum PSA and serum alkaline phosphatase level 
measurement, CT scan, MRI, skeletal X-rays and biopsy (80, 87, 88). PSA testing is 
widely used for prostate cancer screening. With increasing frequency use of PSA and 
biopsy tests, the incidence of prostate cancer has been increased. Early cancer 
diagnosis is critical to ensure the best clinical outcome. However, most of these early-
stage prostate cancers remain indolent. Only about 25% of prostate cancer will 
aggressively progress and kill the patients (89). Currently, it is difficult to 
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differentiate between low- and high-risk prostate cancers diagnosed at the early stage 
(localized in the prostate). Therefore, the management of early stage prostate cancer 
presents a dilemma for clinicians: low-risk cases may be treated unnecessarily and 
high-risk cases may not be adequately treated, missing the opportunity to cure them in 
the early stage (90). 
 
1.2.2.5 Treatment  
Treatments of prostate cancer depend on the stage and grade of disease. Early stage 
tumours are either managed expectantly or treated with hormonal manipulation, 
surgery and/or radiotherapy. The main forms of treatment for metastatic prostate 
cancer include androgen deprivation and chemotherapy. While androgen deprivation 
works in the majority of patients, its effects invariably wear off. When the disease 
becomes androgen-resistant, chemotherapeutic options may be considered but the 
benefits of these are currently limited.  Table 1.1 summarises the hallmarks of cancer 
treatment. 
 
Table 1.1 The history of prostate cancer treatment. 
Years  Treatments 
1904  Radical perineal prostatectomy (64) 
Early 20th century Radiation therapy (64) 
1941 Hormone therapy (64)  
Middle 20th century Transurethral resection of the prostate (91)  
1970’s  Chemotherapy (92)  
 
1.2.2.6 Prognosis 
While most patients with localised prostate cancer live more than 10 years with the 
appropriate therapy, the average life expectancy of patients diagnosed with metastatic 
disease is only 12-16 months (80).  
 
1.2.2.7 Tumour metastasis and circulating tumour cells (CTCs) 
By secreting factors that impact on cell-cell adhesion and the extracellular matrix, 
tumour cells may invade into adjacent structures and even detach from the primary 
tumour. Through the blood and lymphatic circulatory systems, tumour cells can 
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migrate to distant target organs and develop metastases. The common spread sites are 
pelvic lymph nodes, bone, lung and liver (80). Importantly, it is usually the metastatic 
spread of disease that is the major cause of mortality in these patients. Detection of 
CTCs can potentially be used to monitor cancer metastasis. The concept of CTCs is 
not new (93). But CTCs have attracted renewed interest due to their emerging roles as 
potential surrogate endpoints and biomarkers in breast, colorectal and prostate cancers 
(94). Three main techniques, reverse transcription polymerase chain reaction (RT-
PCR), immunohistochemistry (IHC) and magnetic cell sorting, have been applied in 
the detection and collection of CTCs from peripheral blood and bone marrow (Table 
1.2). However, currently it is still difficult to confirm individual CTCs in many cases. 
The molecular attributes, as well as biological and functional significance of these 
cells, are still poorly understood; and work is ongoing to address these issues. 
Furthermore, it is still unclear how CTCs can evade immune surveillance and 
haemodynamic shear forces, in addition to achieving anchorage independence within 
the circulatory system.  
 
Table 1.2 Three main techniques for CTC detection. 
 RT-PCR IHC Magnetic cell sorting 
Principle  Amplify specific 
tumour biomarkers 
Antibody recognize the 
special tissue-type or 
tumour-type biomarkers 
Magnetic beads 
combines to antibodies to 
separate CTCs 
Advantages  Highly sensitive  Specificity  1. Enrich samples for the 
further studies 
2. Only detect intact cells  
Limitations  1. Nonspecific 
amplification. 
2. False positive from 
dead cells or free DNA 
in blood 
1. Protein should be 
expressed 
2. Limited quantitation 
and producibility 
1. Expensive  
2. Time-consuming 
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1.3 Genetic studies in prostate cancer 
The behaviour of cells is dependent on the expression of their genes. Genes that drive 
tumour development are good biomarkers for cancer prognosis and predicting the 
response to treatment. As one of the most common cancers in Western countries, 
numerous molecular biological genetic investigations have been carried out in 
prostate cancer. Many genes associated with prostate cancer development and 
progression have been identified, particularly with the recent development of new 
technologies. However, the mechanisms underlying the origin and development of 
prostate cancer are still unclear. Advanced disease is still untreatable and it is difficult 
to predict the behavior of cancers diagnosed at early stage. 
 
1.3.1 Susceptibility genes in prostate cancer  
The risk of a person developing prostate cancer increases if another relative has 
prostate cancer (95). Tumour susceptibility genes are germ line genetic changes or 
polymorphisms, which increase the risk of cancers. Susceptibility genes include low-
penetrance and high-penetrance susceptibility genes. Low-penetrance susceptibility 
genes cause a small relative risk of cancer, but commonly exist in human population. 
High-penetrance susceptibility genes are rare but significantly increase the risk of 
cancer. Possible susceptibility loci and genes have been identified in hereditary 
prostate cancer by linkage analysis. Candidate chromosomal regions associated with 
prostate cancer include 1p36 (96), 1q24-25 (96, 97), 1q42 (96, 98), 8q24 (83, 99, 
100), 17p (98), 20q13 (98) and Xq27-28 (101, 102). Some genes located in these 
regions have been identified (Table 1.3).  
 
Recently, the application of SNP array technology for GWAS has dramatically 
accelerated the identification of low-penetrance cancer predisposition genes (103). 
GWAS has been applied to identify prostate cancer risk-associated SNPs by several 
large national and international consortiums and more than 30 cancer predisposition 
loci have been identified (82-85, 99, 104-109).  
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Table 1.3 Genetic polymorphisms and prostate cancer. 
Genes Polymorphisms  
AR Short CAG repeat length is related to a high risk of 
prostate cancer (110). The average CAG repeat length is 
23 for Chinese men and 19 for African-American (111). 
However, some studies didn’t find the different repeat 
length between Chinese and Caucasian men (112). The 
length of the GGN repeat is also linked to higher risk of 
prostate cancer (113, 114). 
VEFG -1154A allele is related to a low risk of prostate cancer 
(115). 
CDH1 Increased risk with -160C allele (115). 
EGF +61GG/AG is more frequent in prostate cancer patients 
and G allele is associated with metastatic cases (115). 
MSR1 A major haplotype G-A-C-G-C-G combining five SNPs 
is related with increased risk of prostate cancer (116). 
RNASEL Arg462Gln polymorphism has three times less enzyme 
activity than the wild type (110, 117).  
NBS 657del5 mutation was present more frequent in familial 
than sporadic prostate cancer. Most NBS with the 
mutation lose the wile type allele (115). 
ELAC2 A major haplotype C-G-G-C-G of five SNPs increases 
prostate cancer risk (116). 
VDR Vitamin D BsmI genotype showed higher risk in some 
studies, but some studies didn’t find any association 
(118-122). 
CYP17 A2/A2 allele is more frequent than A1/A2 and A1/A1 in 
Caucasians men with prostate cancer than controls 
(123).  
SRD5A2 The V89L polymorphism is associated with lower DHT 
lever and lower incidence of prostate cancer, especially 
for L/L allele. Hsing reported that Chinese men have 
higher frequency of L/L allele (35%) than the Caucasian 
men (10%) (111, 124).  
 
1.3.2 Somatic genetic alterations  
Somatic genetic changes occur de novo in cells during tumour development. Those 
genetic changes occur not only in sporadic but also in familial cases. Prostate cancer 
contains many somatic genetic alterations, including mutations, deletions, 
duplications/amplifications and translocations. As karyotyping analysis of clinical 
samples is difficult, these alterations, with the exception of mutations, were 
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previously detected mainly in cancer cell lines. In prostate cancer clinical samples, 
large-scale genomic changes are predominately detected as chromosome copy number 
changes using chromosomal comparative genomic hybridisation (CGH) and 
microarray technologies. The most common chromosome copy number aberrations 
are gain of 7, 8q and Xq and loss of 8p, 10q, 13q, 16q and 21q (40, 125). Some of 
these occur at particular stages of prostate cancer development and usually lead to the 
deregulation of oncogenes or inactivation of TSGs. With the technology development 
of microarrays, many genetic alterations of genes were frequently determined, firstly 
by expression arrays. Table 1.4 summarises the genes commonly associated with 
prostate cancer initiation and progression.  
 
 
Table 1.4 Genes involved in prostate cancer development and progression 
Genes Location  Status in prostate cancer  Roles 
EZH2 (95, 
126) 
7q36.1 Expression level 
significantly increases, 
especially in metastatic 
tumour 
Developmental regulatory 
gene. Knock down EZH2 
decreases the prostate cell 
proliferation 
NKX3.1  
(95, 126) 
8p21.2 Deletion occurs in HGPIN 
and early invasive disease.  
Candidate TSG. Down-
regulated expression of PSA 
gene.  Knock-out one allele 
may lead to HGPIN.  
MYC (95, 
110) 
8q24.21 Amplification due to gain of 
whole chromosome 8 or 
regional copy number gain. 
Expression level increases in 
prostate cancer.   
Play an oncogenic role in 
prostate cancer. 
CDKN2 
(126)  
9p21 Mutation was found in 
advanced and metastatic 
prostate cancer. 
Hypermethylation and 
deletion were also reported 
in prostate cancer.  
Control the cells passing 
through G1 phase of cell 
cycle.  
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KLF6 (95, 
110) 
10p15.1 LOH and mutation  Suppress cell proliferation 
PTEN   (95, 
110, 126) 
10q23.31 Deletion, including 
frameshift deletion and 
mutation happen more in 
metastatic than localized 
tumour. Not associated with 
hereditary prostate cancer. 
Putative TSG. Loss of PTEN 
increases proliferation and 
decrease apoptosis. 
Expression of PTEN is often 
reduced in prostate cancer, 
especially in high-grade or 
stage. Loss of PTEN is 
correlated with loss of 
NKX3.1 and P27. 
MXI1 (126) 10q25 High mutation rate was 
found in some study, but not 
in primary tumours.  
Putative tumour suppressor 
KAI1 (95, 
126) 
11p11.2 No mutation found. 
Epigenetic silencing may 
lead to the down-regulation 
Metastasis suppressor gene 
GSTP1(95, 
126) 
11q13 Hypermethylation were 
observed over 70% of high-
grade prostatic 
intraepithelial-neoplasia and 
over 90% of prostate cancer.  
May be a biomarker for the 
early stage of prostate cancer.  
CDH1 (49, 
126) 
16q22.1 Decreased expression is 
related with high-grade and 
metastatic prostate cancer. 
No mutations found 
Involved in cellular 
differentiation through Cell-
to-cell recognition and 
adhesion.  
P53  (95, 
110, 126, 
127) 
17p13.1 Mutations are found 
frequently in BPH and 
prostate cancer. The 
mutations are associated 
with high-grade and high-
stage cases with poor 
prognosis. 
Well-known TSG, promoting 
apoptosis.  
 49 
BCL2 (95, 
126) 
18q21.33 Over expression in advanced 
and metastatic tumours.  
Inhibit programmed cell 
death. Over expression is 
relative to resistance to 
chemotherapy.  
ERG (40) 21q22.2 TMPRSS2:ERG fusion gene 
partner and over-expression 
in prostate cancer. 
Over-expression causes 
improper cell proliferation 
AR (95, 
110, 126) 
Xq12 Amplification and mutation 
are found in refractory 
prostate cancer, related with 
high AR activity. 
Amplification was not found 
in untreated patients.  
Increased activity of AR 
promotes prostate cells 
androgen-independent growth.  
 
Loss of function of GSTP1 and NKX3.1 occurs frequently in HGPIN and early 
invasive disease (95, 126). The aberrations of genes, such as PTEN, MXI1, P53, 
CDH1 and KAI1, are associated with advanced and metastatic prostate cancer (95, 
110, 126, 127). Over-expression of AR and BCL2 promotes androgen-independent 
prostate cancer (95, 110, 126). In prostate cancer, PTEN is commonly inactivated 
(128). Although PTEN can be inactivated as a consequence of DNA mutation and 
methylation events, chromosome deletion events account for the majority of PTEN 
loss-of-function cases. 
 
AR is stimulated by androgens in normal and neoplastic prostate growth. In prostate 
cancer, AR is also implicated in androgen resistance with its amplification or mutation 
(110). Most mutations in AR can increase its function (110), and the amplification 
leads to over-expression of AR, which allows AR stimulated cell growth at castrate 
level of androgen (126). Both amplification and mutation of AR are rarely detected in 
primary tumours (110, 126). 
 
1.3.3 Chromosome translocations and fusion genes in prostate cancer  
At least 328 fusion genes, involving 306 individual genes, have been found in 
malignant diseases (38, 129). Before the identification of TMPRSS2:ERG in prostate 
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cancer, 264 fusion genes were identified in haematological malignancies, accounting 
for 75% of all known fusion genes (38, 129). Only 70 fusion genes have been found 
in solid tumours (of which 41 have been described in sarcomas) (129). Hence, 
chromosome translocations were thought only to play a minor role in carcinomas. 
However, the small number of chromosome translocations and fusion genes reported 
in carcinomas can be due to the difficulty in karyotyping (poor morphology and 
complex chromosome rearrangements) these cancer cells and they may play a 
similarly important role in epithelial cancers as haematological malignancies and 
sarcomas (38). This has been proven by recent studies using advanced technologies, 
which have identified fusion genes at high frequency in carcinomas (38, 45, 129).  
 
In prostate cancer, the first chromosome translocation, t(6;16), resulting in TPC:HPR 
fusion gene was discovered in LNCaP in 1996 (130). Recently, with technological 
advances, chromosomal translocations and fusions have been better characterised in 
carcinomas. Using a bioinformatics approach analysing expression outlier genes from 
microarray data, it was found that the 5’ untranslated region of TMPRSS2 is fused 
with ETS family genes at high frequencies, including ERG, ETV1 and ETV4, in 
prostate cancer clinical specimens and cell lines (40, 41). In addition, ETV1 was 
found to be the fusion partner of a number of prostate specific genes (42). Hence, 
prostate cancer became the first carcinoma significantly associated with chromosome 
rearrangements and fusion genes.  
 
The TMPRSS2:ERG fusion occurrs in ~50% of prostate cancers (38, 40). In individual 
studies, TMPRSS2:ERG has been identified in 15-80% of prostate cancer samples (40, 
131-134). Fusion events are found in the majority cases of haematological and 
sarcomatous malignancies. However, many of them are associated with subtypes of 
these tumours and these diseases are much rarer than prostate cancers, which account 
for 20% of all diagnosed cancers (38, 135). These facts, coupled to the high frequency 
of its occurrence in prostate cancer, makes a higher overall prevalence of the 
TMPRSS2:ERG fusion in human tumours (7.2% to 16% of all cancers). The BCR-
ABL fusion, detected in 100% of CML cases, has a prevalence of only 0.2% of human 
malignancies (the percentage that CML accounts for all malignancies) (38). Hence, 
TMPRSS2:ERG is the most frequently found fusion gene in human malignancies. 
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The TMPRSS2:ERG fusion can be caused by either internal deletion or chromosomal 
translocation (126, 136) and deletion of 21q22.2-22.3 between TMPRSS2 and ERG 
accounts for more than half of the TMPRSS2:ERG fusion cases (137-140). Based on 
the precise breakpoints, fourteen types of TMPRSS2:ERG have been identified in 
previous studies (141-145). The most common TMPRSS2:ERG fusion identified is 
between exon 1 of TMPRSS2 and exon 4 of ERG (T1/E4), as originally reported by 
Tomlins et al. (40). TMPRSS2 is an androgen-regulated gene that is expressed in 
normal and neoplastic prostate tissues. Its expression can be up-regulated by 
androgens in androgen-dependent prostate cancer. The TMPRSS2:ETS fusion events 
lead to the over-expression of the ETS oncogenes from the TMPRSS2 promoter (146). 
ETS family genes can bind to specific DNA sequences and regulate DNA 
transcription. Over-expression of ETS family genes resulting from the fusion with 
TMPRSS2 and other androgen regulated or house-keeping genes generally causes 
improper cell proliferation in a number of malignant diseases (147).  
 
In addition to TMPRSS2:ETS fusion, recurrent TMPRSS2:ETV1 (t(7;21)) has been 
reported, although at much lower frequency (40, 142, 148, 149). ETV1 was over-
expressed in 6-16% samples (42). In 2007, four other partners, namely SLC45A3, 
HERV-K, C15orf21 and HNRPA2B1, were identified as fusion partners with ETV1 in 
prostate cancers (42). HNRPA2B1 is a housekeeping gene with high expression in all 
tissues, while the other three genes are expressed specifically in the prostate (42). 
Moreover, TMPRSS2:ETV4 (t(17;21)) was also found in independent studies (41, 
143). Table 1.5 summarises all fusion genes involved with ETS family genes.  
 
Further genomic-wide transcriptome sequencing has identified many more fusion 
gene transcripts in prostate cancer (150-152). However, almost all of the fusion genes 
not involving ETS family genes were not found to be recurrent fusion genes, such as 
SLC45A3:BRAF and ESRP1:RAF1 (152). 
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Table 1.5 ETS Fusion genes summary in prostate cancer. 
5’-end 3’-end References  
TMPRSS2 ERG (40)  
SLC45A3 ERG (153)  
NDRG1 ERG (154)  
HERPUD1 ERG (151) 
TMPRSS2 ETV1 (40)  
SLC45A3 ETV1 (42)  
HERV-K_22Q11.23 ETV1 (42)  
C15orf21 ETV1 (42)  
HNRPA2B1 ETV1 (42)  
FLJ35294 ETV1 (151, 153) 
EST14 ETV1 (155)  
HERVK17 ETV1 (155)  
ACSL3 ETV1 (156)  
TMPRSS2 ETV4 (41)  
DDX5 ETV4 (153)  
CANT1 ETV4 (157)  
KLK2 ETV4 (157)  
TMPRSS2 ETV5 (158)  
SCL45A3 ETV5 (158)  
SLC45A3 ELK4 (150, 159) 
 
 
1.3.4 Epigenetic changes in prostate cancer 
Epigenetic alterations also contribute significantly to prostate cancer development and 
progression. DNA hypermethylation, which leads to inactivation of TSGs, is a 
common epigenetic aberration in prostate cancer. More than 30 genes have been 
reported with promoter hypermethylation, such as AR, ESR2, CDH1, GSTP1, MGMT 
and RASSF1A (160). Hypermethylation of the GSTP1 promoter is observed in 70%-
93% of prostate cancers (161, 162), 50%-76% of HGPIN (162, 163). GSTP1 is a 
DNA damage repair gene, which is expressed in the basal cells of normal glandular 
prostate epithelium (164). Due to its high frequency, GSTP1 hypermethylation may 
be considered as a prostate cancer biomarker. Methylation of GSTP1 gene can also be 
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detected in plasma and serum, urine, lymph nodes, prostate secretions and biopsy 
specimens in prostate cancer patients (164, 165).  
 
Hypomethylation has also been reported in prostate cancer. Bedford and van Helden 
found that the overall methylation content decreased in BPH and metastatic prostate 
cancer, although some genes were hypermethylated (166). Hypomethylation of 
individual genes has also been investigated. Hypomethylation of CAGE, a novel 
cancer antigen gene, has been detected in 40% of prostate cancers (167).  
Hypomethylation of PLAU commonly leads to its over-expression and results in the 
promotion of tumour invasion and metastasis (168). 
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1.4 Research techniques in cancer genetics 
 
1.4.1 Overview 
Many genetic and molecular biological techniques have been developed to study the 
complex genetic alterations in human cancers. Several molecular biological 
techniques, such as southern blotting, PCR and traditional DNA sequencing, can 
illustrate detailed genetic changes, but only on pre-selected genomic regions or genes. 
In contrast, a whole genomic screen strategy offers the ability to systematically detect 
genetic alterations. In relation to my study, I will focus on the technologies for 
genome-wide analysis. At the end, I will also review fluorescence in situ 
hybridisation (FISH) and PCR technologies, which are commonly used in 
combination with genome-wide analysis. 
 
1.4.2 Low resolution chromosome level genome-wide genetic analysis 
Before the development of array technology, genome-wide genetic studies were 
carried out with low resolution at chromosome level. There are two main 
technologies: karyotyping and CGH.  
 
1.4.2.1 Karyotyping 
Karyotyping was the first technique used to analyse the whole genome, mainly for 
chromosome abnormalities, including numerical and structural changes in 
chromosomes. Chromosomes were first identified in plant cells in 1842 (169) and in 
the early 20th century, chromosomes were known as the carriers of genes. In the 1920s, 
Levitsky initially defined the karyotype as the phenotypic appearance of the somatic 
chromosomes (170). In 1956, it was confirmed that there are 46 chromosomes in a 
normal human cell (171).  
 
For karyotyping, chromosome is stained by chemicals, such as giemsa, making the 23 
pairs of human chromosomes in normal cells or abnormal chromosomes in disease 
conditions visible under microscopy. Karyotype analysis can identify gross 
chromosomal structural changes, such as amplifications, deletions and translocations, 
as well as gross whole chromosome copy number gains or losses. There have been 
two major further technical developments in karyotype analysis. The first is the G-
banding technique, which was developed in 1970s and stains each chromosome in 
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metaphase with special bands (37). Hence, chromosomal rearrangements can be 
identified by the changes of chromosome banding pattern (Figure 1.12A). However, 
banding analysis needs highly skilled cytogenetic expertise and in many human 
cancers, due to the complexity of chromosome changes, it is not possible to identify 
fully the abnormal chromosomes (43). 
 
A 
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Figure 1.12 The G-banding (A) and spectral karyotyped (B) karyotypes of HeLa 
metaphase cells from the same subclone (172).  
(Adapted from Macville et al., Cancer Res 1999; 59:141-150) 
 
The second development is multicolour karyotyping, which includes multiple 
fluorescence in situ hybridisation (M-FISH) and spectral karyotyping (SKY). Both of 
these techniques were reported in 1996 (173, 174). Fluorescence dyes are used to 
stain metaphase chromosomes such that each chromosome is stained with one colour 
and the changes of the colour highlight the rearrangement of chromosomal (Figure 
1.12B). This technical development improved the ease with which abnormal 
chromosomes were identified. However, all these technical developments cannot 
9 
 
P
5
5 
 
P
6
8 
 
P
9
8 
 56 
resolve the fundamental problem in karyotyping for cancer analysis: the requirement 
of good quality metaphase chromosome spreads from samples under investigation. 
Metaphase spread preparation from solid tumours is very difficult. This largely 
explained why the genetic study of solid tumours dramatically lagged behind that of 
haematological malignancies. 
 
1.4.2.2 Chromosomal CGH 
In 1992, Ann Kallioniemi and colleagues developed a new genome-wide analysis 
technique, CGH (175). CGH is based on molecular hybridisation technology and can 
be considered as an extension of the FISH technique. In CGH, the whole genomic 
DNA from a tumour sample and a control sample are labelled differentially in two 
different colours, eg red and green. In the early stage of CGH analysis, these labelled 
probes were hybridised onto normal metaphase chromosomes and the fluorescence 
intensity ratio between the two samples was analysed along the chromosomes to find 
the chromosome regions with genomic copy number gains or losses. Compared to the 
later developed CGH analysis using microarrays, this early stage CGH analysis using 
metaphase chromosomes as hybridisation templates was referred to as chromosomal 
CGH. The development of CGH conceptionally changed the genome-wide genetic 
analysis approach, which leads to the development of microarray technology. As 
normal metaphase slides are much easier to make than metaphases from solid 
tumours, chromosomal CGH have been widely used to study a range of solid tumours 
soon after it was developed (176). However, chromosomal CGH did not increase the 
resolution of G-banding. Extensive breakpoint mapping is still necessary to identify 
associated genes. In addition, cytogenetic knowledge is still required to identify 
individual normal chromosomes for chromosomal CGH analysis. 
 
1.4.3 Microarray technology and genomic analysis 
The use of DNA chips was first reported by Pease (177). The light-generated 
oligonucleotide array was designed with 256 probes. The differences between 
hybridization signals provide a rapid way to analyse sequence information. With the 
development of DNA chips, different designs were introduced for multiple 
applications in cancer research. Nowadays, DNA arrays include bacterial artificial 
chromosomes (BAC), cDNA, oligo and single nucleotide polymorphism (SNP) 
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arrays. They can be used for CGH, genotype, gene expression, DNA methylation and 
protein DNA binding domain analysis (178, 179). Here I discuss genomic microarrays 
that are relevant to my study. 
 
1.4.3.1 Array CGH 
As mentioned above, the development of chromosomal CGH opened new avenues in 
genome-wide analysis of human cells (175). However, the resolution of chromosomal 
CGH is limited and expert cytogenetic input is required (180). Array CGH is 
developed from traditional chromosomal CGH. Instead of hybridising chromosomes 
with the differentially labelled genomic DNA from tumour and control samples, 
spotted DNA fragments are used for Array CGH analysis. Those spotted DNA 
fragments can be BAC clones (BAC array), cDNA (cDNA array) or synthesized 
nucleotide oligos (oligo array). The introduction of DNA chips makes a high-
resolution whole genome analysis possible (43). Following the concept of 
chromosomal CGH, in array CGH, two samples are labeled differentially and 
hybridised simultaneously onto the same array slide. An array platform has been 
developed by Affymetrix where only one sample is hybridised to the array chip in 
each experiment. As the technology is robust, the results from different arrays of the 
same type can be compared for relative genomic copy number changes. 
 
1.4.3.2 SNP array  
In addition to genomic copy number changes identified by array CGH, SNP array was 
developed for genome-wide genotype analysis. It is estimated that there are about 15 
million SNPs throughout the human genome, which consists of about 3.2 billion base 
pair. Therefore, there is, on average, one SNP every 200 base pairs (181). Since its 
development in 1998 for genotyping (182), SNP array has been improved 
dramatically and has become one of the most powerful genomic analysis tools. The 
different developmental stages of SNP array technology are listed in Table 1.6.  
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Table 1.6 Historical Stages of the SNP Array Technology and Application 
Development. 
Years Events 
1998 First test of SNP array analysis (558 SNPs) (182)  
2000 First application of SNP array analysis on cancer 
2003 Affymetrix developed 10K SNP array using single primer 
amplification of restriction enzyme digested genomic DNA 
2004 SNP array validated for DNA copy number analysis 
2004 SNP array application whole genome amplified DNA samples 
2005 Development of whole-genome genotyping approach which should 
be scalable for simultaneous analysis of all SNPs in the genome 
2005 GWAS was developed to define susceptible loci for disease (183)  
2006 Development of the high resolution karyotyping approach by 
combined SNP and 24-color FISH analyses (43) 
2007 Array 6.0 with SNP and copy number variation probes was 
developed by Affymetrix 
 
Simultaneous analysis of the status of multiple SNPs was first done using the PCR 
technique with multiple specific primers. A large amount of primers were used to 
amplify DNA for these multiple SNPs in a sample in the multiplex PCR approach for 
array analysis. Therefore, the sample preparation using this protocol was still labour 
intensive for high density SNP array analysis. In 2000, two groups separately applied 
SNP array analysis for multiple detections of LOH and allelic imbalance (AI) in 
human cancers (184, 185). The microarray company, Affymetrix, has improved the 
reliability of SNP array genotyping by interrogating on the array additional offset 
probes for each SNP locus (185). The low-resolution SNP arrays have been applied to 
human tumour samples mainly for LOH and allele imbalance analyses (184, 185). 
Several approaches have been used to improve the capacity of multiplex PCR for 
array analysis (186). Among them, the GoldenGate assay (187) is one of the 
successful highly multiplexed PCR-based SNP genotyping method which the 
company Illumina has adopted for their commercial SNP array chips. Although these 
modifications improved the number of SNPs that can be analysed, the multiplex PCR 
approach still limits the member of SNPs that can be analysed. In 2003, researchers at 
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Affymetrix developed the whole genome sampling method for SNP genotyping (188, 
189). The whole approach is illustrated in Figure 1.13.  
 
 
Figure 1.13 The process for Affymetrix’s SNP array to detect the sample. 
(Adapted from  
http://media.affymetrix.com:80/support/technical/datasheets/genomewide_snp6_datasheet.pdf) 
 
Since the first Mapping10K SNP array was released in 2003, the SNP array technique 
has been rapidly applied to many human tumors. The application of whole-genome 
DNA amplification techniques in combination with SNP array genotyping (190-192) 
and genomic copy number analysis have been evaluated (193). The combined 
genotyping and genomic copy number analysis has made the SNP array a unique 
technique in cancer genomic research, and revealed many new genetic features in 
cancer cells such as acquired uniparental disomy (UPD) (194, 195). In the last couple 
of years, Affymetrix has improved the coverage of their SNP array chips further into 
100K, 500K and more recently, one million SNPs by selecting different enzymes to 
fragment genomic DNA. The latest Genome-Wide Human SNP Array 6.0 not only 
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includes 900K SNPs, but also 950K probes for the detection of copy number 
variation.  
 
However, the Affymetrix enzyme digestion and the single primer amplification 
approach still have their limitations. While the selection of enzyme digested DNA 
fragments reduces the genomic complexity, the selected DNA only represents SNPs 
in a proportion of the human genome. The PCR amplification of digested DNA also 
limits the application of these SNP arrays in analysing degraded DNA from paraffin-
embedded samples (FFPE). Many of the DNA fragments are not long enough to be 
cut twice by the enzyme, and are therefore subsequently excluded from PCR 
amplification.  
 
In parallel with Affymetrix SNP array, Illumina developed another high throughput 
genotyping method, beadsarray (196-198). This principle of SNP array analysis 
makes the number of SNPs in one chip scalable. Using this approach, all SNPs 
existing in the genome can be theoretically analysed in one experiment, and in 
principle, it is applicable to degraded DNA, such as that extracted from FFPE 
materials. Illumina’s high density BeadChips are based on an Infinium Whole-
Genome Genotyping Assay, in which the whole genomic DNA is hybridised to an 
array of locus-specific capture probes and scoring the SNP genotypes using enzymatic 
allelic discrimination (196, 197). Currently, the highest-density Illumina Human1M-
Duo SNP array contains 1.2 million SNPs 
(http://www.illumina.com/products/human1m_duo_dna_analysis_beadchip_kits.ilmn)
. 
 
The initial purpose of SNP array development was to genotype multiple SNPs 
simultaneously. Therefore they were first used in cancer research for LOH and AI 
analyses, which are important for TSG identification. Indeed, SNP array analysis 
detected AI and LOH patterns associated with tumour subgroups, stage (199), relapse 
and prognosis (200). With the development of the high-density SNP arrays, they have 
also been explored for DNA copy number analysis (193, 201).  
 
This combined analysis of LOH and DNA copy number changes led to the 
identification of certain new genomic alteration patterns such as UPD. In acute 
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myeloid leukemia, high frequencies of UPDs were found in chromosome regions with 
mutated genes, such as CEBPA, WT1, FLT3, RUNX1 (194, 202, 203). In basal cell 
carcinoma, UPD at 9q21-31 was found and PTCH at UPD region was mutated in 
more than half of cases with LOH (195). These studies demonstrated that mitotic 
recombination can act as a "second hit", similar to chromosome deletion, and can be 
responsible for removal of the remaining wild-type allele of those tumour suppressor-
like genes. A high frequency of large-scale homozygous chromosome regions (HCR) 
was found for the whole chromosome without loss of chromosome copy number in 
the nonseminomatous subtype of male germ cell tumors (204). Since then, UPD has 
been found using SNP array analysis in many human tumours, including malignant 
lymphoma (205, 206), myeloma (207), hepatocellular carcinoma (208, 209), 
colorectal cancers (210, 211), and leukemia (212, 213).  
 
As SNP arrays can analyse genome-wide constitutional DNA polymorphisms in 
individuals, they are applicable for linkage analysis to identify cancer predisposition 
genes. In 2004, Schaid et al. first validated the application of SNP array in linkage 
screen for cancer-susceptibility loci in prostate cancer (214). Since then, SNP arrays 
have been used in other human tumours to identify susceptibility loci, such as 11p11, 
5q22-23, 6p22 and 10q25 in chronic lymphocytic leukaemia, 3q21-24 in colorectal 
cancer (215), 7 cM region on 10q23 in hereditary mixed polyposis syndrome (216), 
and 11q12–11q13 in pituitary adenoma (217). From section 1.3.1, we know that the 
susceptibility loci include limited high-penetrance, but many low-penetrance loci. The 
combination of low-penetrance loci can significantly increase cancer risk. High-
density SNP arrays provide an excellent tool to discover these low-penetrance cancer 
susceptibility loci using the GWAS approach. In GWASs, SNP array analysis is 
carried out to determine the genotype of each individual in two large groups of 
participants, disease (cases) group and a similar population without disease (controls) 
group. Hence, different genetic variations can be associated with different diseases or 
traits. In the last few years, about 600 GWASs have been carried out to examine 150 
human diseases and traits and resulting in the discovering of at least 800 SNP 
associations (218). In cancer research, GWAS has been used to look for susceptible 
loci in breast cancer (219-221), pancreatic cancer (222), lung cancer (223), prostate 
cancer (83, 99, 107), ovarian cancer (224), melanoma (225), testicular germ cell 
tumour (226), leukaemia (227, 228) and colorectal cancer (229). As previous 
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mentioned, several GWASs have been performed to study prostate cancer and many 
susceptibility SNPs have been found in prostate cancer (82-85). 
 
Compared with other array technologies, the high-density resolution of SNP arrays is 
clearly an advantage. The whole-genome genotyping SNP array technology under 
current development has the potential to comprise almost all known SNPs into a 
single experiment. Moreover, SNP array can identify the small regions of alterations, 
which are undetectable by FISH or array CGH. The genetic abnormalities picked up 
by high-density SNP array analysis will be more than sufficient for direct PCR and 
sequencing analysis. Another strength of SNP array technology is its allowance for 
the concurrent analysis of both genotype and DNA copy number changes. However, 
the SNP array still has its limitations. SNP array analysis cannot detect balanced 
chromosomal translocations, inversions and whole-genome ploidy changes without 
combination with other techniques. In my study, data from individual cell analysis 
methods, such as FISH or 24-color FISH karyotyping, were applied in combination 
with SNP array data. In the case of evaluating known genes or established genetic 
markers in a large series of samples, PCR and tissue array analyses will be more 
efficient. As with most other molecular biological techniques, SNP array analyses 
DNA generated from a large number of cells instead of individual ones, thus reducing 
its sensitivity when applied to mixed, heterogeneous populations of cells. 
Contamination by normal tissue poses considerable challenges in prostate cancer 
study. The newly developed next-generation sequencing can detect the genetic 
changes in individual cells and overcome this limitation. 
 
1.4.3.3 Other applications of array technology  
In addition to genomic studies, microarrays can also be used to investigate gene 
expression, DNA methylation and DNA regions bound by certain proteins. Early 
stage expression arrays are mainly designed to identify gene expression level changes. 
Exon arrays provides expression information for each exon or putative exon, which 
can be used to detect not only gene over- or under-expression, but also alterative 
splicing and potential truncated genes (230).  
 
The methylation array was originally designed to specifically pick up DNA 
methylation changes. It is usually made by only gridding on the chips the DNA 
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sequence around the CpG island of gene promoter and first exon regions (231). Later 
on, BAC and SNP arrays have also been used for genome-wide DNA methylation 
analysis (232, 233).  
 
The ChIp-on-chip technique combines chromatin immunoprecipitation and 
microarray to investigate the interaction between protein and DNA. ChIP-on-chip can 
be used to localise protein binding sites that may help identify functional elements in 
the genome, such as transcription factors, enhancers, repressors and insulators (234, 
235). ChIp-on-chip can aid understanding of the machinery behind gene regulation, 
cell proliferation, and disease progression. Specifically, in prostate cancer, ChIp-on-
chip has been used to investigate AR binding and AR-dependent transcription (236).  
 
1.4.4 Next-generation sequencing  
Next generation sequencing is a newly developed high throughout sequencing 
technique, which can produce millions of sequences simultaneously. The idea was 
first developed in 2005 by 454 life sciences (237). They applied a novel highly 
parallel sequencing system to sequence 25 million bases in a single four-hour run with 
at least 99% accuracy (237). The principles of sample preparation and sequencing are 
illustrated in Figure 1.14 and 1.15. 
 
Following the initial model, other developments have been made using slightly 
different sequencing approaches. Currently, there are three main next-generation 
sequencing systems: 454 pyrosequencing from Roche, Solexa sequencing from 
Illumina and SOLiD sequencing from Applied Biosystems (238). The next-generation 
sequencing systems can be used for full genome sequencing, amplicon sequencing, 
transcriptome sequencing and fusion gene detection (239, 240). 
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Figure 1.14 Sample preparation for 454 sequencing. 
A: Genomic DNA is isolated, fragmented, ligated to adapters and separated into single strands. 
B: Each fragment is bound to one bead. The bead carries the droplets of a PCR-reaction-
mixture-in-oil emulsion. DNA amplification occurs within each droplet, resulting in beads 
each carrying ten million copies of a unique DNA template. C: DNA strands are denatured in 
the beads, and then beads carrying single-stranded DNA are deposited into wells of a fibre-
optic slide. D: Smaller beads carrying immobilized enzymes required for pyrophosphate 
sequencing are deposited into each well (Adaped from Margulies et al., Nature 2005;437:376-
80 (237)).  
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Figure 1.15 High throughout sequencing. 
A: Add the biotinylated dNTP into the universal primers for all fragments. B: remove the 
uncombined nucleotides. C: CCD detects the signals. D: inactivate biotin. Repeat step A to D 
until sequencing the whole fragment. (Adapted from http://molonc.bccrc.ca/?page_id=191)  
 
 
Overall, next-generation sequencing is a rapid and economical method for high 
throughout sequencing. Owing to the sequencing of individual fragments, genetic 
changes can be detected even diluted with normal samples. Although the next-
generation sequencing is cheaper and faster to sequence per basepair, as it generates 
millions of basepairs per run, each run is still expensive.  
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1.4.5 Molecular genetic techniques commonly used in combination with 
genome-wide analysis to investigate specific genomic regions or genes 
 
1.4.5.1 FISH 
FISH is a cytogenetic technique first used in 1980 (241). It can be used to detect the 
status of specific DNA sequences in chromosomes. The probes are normally labelled 
by fluorescence and hybridised to matched DNA sequence in the cells. The signals 
have to be checked by fluorescence microscopy. Using M-FISH, where each probe is 
labelled by a different colour of fluorescent, two or more genomic loci can be 
analysed simultaneously to confirm genomic copy number gain or loss, chromosome 
translocation and genomic split due to chromosome rearrangements. Therefore, FISH 
is commonly used to confirm the genomic alterations detected by SNP array or array 
CGH (242, 243). In the karyotyping and low-resolution CGH analysis era, FISH also 
can be used to map chromosome breakpoints more precisely (244, 245). As FISH 
indicates the genomic changes in individual cells, counting signals from a big 
population of cells in one sample can assess genomic instability, which is common in 
cancer (246). With the development of the TMA technique, application of FISH on 
TMA samples also provides a quick approach to study genomic changes in a large 
cohort of samples. Consequently, the prevalence of the genomic alterations in a 
cancer or several types of cancers can be determined efficiently (140).  
 
1.4.5.2 PCR and Molecular copy-number counting (MCC) 
In 1983, Mullis developed PCR and it was immediately widely used in molecular 
biology (247). PCR is used to amplify a specific DNA sequence, generally up to 10 
Kb, to hundreds and thousands fold in 20-40 cycles. It is a very sensitive and 
multiplexable analysis, which is a rapid method to analyse a large number of samples 
to detect specific DNA sequence existing in a small cell population. PCR products 
can be easily sequenced to reveal genomic information at the DNA sequence level, 
including mutations, small deletions and insertions. Quantitative-PCR (qPCR) can 
also be used to detect the relative copy numbers of genomic region or gene transcripts 
(q-RT-PCR for gene expression). In qPCR, PCR product is labelled by fluorescence 
dye and the fluorescence signal is positively associated with the expression level. 
Moreover, nested PCR can be used to increase the specificity and sensitivity of DNA 
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amplification. In nested PCR, two sets of PCR primers are designed. 2nd set of primers 
is used to amplify the 1st round PCR product to increase the specificity and sensitivity. 
 
MCC is alternative application of the PCR method, which can be used to define the 
chromosome breakpoints involving genomic copy number changes (248). MCC is a 
semi-nested PCR-based analysis, which is more accurate than qPCR to determine 
genomic copy numbers and can be applied to miniscule amount of genomic DNA. 
Figure 1.16 describes the principle of this method. MCC can be applied for quick fine 
mapping of chromosome breakpoints. With a breakpoint defined at about 100 kb, 
after several rounds of PCR, the breakpoint can be narrowed down to a 300 to 400 bp 
region. This region can be cloned by inverse PCR to determine the breakpoint 
sequence as well as the sequence of the fusion partner.  
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Figure 1.16 MCC method at the region of a nonreciprocal translocation.  
A: The green marker represents two copies and the red one represents one copy of DNA in 
the genome. B: DNA is prepared and diluted less than 0.09 pg/µl. C: DNA is aliquot into each 
well with less than one genome. D: The forward and reverse primers for both markers were 
used to amplify DNA template. E and F: The 1st phase PCR products were split into two 
replica plates. The red and green markers were amplified by related primers in separate plates. 
G and H: PCR products were analysed by gel electropheresis. The red markers were detected 
in 24 wells (G) and the green marker was detected in 46 wells (H). The breakpoint can be 
confirmed between the two markers (248).  
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1.5 Aims of thesis 
 
The aims of this project were to identify novel genomic changes in prostate cancer, to 
reveal genetic mechanisms of prostate carcinogenesis and to discover potential 
genetic markers for cancer development or progression. 
 
Although many genetic studies have been done in prostate cancer, the critical 
genomic changes in prostate cancer development and progression are still not fully 
described. In this study, I used SNP array technology to analyse the genome-wide 
genomic alterations in prostate cancer to identify novel genomic changes. Owing to 
their high-resolution, the SNP arrays used in this study (500K array or array 6.0) 
provided genomic copy number changes with better defined boundaries than previous 
genome-wide analysis technologies used in prostate cancer. The potential oncogene(s) 
and TSG(s) at the breakpoints can be identified directly.  
 
Recently, the high-frequency TMPRSS2:ERG fusion gene was found in prostate 
cancer and might be associated with diagnosis, treatment and clinical outcome. I 
aimed to find more recurrent genomic fusions, in particular fusion genes, in prostate 
cancer using a novel in-house array analysis software, Genome Oriented Laboratory 
File system (GOLF), developed by Prof. Bryan Young. I also attempted to develop or 
apply new genetic analysis approaches to assist the discovery of novel genomic 
changes and the better understanding of prostate cancer genomics.  
 
The incidence of prostate cancer is significantly higher in Western countries than 
Asian ones. This difference can be a result of differential presentation of risk factors, 
such as genetic predisposition, diet, environment and lifestyle. Differential 
presentation of these risk factors in different populations may lead to the activation of 
different development pathways in cancers and also cause a difference in the somatic 
genomic alterations of each population. I investigated the above hypothesis by 
comparing genomic alterations in Western and Chinese prostate cancer samples using 
Affymetrix SNP arrays.  
 
As TMPRSS2:ERG was found in approximately half of prostate cancer cases, I 
investigated its potential as a genetic marker to monitor CTCs in prostate cancer 
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patients. During this study, I also observed extensive genomic variation in cancer 
cells within the same prostate cancer specimens. Due to the heterogeneity of prostate 
cancer, I also investigated the general existence of genomic instability in human 
cancer using cell line models.   
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CHAPTER II MATERIALS AND METHODS 
 
2.1 Materials  
 
2.1.1 Cell lines 
Four prostate cancer cell lines (PC3, DU145, LNCaP and VCaP), a human 
rhabdomyosarcoma cell line (A204), a human uterus leiomyosarcoma cell line (SK-
UT-1B), a human breast carcinoma cell line (CAL51) and a human ovarian carcinoma 
cell line (CH1) were used. CAL51 was obtained from Dr. J. Gioanni, Centre Antoine-
Lacassagne, Nice, France. CH1 was obtained from Dr. Lloyd Kelland at The Institute 
of Cancer Research, London, UK. All other cell lines were obtained from American 
Type Culture Collection (ATCC) in the USA.  
 
2.1.2 Fresh frozen prostate cancer clinical samples 
Fifty UK and sixty-six Chinese prostate cancer samples were collected from St Barts 
Hospital (London, UK), Whipps Cross Hospital (London, UK) and Changhai Hospital 
(Shanghai, China). All samples were obtained with patients’ consent and local 
research ethical committee’s approvals. Each fresh tissue was frozen in liquid 
nitrogen immediately after surgical removal, and approximately 0.05g tissue was used 
for DNA or RNA extraction. Most of these samples were reviewed for Gleason 
grading and the percentage of tumour cells in each sample using hematoxylin and 
eosin (H&E) stained frozen sections. 
 
2.1.3 Prostate cancer circulating tumour cells (CTC) 
Fifteen CTC samples were separated from peripheral blood of prostate cancer 
patients. The sample collection was performed in collaboration with Dr. Greg Shaw 
and Dr. David Prowse. 
 
2.1.4 Tissue microarrays (TMAs) containing FFPE prostate tissue samples 
In total, eleven TMAs were used. One UK BPH TMA slide contains 29 UK BPH 
samples. Six UK TMA slides contain 199 UK prostate cancer cases (<10% cases were 
of Asian and none were of Chinese origin). All the UK cases were collected from St. 
Barts Hospital and Whipps Cross Hospital. Each case had triplicate cores in the 
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TMAs and each core was measured 0.6 mm in diameter. The four TMA slides 
contained 168 Chinese prostate cancer cases and 48 Chinese normal prostate cases (all 
Chinese ethnicity and from China). All the Chinese cases were collected from The 
First Affiliated Hospital, Zhijiang University Medical College, Hangzhou, China. 
Each case had three replicates and each core was measured 1 mm in diameter.  
 
2.1.5 Bacterial artificial clones (BACs) 
Eight BAC clones were ordered from Sanger Centre (www.sanger.ac.uk). Probes and 
their locations are summarized in Table 2.1.  
 
Table 2.1 The BAC probes for FISH analysis. 
BAC clone probes Probe location 
RP11-476D17 21q22.2 (38,604-38,787 Kb, ERG 3’ undeleted region) 
RP11-95I21 21q22.2 (38,811-39,021 Kb, ERG 5’ deleted region) 
RP11-79A11 2q22.1-31.1 (151,030-151,196 Kb) 
RP11-98P2 8p21.2 (26,070-26,170 Kb) 
RP11-348L18 6q26-27 (161,408–168,064 Kb) 
RP11-48J22 11p15.4-15.2 (9,328–12,890 Kb) 
RP11-428P16 10q22.3 (78,979–79,402 Kb) 
RP11-22M5 22q11.21-11.23 (19,894–23,041 Kb) 
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2.2 Methods 
The 5417R centrifuge was used for all centrifugation steps, except where otherwise 
stated. 
 
2.2.1 Sample preparation 
 
2.2.1.1 Tissue culture 
The prostate cancer cell lines were kept frozen in liquid nitrogen. Cells were thawed 
at 37ºC water bath immediately after removal from liquid nitrogen. The cells were 
transferred into 15 ml centrifuge tubes and spun at 1000 rpm for 5 minutes. The 
supernatant was discarded. 5 ml of medium (DMEM for A204, SK-UT-1B and 
CAL51; RPMI1640 for CH1, PC3, DU145, LNCaP and VCaP) with Glutamax I 
supplemented with 10% foetal calf serum (FCS) and 1% penicillin were then added 
into the collected cells. The re-suspended cells were then transferred to a small flask 
(50 ml) and incubated at 37ºC with 5% CO2. When cells grew to confluence, they 
were passaged by 1X trypsin digestion. Digested cells were collected into a tube and 
spun at 800 rpm for 5 minutes. The supernatant was discarded and cells were washed 
with phosphate-buffered saline (PBS), spun at 800rpm for another 5 minutes. Again, 
the supernatant from the preceding step was discarded and the cells were mixed with 
fresh medium and transferred to new flasks and incubated at 37ºC with 5% CO2. The 
ALLEGRATM X-12R centrifuge was used.  
 
2.2.1.2 Bacterial culture 
BACs were stored at -80ºC in LB broth with 20% glycerol. To initiating single clone 
culture, BAC clones were incubated on LB agar containing 0.1% chloramphenicol in 
a culture plate at 37ºC overnight. Single clone was selected and cultured in 20 ml of 
LB broth on a shaking incubator at 37ºC overnight. 
 
2.2.1.3 CTC separation  
Circulating prostate cancer cells were separated from the whole blood using magnetic 
cell sorting (Figure 2.1). The Oncoquick kit (includes Oncoquick tube and Oncoquick 
washing buffer) was used to separate CTCs from the blood cells. Briefly, 20 ml of 
peripheral blood was loaded gently into the upper compartment of pre-cooled 
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Oncoquick tube and centrifuged at 1600 g for 20 minutes at 4ºC using Allegratm X-
12r centrifuge. The epithelial cells together with a few blood cells, would be 
suspended between the upper plasma phase and lower blood cell phase, forming an 
interphase (Figure 2.2). This interphase was collected by pipette and washed twice 
with Oncoquick washing buffer by mixing and spinning (200 g for 10 minutes). The 
cells were then re-suspended in 80 µl of MACSTM running buffer for further cell 
separation. 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Summary of protocol to isolate CTCs from peripheral blood samples. 
 
Figure 2.2 Whole blood before, during and after separation. 
(Adapted from http://www.hexal-gentech.com/products/man_e.pdf ) 
 
The cells re-suspended in MACS™ running buffer were mixed with 20 µl of CD45RO 
microbeads and incubated at 4-8ºC for 15 minutes. After mixing with 2 ml of running 
buffer, the sample was spun at 200 g for 10 minutes. The cells were then re-suspended 
in 500 µl of MACS™ running buffer to remove the CD45 positive lymphocytes using 
the AutoMACS™ machine.  
20 ml whole blood 
Percipitate (lymphocytes and 
erythrocytes) 
Supernatant  
CD45 positive cells 
(lymphocytes) 
CD45 negative cells  
HEA negative cells 
(lymphocytes) 
HEA positive cells (enriched 
epithelial cells) 
Oncoquick spin 
CD45 selection 
HEA selection 
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After the number of selected cells was counted, they were spun down and then 
resuspended in a suitable volume of MACS™ running buffer (300 µl per 5x107 cells, 
minimum volume of 300 µl). The cells were then incubated at 6-12ºC for 30 minutes 
with FcR blocking reagent EpCAM microbeads (100 µl each per 5x107 cells). After 
mixing with 10X volume of running buffer, the cells were spun and re-suspended in 
500µl of MACS™ running buffer to remove HEA negative lymphocytes using the 
AutoMACS™ machine. The HEA positive epithelial cells were kept in PBS for 
further use.  
 
2.2.1.4 Dissection of tumour lesions from fresh frozen and FFPE clinical samples  
Prostate cancer is a heterogeneous disease. The tumour tissue is commonly 
contaminated by normal tissue and stroma. It was therefore necessary to collect the 
pure tumour tissue (>80%) before DNA and RNA extraction.  
 
2.2.1.4.1 Tissue section cutting  
Fresh frozen samples were cut into 8µm sections using Cryotome® E electronic 
cryostat. The sections were placed on normal glass microscope slides for 
macrodissection and on membrane slides for microdissection. The membrane slide 
was treated by UV for 30 minutes before using. 
 
FFPE samples were cut into 15 µm pieces and placed on normal slides using a rotary 
microtome (Leica RM 2125).  
 
2.2.1.4.2 H&E staining 
Fresh frozen samples: The section was placed in Gill’s Hematoxylin for 30 seconds, 
washed in running water, placed in Eosin for 10 seconds and washed in running water 
again. The section was then dehydrated through 70%, 95% and 100% ethanol and air 
dried, followed by two xylene washes for 1 minute each and air dried.  
 
FFPE samples: the section was heated at 65ºC for 1-2 hours and then placed in two 
xylene washes for 5 minutes each, before being air dried. The section was kept in 
Gill’s Hematoxylin for 3 minutes, and washed under running water for 5 minutes. The 
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section was briefly dipped in acid alcohol (50 ml of 30% hydrochloric acid and 450 
ml of ethanol) and washed under running water for 5 minutes. The section was then 
placed into Eosin for 10 seconds and washed by running water. The section was then 
dehydrated through 70%, 95% and 100% ethanol, and air dried, followed by xylene 
treatment for 5 minutes twice and air dried.  
 
Both fresh frozen and FFPE sections to be reviewed by pathologists were sealed using 
a coverslip and Di-n-butyl phthalate in xylene mounting medium.  
 
2.2.1.4.3 Macro- and micro- dissection 
Macrodissection: H&E stained slide was examined by a pathologist to label the 
tumour lessions. Being compared with the H&E stained slide, cancer lesions either 
from fresh frozen or FFPE tissue sections were scraped from unstained slide using a 
sterile scalpel and collected into 1.5 ml tubes. FFPE sections were de-waxed in three 
xylene washes, each for 5 minutes and air dried before macrodissection. Ten to 
twenty sections were dissected for each case. 
 
Microdissection: Tissue on each membrane slide was stained with H&E. The tumour 
lesions were identified and captured by laser capture microdissection (LCM) using 
PALM MicroBeam system. Minimum 1,000 cells were dissected. 
 
2.2.2 DNA extraction  
 
2.2.2.1 Cell lysis 
Clinical samples including fresh frozen and FFPE tissue: 5 ml of suspension buffer 
(Table 2.2) was added into approximately 50 mg of tissue. 250 µl of 20% SDS and 
250µl of Proteinase K (10 mg/ml) were added into 5 ml of the mixture immediately. 
The suspended mixture was incubated overnight at 55ºC. If undigested tissue was 
observed in the solution after the initial incubation, 250 µl of Proteinase K (10 mg/ml) 
was added into the sample and further incubated overnight at 55ºC. This step was 
repeated until no visible solid tissue in the solution. In general, FFPE samples 
required an incubation period of three days at 55ºC with Proteinase K. 250 µl of 
Proteinase K was added to the sample each day. When no tissue was observed, 50 µl 
of RNaseA (10 mg/ml) was added into the solution and incubated at 37ºC for 1 hour 
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to remove RNA. 250 µl of Proteinase K was added and incubated at 55ºC for another 
4 hours. DNA isolation from the tissue was performed by phenol/chloroform 
extraction as described below. 
 
Table 2.2 Suspension buffer for DNA extraction. 
Components Volume (ml) 
5 M NaCl 7.5 
0.5 M EDTA (pH8.0) 25 
1 M Tris-HCl (pH8.0) 50 
Water  417.5 
 
Cell lines: Cells (about 1X106) were digested by trypsin, collected into a tube and 
spun at 800 rpm for 5 minutes using ALLEGRATM X-12R centrifuge. The medium 
was removed and the cells were PBS-washed twice, prior to suspension in 1 ml of 
suspension buffer. After 50 µl of Proteinase K and 50 µl of 20% SDS were added into 
the mixture, the sample was incubated overnight at 55ºC. 10 µl of RNaseA (10 
mg/ml) was added to sample and incubated at 37ºC for 1 hour. Another 50 µl of 
Proteinase K was then added into the sample and kept at 55ºC for 4 hours. The DNA 
was extracted by the phenol/chloroform method. 
 
2.2.2.2 Phenol/chloroform extraction  
An equivalent volume of phenol was added to the sample and mixed vigorously for 5 
minutes. This mixture was then centrifuged at 13000 rpm for 15 minutes at room 
temperature. Following centrifugation, the mixture separated into an aqueous and an 
organic phase. The upper (aqueous) phase containing DNA was transferred into a new 
tube. An equivalent volume of phenol:chloroform (1:1) mixture was added to the 
aqueous fraction, mixed well and centrifuged at 13000 rpm at room temperature for 
15 minutes to separate the two phases. The upper phase was transferred into a new 
tube and added with equivalent volume of chloroform and centrifuged at high speed 
again for 15 minutes at room temperature. The upper phase was transferred into a new 
tube, mixed with 1/10 volume of 3 M sodium acetate (NaAc) and 2.5 volumes of 
absolute ethanol, and placed in a -70ºC freezer for at least 30 minutes to precipitate 
the DNA. After centrifugation at the highest speed for 15 minutes at 4ºC, a DNA 
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pellet was observed at the bottom of the tube. The supernatant was decanted and the 
DNA pellet was washed in 70% ethanol and spun at 13000 rpm at 4ºC for 5 minutes. 
After the supernatant has been discarded, the DNA pellet was air dried, suspended in 
ultra pure DNAse and RNAse free water and stored at -20ºC.  
 
2.2.2.3 BAC clone for FISH analysis  
20 ml of medium with cultured bacteria was used for DNA extraction using EndoFree 
plasmid mini kit (includes P1, P2, P3 and TE buffer). The medium was centrifuged at 
2000 rpm for 15 minutes at 4ºC, and the supernatant was removed. 200 µl of P1 
buffer was added to the bacteria and transferred into a 1.5 ml tube. This mixture was 
incubated at room temperature for 5 minutes and on ice for another 5 minutes. Next, 
400 µl of P2 buffer was added into the sample, and the mixture was inverted gently 10 
times and then incubated for 5 minutes at room temperature. 300 µl of P3 buffer was 
added, followed by the gentle inversion of the mixture 5 times and incubation for 15 
minutes at -80ºC. The frozen mixture was then thawed at room temperature and 
subsequently spun at 12000 rpm for 15 minutes at room temperature. The supernatant 
was finally transferred into a fresh tube (about 850 µl) and centrifuged at 13000 rpm 
for 5 minutes. The supernatant was transferred to a fresh tube and mixed with 0.8 vol 
ice cold isopropanol. The tube was kept at -20ºC for 30 minutes and centrifuged at 
13000 rpm for 15 minutes. The supernatant was decanted and the DNA pellet was 
washed in 80% fresh made ethanol and centrifuged at 13000 rpm at 4ºC for 5 minutes. 
After the supernatant was poured off, DNA pellet was air dried, suspended in TE 
buffer and stored at -20ºC. 
 
2.2.3 DNA quantity and quality measurements 
DNA concentration and quality were checked by Nanodrop and agarose gel 
electrophoresis. If the ratio of 260/280 and 260/230 is at 1.8 and 2.2, DNA is not 
contaminated by protein and salt. The integrity of DNA was assessed by agarose gel 
electrophoresis. 4 µl of DNA mixing with 1 µl of loading buffer was loaded into 1.2% 
gel (1.2 g agarose in 100 ml of 1X TBE buffer supplemented with 5% ethidium 
bromide). DNA was run on the gel at 120V for half an hour in 1X TBE buffer, and 
the resolving band in the gel was checked under UV light.  
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2.2.4 RNA extraction 
 
2.2.4.1 Fresh frozen sample 
0.05 g of fresh frozen tissue was cut from a fresh tissue biopsy as 10 µm thick slices 
and immersed into 1 ml of TRIzol. The tissue was homogenised by pipetting and 
incubated at room temperature for 5 minutes. 0.2 ml of chloroform per 1 ml of TRIzol 
was added into the sample and centrifuged at 14000 rpm for 15 minutes at 4 ºC. The 
solution was separated into three phases. The upper aqueous phase contained the 
RNA, the lower red phase contained protein, and the interphase contained DNA. The 
upper phase was transferred into a new tube and precipitated by adding 0.6 ml of 
isopropanol. The mixture was left at room temperature for 10 minutes and spun at 
14000 rpm for 15 minutes at 4ºC. The supernatant was removed and the RNA pellet 
was washed by 75% ethanol and spun at 7500 rpm for 5 minutes at 4ºC. After the 
supernatant was discarded, the RNA pellet was air dried. The pellet was dissolved in 
RNase free water and kept at -70ºC. RNA was analysed by the Bioanalyzer to check 
the concentration and integrity. 
 
2.2.4.2 CTCs 
RNA was extracted from CTCs using an RNeasy Mini Kit (includes Buffer RLT, 
QIAshredder, Buffer RW1 and Buffer RPE). Briefly, CTCs were added with 350 µl 
of Buffer RLT and vortexed. The lysate was loaded onto a QIAshredder spin column, 
placed in a 2 ml centrifugation tube and spun at 13000 rpm for 2 minutes. An equal 
volume of 70% ethanol was added to the lysate and mixed well. The sample (about 
700 µl) was transferred into an RNeasy spin column placed in a 2 ml collection tube 
and centrifuged at 8000 g for 15 seconds. The flow-through was discarded. 700 µl of 
Buffer RW1 was added to the RNeasy spin column and centrifuged at 8000 g for 15 
seconds. The flow-through was once again discarded. The RNeasy spin column was 
then washed twice with 500 µl of Buffer RPE, once for 15 seconds at 8000g and the 
other time for 2 minutes at 8000 g. The RNeasy spin column was placed in a clean 1.5 
ml tube and 30 µl of RNase-free water was added onto the spin column membrane 
and spun at 8000 g for 1 minute to elute the RNA. The sample was incubated with 
DNase at 37ºC for 1 hour in order to remove genomic DNA. 1/10 volume of 3 M 
NaAc (pH 5.5) and 2.5 volumes of absolute ethanol were added and mixed. The 
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sample was kept at –70ºC for 45 minutes and centrifuged at 14000 prm at 4°C for 25 
minutes. The supernatant was discarded and the pellet washed with 70% nuclease free 
ethanol and centrifuged. The sample was resuspended in nuclease free water after air-
drying. The small quantity of RNA from CTCs was amplified using the 
MessageAmp™ II RNA amplification kit according to the manufacturer’s instructions 
in order that adequate quantities were available for further studies.  
 
2.2.5 cDNA synthesis  
The cDNA was synthesized from mRNA using Superscript II Reverse Transcriptase 
kit (includes 5x First-Strand buffer, 0.1 M DTT and Superscript II reverse 
transcriptase). 1 µl of total RNA (1 ng-5 ug) was added with 1 µl of random primer 
(50-250 ng) and 10 µl of in-house Diethylpyrocarbonate (DEPC) treated water, 
incubated at 70ºC for 10 minutes to denature the secondary structure of RNA and 
chilled on ice. The denatured RNA was mixed with 4 µl of 5x First-Strand buffer, 2 µl 
of 0.1 M DTT 1 µl of 10 mM dNTP and 1 µl of Superscript II reverse transcriptase, 
and incubated at 25ºC for 20 minutes and 42ºC for 8 hours. Reverse transcription of 
RNA from CTC was performed using the Superscript III enzyme with the same 
mixture of the other reagents as described above. The mixture was heated at 42ºC for 
50 minutes. The reaction was then inactivated by heating at 70ºC for 15 minutes. 
 
2.2.6 RT-PCR 
All the primers were ordered from Sigma-Aldrich. The PCR mixture for one reaction 
was prepared as detailed in Table 2.3.  
 
ß-actin was used to control the quality of synthesized cDNA with the forward primer 
5’-GATGAGATTGGCATGGCTTT-3’ and reverse primer 5’-
CACCTTCACCGTTCCAGTTT-3’. The PCR amplification started with 94°C for 1 
minute, followed with 35 cycles of 95°C for 30 seconds, 62°C for 30 seconds and 
72°C for 1 minute, and completed by further extention at 72°C for 1 minute. The PCR 
product is 233 bp.   
 
PCR primers used for each fusion/putative fusion transcript are listed in Table 2.4.  
The primer pair for TMPRSS2:ERG is the same as previous reported by Tomlins et al 
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(40). MAMDC1:SLC25A21 primers were designed using PrimerSelect function in 
DNAStar. The amplification was started with an initial denaturation of 94°C for 5 
minutes, followed by 35 cycles of 94°C for 30 seconds, 65°C for 45 seconds for 
TMPRSS2:ERG and 55°C for 1 minute for MAMDC1:SLC25A21, and 72°C for 1 
minute, and completed by a final extension step of 72°C for 10 minutes. 
 
Table 2.3 PCR reaction mixture preparation. 
Components Volume (µl) 
10X PCR buffer 5 
AmpliTaq® DNA polymerase, LD (5 U/µl) 0.4 
10 µM dNTP 1 
10 µM Forward primer 1 
Reverse primer 1 
Water  40.6 
cDNA 1 
Total   50 
 
 
Table 2.4 Oligonucleotide primers used for RT-PCR. 
Gene  Exon  Sequence 5’ to 3’ 
TMPRSS2 (forward 
primer) 
1 CAGGAGGCGGAGGCGGA 
ERG (reverse primer) 6 GGCGTTGTAGCTGGGGGTGAG 
1 ATGGATTTACTGTACGGTCTCG 
3 GGGGTCTCCAGCGATAAAGTC 
6 CAATAAAACAGCATCACCGTCAA 
MAMCD1 
(forward primer) 
9 GCTGGAGCTGGGAGATG 
4 TGCTCTTTTTGGGGTTTCAG 
6 AGGGTTAACTACAATGGCTTCT 
8 CCACCTGGTCCAAGTCTCATAAT 
10 CTCTTGAAGCCATGAATAGGT 
SLC25A21 
 (reverse primer) 
3 CTGGCGCGAAATCTCAATGCT 
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2.2.7 MCC and inverse PCR 
 
2.2.7.1 MCC 
MCC was used to map the MAMDC1:SLC25A21 fusion gene. Two rounds of MCC 
mappings were used to define the breakpoint. Eight sets of primers were designed for 
the first round of semi-nested PCR (36,277,603-36,240,748) and based on the first 
round results, four sets of primers were designed for the second round of semi-nested 
PCR (Table 2.5). Each set includes three primers: extend forward (EF), internal 
forward (IF) and common reverse (CR) primers. DNA from DU145 was diluted to 
less than 0.09 pg/µl to be used as a template.  
 
For confirmation of the deletion associated with the TMPRSS2:ERG fusion gene, two 
sets of primers were designed for the semi-nested PCR (Table 2.6). DNA samples 
were diluted to less than 0.09 pg/µl to be used as tempaltes.  
 
Table 2.5 The MCC primers for breakpoint of SLC25A21. 
Marker  Primer  Primer sequence (5’-3’) Chromosome 14 position 
1st round MCC mapping 
EF GACTCTTTCTTCTAGTTGG 36,277,548-36,277,602 
IF CCATTCATCCAGCAAGTAG 36,277,466-36,277,484 
1 
CR AGCCTACAGCTTACCAGG 36,277,356-36,277,373 
EF AACCACATAACTGTAGAGG 36,272,869-36,272,887 
IF CATAGCGACTCTGACAGG 36,272,726-36,272,743 
2 
CR TCTTTCAGGAGTACTGCG 36,272,613-36,272,630 
EF AATTGGCAATGTACTCCAG 36,267,715-36,267,733 
IF CCTGTTAGGAAACCTAATAG 36,267,562-36,267,581 
3 
CR TCACTGCTCCTCTCTAGG 36,267,469-36,267,486 
EF GAAGCTTGTCTTGAAGCAG 36,262,859-36,262,877 
IF TGGGACAGAGCATCAAGG 36,262,763-36,262,780 
4 
CR ATTAGCAGCTCTTACTTGG 36,262,644-36,262,662 
EF GAGTCGTAACCCATGTGG 36,256,575-36,256,592 
IF GGCTATTGAATAGCAATTTG 36,256,433-36,256,452 
5 
CR GCACCCTCCATACCTAAG 36,256,315-36,256,332 
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EF GAACCTGTGTTAGTCAGG 36,252,024-36,252,041 
IF TTACTCAGCACTTCCAGG 36,251,901-36,251,918 
6 
CR TTTCTGTTTGACAACATGAG 36,251,774-36,251,793 
EF ATGAGCAACCATGCCTGG 36,246,801-36,246,818 
IF GTTGCACCACTGAAGAATG 36,246,601-36,246,619 
7 
CR TTGGAGGCTAAAGCTTGG 36,246,719-36,246,735 
EF GGAACTAAATGGACATGGG 36,240,981-36,240,999 
IF TCAGTGTGCTCCCTCTGG 36,240,864-36,240,881 
8 
CR GCAGGATATTTCTGTTGTAG 36,240,749-36,240,768 
2nd round MCC mapping 
EF TCAGTGTGTGCCTCATGG 36,251,323-36,251,340 
IF AGAGATATCTTTTGTACAGTG 36,251,241-36,251,261 
1 
CR TGCTAGAATCCAGTCTGG 36,251,114-36,251,131 
EF TATAGGCTGGGTGCAGTG 36,249,672-36,249,689 
IF CTGGGCAACACAATGGG 36,249,579-36,249,595 
2 
CR CAATCATAGCTCACTGCAG 36,249,448-36,249,466 
EF CAGCTGAATCTACACCATG 36,248,639-36,248,657 
IF GTCTGAAATCCTTGATTGG 36,248,507-36,248,525 
3 
CR TGTCATCCAGAACCACAG 36,248,388-36,248,405 
EF GTTCAAGACCAGCCTGG 36,247,600-36,247,616 
IF TGCTTGAGCCTGGAAGG 36,247,481-36,247,497 
4 
CR GCTGGTTGACATTTCACTG 36,247,345-36,247,363 
 
AmpliTaq Gold DNA polymerase and PCR buffer was used for MCC. Each semi-
nested PCR was a composite of two phases of PCR reactions. The 1st phase semi-
nested PCR contained 1 X PCR buffer, 2 mM MgCl2, 200 µM each dNTP, 0.15 µM 
of each oligo external forward (EF) and common reverse (CR) primer (including all 
eight sets), 0.1 U/µl AmpliTaq Gold DNA polymerase, about 0.09 pg of genomic 
DNA and water to 10 µl of final volume. The PCR reaction was set in a 96-well plate, 
in which 88 wells had this PCR mixture and 8 wells had the mixture without DNA 
template as negative controls. The amplification for SLC25A21 was started with 94ºC 
for 2 minutes, followed by 35 cycles of 94ºC for 30 seconds, 52ºC for 30 seconds and 
72ºC for 1 minute, and then 72ºC for 7 minutes. The amplification for TMPRSS2:ERG 
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was started with 95ºC for 5 minutes, followed by 35 cycles of 95ºC for 30 seconds, 
65ºC for 45 seconds and 72ºC for 1 minute, and then 72ºC for 10 minutes. 
 
Table 2.6 The MCC primers for TMPRSS2:ERG. 
Marker  Primer Primer sequence (5’-3’) Chromosome 21 
position 
EF TCACTGCCCTAAAAACCCTC 38,759,761-38,759,780 
CR GTGCCAATCAAGTTCCCCAT 38,759,967-38,759,986 
ERG(+) 
IF TCAGTGCTCCACCTGTTCA 38,759,779-38,759,797 
EF GCAGCCTTAAAACCATTCAAC 39,500,573-39,500,592 
CR CTGTCACCCACTTCTTCTGT 39,500,796-39,500,815 
ERG(-) 
IF GGGGTTTGTACATACAGATG 39,500,626-39,500,646 
 
PCR products from the first phase were diluted to 200 µl with water. The PCR 
mixture for 2nd phase semi-nested amplification contained 1 X PCR buffer, 1.2 mM 
MgCl2, 200 µM each dNTP, 1 µM of the relevant IF and CR primers and 0.1 U/µl 
AmpliTaq Gold DNA polymerase. 2 µl of PCR product from 1st round was used as 
DNA template and the final volume was 10 µl. The same PCR program as before was 
used for the 2nd round PCR amplification. PCR products were checked on a 1.5% 
agarose gel. The number of PCRs with specific PCR products from each primer pair 
was accounted to find out the number difference of PCR products from these two 
primer pairs.  
 
2.2.7.2 Inverse PCR  
After the breakpoint region in SCL25A21 was confirmed by MCC, the inverse PCR 
was applied to obtain the fusion fragment (249). In brief, PCR product from the 2nd 
MCC mapping PCR was digested by ApaLI and EcoRI, and ligated by T4 ligase. A 
semi-nested PCR was applied to amplify the fusion sequence (EF: 
GTTGCACCACTGAAGAATG; IF: ATGTGCCATGTGGCTCAG; CR: 
GAAAGCCAGGCATGGTTG) using Green GoTaq® Flexi DNA Polymerase 
(includes Green GoTaq® Flexi DNA Polymerase and 1x green GoTaq® Flexi buffer). 
The PCR reaction contained 1x green GoTaq® Flexi buffer, 4 mM MgCl2, 0.2 mM 
each dNTP, 0.2 µM each forward and reverse primer, 1.25 U GoTaq® DNA 
Polymerase, 1µg DNA template, and water was added to a final volume of 50 µl. The 
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DNA template was denatured at 95ºC for 2 minutes, followed by 35 cycles of 95ºC 
for 30 seconds, 56ºC for 1 minute, 72ºC for 1 minute, and then 72ºC for 5 minutes. 
After purification, PCR products were sent to Eurofins MWG Operon (Ebersberg, 
Germany) for sequencing. 
 
2.2.8 Microsatellite analysis 
In this study, microsatellite analysis was used to check CAG repeat polymorphism of 
AR in prostate cancers and MIN using BAT-26 in four cell lines, CH1, SK-UT-1B, 
A204 and CAL51. 
 
2.2.8.1 CAG repeat polymorphism in AR  
The HotStarTaq DNA polymerase kit (includes 10x PCR buffer, Q solution and 
HotStarTaq DNA polymerase) was used to amplify the AR CAG repeat region. The 
forward primer 5'-5-carboxyfluorescein(FAM)-ACCCAGAGGCCGCGAGCGCAG-
3’ and reverse primer 5’-TTGCTGTTCCTCATCCAGGA-3’ previously reported by 
Sircar et al. were designed to amplify the 5’ upstream CAG repeat region of AR (250). 
The amplification was started with 50 ng of genomic DNA. The PCR mixture was 
described in Table 2.7. The amplification was started with an initial denaturation of 
95°C for 15 minutes, followed by 40 cycles of 95°C for 30 seconds, 58°C 45 seconds, 
and 72°C for 30 seconds, and completed by a final extension step at 72°C for 5 
minutes. PCR products were checked on a 1.2% agarose gel. The PCR products were 
passed to the Genome Centre, Charterhouse Square, Queen Mary University of 
London, to check the length and intensity using the ABI Prism® 3730xl DNA 
Sequencer. 
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Table 2.7 PCR mixture preparation for CAG repeat polymorphism in AR.  
Components Volume (µl) 
10x PCR buffer 5 
Q solution 10 
10 mM dNTP 1.875 
10 µM Forward primer 1.25 
10 µM Reverse primer 1.25 
HotStarTaq DNA polymerase (5 U/µl) 0.75 
Water  28.875 
DNA 1 
Total  50 
 
2.2.8.2 BAT-26 instability 
The microsatellite marker, BAT-26, was used to check the MIN of all cell lines. The 
primers used were 5’-5-FMA-TGACTACTTTTGACTTCAGC-3’ and 5’-
AACCATTCAACATTTTTAACCC-3’. The PCR mixture with 50 µl final volume 
consisted of 1X PCR buffer, 0.4 U/µl Taq enzyme, 0.2 mM of each dNTP, 0.2 µM of 
each primer and 30 ng of genomic DNA. The amplification was started with an initial 
denaturation of 95°C for 5 minutes, followed by 30 cycles of 95°C for 30 seconds, 
50°C for 1 minute, and 72°C for 1 minute, and completed by a final extension step of 
72°C for 10 minutes (251). PCR products were separated using 6% denaturing 
polyacrylamide gel and detected using the ABI Prism® 377 DNA Sequencer. 
 
2.2.9 DNA sequencing  
 
2.2.9.1 The cloning of PCR product  
PCR products were cloned into PCR 2.1-TOPO vector using TOPO TA cloning kit 
(includes salt solution, 2.1-TOPO vector, SOC medium and E. coli). 4 µl of fresh 
PCR product was mixed with 1 µl of salt solution and 1 µl of 2.1-TOPO vector 
containing M1 forward and reverse primer sites, and the mixture was incubated at 
room temperature for 5 minutes. 2 µl of this mixture was incubated with 1 vial of E. 
coli (defrosted on ice) on ice for 30 minutes, followed by heat shock treatment at 
42°C for 30 seconds, and then cooled down on ice for 2 minutes. 250 µl of SOC 
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medium was added to the vector, and incubated at 37°C for 30 minutes with constant 
shaking. 70 µl of medium containing vectors was added into LB agar plate with 25 
mg/ml kanamycin and 0.1% X-gal, and incubated at 37°C overnight. Single white 
clones were selected and directly lysed in PCR mixture (1 X PCR buffer, 0.04 U/µl 
AmpliTaq enzyme, 0.2 mM dNTP, 0.2 mM M13 forward primer, 0.2 mM M13 
reverse primer, 1 µl DNA template, adding water to 50 µl). PCR amplification was 
initiated with 94°C for 5 minutes, followed by 35 cycles of 94°C for 45 seconds, 58°C 
for 45 seconds and 72°C for 45 seconds, and finished with final extension at 72°C for 
10 minutes.  
 
2.2.9.2 PCR product purification  
PCR products were purified using QIAquick PCR Purification Kit (includes PB 
buffer, PE buffer and column). The PCR product was mixed with 5 volumes of PB 
buffer, added into column and spun at 13000 rpm for 1 minute. The flow-through was 
discarded. 750 µl of PE was added into the column and spun at 13000 rpm for 1 
minute. The flow-through was again discarded, after which the column was placed in 
a clean 1.5 ml centrifuge tube. 30 µl of water was added to the column and left for 1 
minute. The column was then centrifuged at 13000 rpm for 1 minute and the flow-
through was collected. 
 
2.2.9.3 DNA labelling and sequencing 
Purified PCR products were labelled by fluorescence before sequencing using the 
Terminator Reaction Kit (includes 5x BDT buffer and BDT) (Table 2.8). 
 
Table 2.8 DNA labelling mixture preparation. 
Components Volume (µl) 
5x BDT buffer 3.7 
BDT 0.5 
Forward or reverse primer (3.3 µM)* 1 
DNA (5-10 ng) 1 
Water  13.8 
Total 20 
*: Each reaction contains either forward or reverse primer. 
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The labelling was started with 96°C for 1 minute, and then 25 cycles of 96°C for 30 
seconds, 50°C for 15 seconds and 60°C for 4 minutes. DNA was precipitated by 
adding 2 µl of 3M NaAc (pH5.2), 2 µl of EDTA (125 mM) and 50 µl 100% ethanol to 
the mixture. After incubating at room temperature for 30 minutes, the sample was 
spun at 14000 rpm for 20 minutes at room temperature. The supernatant was 
discarded and the precipitate was washed in 1 ml of 70% ethanol, and spun at 14000 
rpm for 15 minutes at room temperature. Then the supernatant was decanted off and 
the sample was air dried. The samples were sequenced at CR-UK London Institute, 
Lincoln's Inn Fields or the Genome Centre, Queen Mary, University of London, John 
Vane Science Building, Charterhouse Square using the ABI Prism® 3700 DNA 
Analyzer. The sequencing results were analysed by 4peaks software (Alexander 
Griekspoor and Tom Groothuis, Netherland). 
 
2.2.10 High density SNP array analysis 
In this study, the Affymetrix Human Mapping 500K Assay set and Genome-Wide 
Human SNP array 6.0 were used to analyse genomic copy number alterations for 
samples. The Human Mapping 500K Assay set includes Nsp and Sty arrays. Genome-
Wide Human SNP array 6.0 contains the probes for both Nsp and Sty. The methods 
used for 500K and array 6.0 chips are similar. The SNP array assay is a multi-step 
assay, including genomic DNA digestion, ligation, dilution, PCR, fragmentation, 
labelling, hybridisation, washing, staining, scanning and SNP data analysis. Genome-
Wide Human SNP Nsp/Sty Assay Kit 5.0/6.0 was used for SNP array DNA 
preparation and hybridisation. 
 
2.2.10.1 Restriction enzyme digestion  
Genomic DNA was diluted to 50 ng/µl using reduced TE buffer (10 mM Tris-HCl, 
0.1 mM EDTA, pH 8.0). Digestion master mix (Table 2.9, adapted from Affymetrix’s 
protocol) was prepared on ice in pre-PCR clean hood.  
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Table 2.9 Restriction digestion mix preparation. 
Components  Volume of one sample (µl) 
NE buffer 2 (10x) (for NspI)/NE buffer 3 (10x)  (for StyI) 2 
BSA (10x (1 mg/ml))  2 
NspI (10 U/µl) or StyI (10 U/µl)  1 
H2O 9.75 
Total  14.75 
 
5 µl of genomic DNA was added to a digestion master mix in a PCR thin-wall tube. 
The tube was placed in a PCR machine running the following program: 37ºC for 2 
hours, 65ºC for 20 minutes and 4ºC forever. 
 
2.2.10.2 Ligation  
Ligation master mix (Table 2.10, adapted from Affymetrix’s protocol) was prepared 
on ice in pre-PCR clean hood.  
 
Table 2.10 Ligation mix preparation.  
Components  Volume for one sample (µl) 
Adaptor Nsp I or Sty I * 0.75  
T4 DNA Ligase (400 U/µl) 2 
T4 DNA Ligase buffer (10x) 2.5 
Total  5.25 
*: The reagent was included in Genome-Wide Human SNP Nsp/Sty Assay Kit 
5.0/6.0. 
 
The ligation master mix was added to diggested DNA to obtain a 25 µl final volume. 
The sample was then processed on the ligation program (16ºC for 3 hours, 70ºC for 
20 minutes and 4ºC for ever). The ligated DNA sample was diluted with 75 µl water 
to 100 µl final volume for PCR.  
 
2.2.10.3 PCR 
The PCR master mix (Table 2.11, adapted from Affymetrix’s protocol) was prepared 
on ice in a pre-PCR clean hood.  
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Table 2.11 PCR master mix preparation. 
Components  1 PCR (µl) 
TITANIUMTM Taq PCR buffer (10x)  10 
G-C melt (5 M) 20 
PCR Primer 002 (100 µM) * 4.5 
dNTP (2.5 mM each) 14 
TITANIUMTM Taq DNA Polymerase (50x) 2 
H2O 39.5 
Total 90 
*: The reagent was included in Genome-Wide Human SNP Nsp/Sty Assay Kit 5.0/6.0. 
 
The Human Mapping 500K Assay set needs 3 PCR reactions for each StyI or NspI 
digested sample. The Genome-Wide Human SNP array 6.0 requires 3 PCR reactions 
for each StyI digested sample and 4 PCR reactions for each NspI digested sample. 
Each reaction contained 10 µl diluted ligated DNA sample and 90 µl PCR master 
mix. One negative control PCR reaction, consisting of 10 µl water and 90 µl PCR 
master mix, was also prepared. The PCR program was set as: 94ºC for 3 minutes to 
denature DNA, then 30 cycles of 94ºC for 30 seconds, 60ºC for 30 seconds and 68ºC 
for 15 seconds. The final additional extension was at 68ºC for 7 minutes. Products 
were left in the machine at 4ºC before further processing. 
 
3 µl of PCR product mixed with 3 µl loading buffer was run on 2% agarose gel at 120 
V for 30 minutes to confirm the average size of PCR product, which should be 
between 200 and 1100 bp.  
 
2.2.10.4 PCR product purification 
Human Mapping 500K Assay set: 32 µl of 0.1 M EDTA and 100 µl of sterile 
ultrapure water were added to the PCR product (300 µl PCR product from 3 PCR 
reactions). The mixture was loaded onto an Amicon Ultrapure MC column, and spun 
at 2000 g for 50 minutes at room temperature. After centrifugation, there would be 
approximately 20 µl of liquid left in the column. 250 µl of sterile ultrapure water was 
added into the column and spun at 2000 g for 30 minutes at room temperature. There 
is approximately 5 µl of liquid left in the column. 45 µl of RB buffer was added to the 
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column and left for one minute. The eluate was transferred into a clean tube. The 
quantity and quality of the sample were checked using a Nanodrop 
spectrophotometer. 
 
Genome-Wide Human SNP array 6.0: 7 PCR reaction products for each sample were 
transferred to the pooling plate and 1 ml of magnetic beads was added. The 
suspension was mixed by pipetting at least 10 times and incubated at room 
temperature for 10 minutes. The mixture was transferred to a filter plate. Unused 
wells in the filter plate were covered by MicroAmp Clear Adhesive Film to ensure 
proper vacuum pressure. The filter plate was placed under vacuum using the 
LABOPORT® Mini Diaphragm Vacuum Pump under pressure between 20 and 24 
inHg for 60-90 minutes. If the filters were not dry, the filter plate should be placed 
back to vacuum pump to resume filtering until the filters were dry. 1.8 ml of freshly 
prepared 75% ethanol was added to each well and the filter plate was placed back on 
the vacuum pump under pressure between 20 and 24 inHg for 10-20 minutes or 
longer until the filters dried. When all filters were completely dry, the filter plate was 
removed from the vacuum pump and tapped several times on towels to blot off any 
excess ethanol from the bottom of the filter well. The filter plate was returned back to 
the vacuum pump under the same pressure for an additional 10 minutes, and then 
removed and tapped on towels again to remove any excess ethanol from the bottom of 
the filter well. The 96 wells plate was attached to the bottom of filter plate using lab 
tape. 55 µl of EB buffer (10mM Tris-Cl, pH 8.5) was added into well. The plates were 
placed on a benchtop MixMate® mixer and shaked at 1150 rpm for 30 minutes to mix 
the beads and EB buffer. The plates were then placed on the vacuum pump under 
pressure between 20 and 24 inHg for 15 to 30 minutes. The plates were centrifuged at 
1500 rpm for 5 minutes using ALLEGRATM X-12R centrifuge and then placed back 
on the vacuum pump under the same pressure until the filter were completely dry. The 
eluate was collected into the 96-well plate. The quantity and quality of the sample 
were checked using a Nanodrop spectrophotometer.  
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2.2.10.5 Fragmentation  
For both 500K and array 6.0, 5 µl of 10X Fragmentation Buffer was added to 45 µl of 
purified PCR product. Fragmentation Reagent was diluted into 0.05 units/µl using 
10x Fragmentation Buffer and Molecular Biology grade Water (Table 2.12, adapted 
from Affymetrix’s protocol). 
 
Table 2.12 Fragmentation mix preparation. 
Components  Volume (µl) 
10x Fragmentation Buffer* 12 
Fragmentation Reagent (3 U/µl)* 1 
H2O 106  
Total  120  
*: The reagents were included in Genome-Wide Human SNP Nsp/Sty Assay Kit 5.0/6.0. 
 
50 µl of sample mixed with Fragmentation Buffer was added by 5 µl of diluted 
Fragmentation Reagent. The mixture was processed using the following program: 
37ºC for 35 minutes, 95ºC for 15 minutes and 4ºC forever. 
 
When the reaction finished, 4 µl of fragmented PCR product was run on 2% agarose 
gel at 120 V for 30 minutes. The average size of the fragment should be lower than 
180 bp.  
 
If the size was still too big, the fragmented PCR product was refragmentated by 
adding another 5 µl of diluted Fragmentation Reagent, and incubated at 37ºC for 15 
minutes, 95ºC for 15 minutes and hold at 4ºC. The fragmented sample was run on the 
gel again. Once the correct size of DNA was obtained, it underwent a labelling step as 
described below. 
 
2.2.10.6 Labelling 
Labelling mix was prepared as described in Table 2.13 (adapted from Affymetrix’s 
protocol). 19.5 µl of labelling mix was added to all fragmented DNA, and then run 
using the labelling program: 37ºC for 4 hours, 95ºC for 15 minutes and hold at 4ºC. 
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Table 2.13 Labelling mix preparation. 
Components  Volume (µl) 
5X TdT Buffer* 14 
TdT (30 U/µl)* 3.5 
Genechip® DNA Labelling Reagent (30 mM)* 2 
Total  19.5 
*: The reagents were included in Genome-Wide Human SNP Nsp/Sty Assay Kit 5.0/6.0. 
 
2.2.10.7 Hybridisation 
Hybridisation Cocktail was prepared as shown in Table 2.14 (adapted from 
Affymetrix’s protocol). The hybridisation cocktail was given to the array platform 
controller, Tracy Chaplin, to perform the following procedures. The hybridisation mix 
was incubated at 100ºC for 10 minutes to denature DNA, and cooled down on ice 
immediately. The sample was briefly centrifuged to collect any condensate. After 
being left at 49ºC for 1 minute, 200 µl of hybridisation cocktail was injected onto a 
SNP array and incubated at 49ºC for 16 to 18 hours in a rotating GeneChip® 
hybridisation oven 640 at 60 rpm. 
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Table 2.14 Hybridisation Cocktail preparation. 
Components  Volume (µl) 
MES (12X; 1.22 M)* 12 
DMSO (100%) 13 
Denhardt’s Solution (50X) 13 
EDTA (0.5 M) 3 
Herring sperm DNA (HSDNA) (10 mg/ml) 3 
Human Cot-1 DNA® (1 mg/ml) 3 
Tween-20 (3%) 1 
Tetramethylammonium chloride (TMACL) (5 M) 140 
OCR,100** 2 
Labelled DNA 70 
Total  260 
*: 1000 ml of 12xMES Buffer: 70.4 g of MES hydrate, 193.3 g of MES sodium salt, 800 ml 
of Molecular Biology Grade water and filtered through 0.2 µM filter. PH should be between 
6.5 and 6.7.  
**: The reagent was included in Genome-Wide Human SNP Nsp/Sty Assay Kit 5.0/6.0. 
 
2.2.10.8 Washing and Staining 
After 16 hours hybridisation, unhybridised probes were removed from the chip, and 
then washed and stained following the Fluidics Protocol (Table 2.15, adapted from 
Affymetrix’s protocol), named Mapping 500Kv2_450, using GeneChip® Fluidics 
Station 450. 
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Table 2.15 Washing and staining process. 
Post Hyb Wash 6 cycles of 5 mixes/cycle with Wash Buffer Aa at 25ºC 
Post Hyb Wash 6 cycles of 5 mixes/cycle with Wash Buffer Bb at 45ºC 
Stain Stain the probe array for 10 minutes in Streptavidin Phycoerythrin 
(SAPE) at 25ºC 
Post Stain Wash 6 cycles of 5 mixes/cycle with Wash Buffer A at 25ºC 
2nd Stain Stain the probe array for 10 minutes in antibody solutionc,d at 
25ºC 
3rd Stain Stain the probe array for 10 minutes in SAPE solutione at 25ºC 
Final Wash 10 cycles of 6 mixes/cycle with Wash Buffer A at 30ºC. The 
holding temperature is 25ºC 
Filling Array Fill the array with Array Holding Bufferf. 
a: Wash Buffer A: 300 ml of 20xsaline-sodium-phosphate-EDTA (SSPE), 1 ml of 10% Tween 
20, 699 ml of water, and filtered through a 0.2 µM filter. 
b: Wash Buffer B: 30 ml of 20xSSPE, 1 ml of 10%Tween 20, 969 ml of water, and filtered 
through a 0.2 µM filter. 
c: Stain Buffer: 666.7 µl of water, 300 µl of 20x SSPE, 3.3 µl of 3% Tween 20, 20 µl of 50x 
Denhardt’s.  
d: Antibody stain solution: 5 ml of 0.5 mg/ml biotinylated antibody and 495 µl of Stain 
Buffer. 
e: SAPE solution: 5 µl of 1 mg/ml SAPE and 495 µl of Stain Buffer. 
f: Array Holding Buffer: 8.3 ml of 12xMES Stock Buffer, 18.5 ml of 5M NaCl, 0.1 ml of 10% 
Tween 20 and 73.1 ml of water. 
 
2.2.10.9 Scanning  
After post-hybridisation washing, the array chip was scanned by Affymetirx Scanner 
7G and controlled by Affymetrix GeneChip Operating Software 1.4.  
 
2.2.10.10 SNP array data analysis 
Signal intensity data from SNP arrays were analysed using Partek Genomics Suite 
(V6.5) (Partek Incorporated, St. Louis, USA) and in-house GOLF (V4.1) software 
(43, 252). The signal intensity ratio between test and normal samples was plotted for 
DNA copy-number alterations. Ensembl Genome Browser Build 36.2 was applied to 
define the genomic regions. For paired samples, tumour data were compared to case-
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matched normal controls. Unpaired Chinese tumour samples were analysed against 
eight normal samples that were representative of the majority germline copy number 
variations. Cell lines and unpaired UK clinical samples were analysed against the 
average signal density of seven normal lymphocyte samples generated from 
HAPMAP. Within Partek Genomics Suite, the copy-number workflow was used with 
minimum 25 probes, p value 0.00001 and signal to noise 0.7. With GOLF, 
chromosomal gain/loss events were considered if the signal intensity ratio of the mean 
of 20 contiguous probes was significantly outside 0±0.4 log2 ratio.  
 
The commercial software, Partek can rapidly analyse a large number of SNP array 
results. The user can set different parameters to modify the result. For example, a 
smaller p value and a longer continuous SNP number provide the regions with more 
significant copy number changes. Partek applies the parameters for all the 
chromosomes to identify the regions with copy number changes and it also provides a 
visualisation tool to generate the figure for copy number changes. Although the copy 
number changes can be adjusted by setting the different parameters, the copy number 
change regions cannot be selected manually. If the ratio change is not big enough, 
such as in cells with multi copies of chromosomes, Partek may fail to identify the 
regions with single copy additon or loss, or pick the regions caused by noise. GOLF 
can avoid this problem. GOLF does not require any parameters to filter SNP data. 
Regions with copy number alterations can be selected from the original SNP intensiy 
plot for copy number variation manually. Although this software is more flexible and 
less error prone, it takes longer time for analysis to be completed manually. This may 
also bring in individual user variations. In this study, both software programs were 
used to analyse SNP array data. Most of the alterations analysed by GOLF and Partek 
were similar. Regions considered positive by only one software (<5%) were subtle 
changes and were excluded from the final results. 
 
2.2.11 Exon array 
Amplified and biotinylated DNA for use with the Exon Arrays was prepared using the 
Genechip Whole Transcript Sense Target Labelling Assay according to 
manufacturer’s instructions (Affymetrix). First, 28S and 18S rRNA were removed 
from total RNA (2 µg) using the RiboMinus Human/ Mouse Transcriptome Isolation 
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kit. After cleanup of the sample using the Affymetrix Genechip IVT cRNA Cleanup 
kit, double-stranded cDNA was synthesized with T7 promoter sequence-tagged 
random hexamers. Using the double-stranded cDNA as a template, an in vitro 
transcription reaction was performed to generate antisense cRNA using T7 RNA 
polymerase. After cleanup 10 µg cRNA was reverse transcribed again into sense 
single-stranded DNA. Following hydrolysation of residual cRNA, fragmented 5.5 µg 
of single stranded DNA was fragmented, labelled with biotin and then passed onto 
Mrs Tracy Chaplin for hybridisation of 16 hours at 45°C in the GeneChip 
hybridisation oven 640. Following hybridisation and post hybridisation washes, the 
array chip was scanned using the Affymetrix GeneChip Scanner 3000 7G. Exon 
expression signals were analysed using the Affymetrix Exon Array Computational 
Tool (ExACT) software package. Exon array data was normalised and graphic files 
was generated using the Integrated Genome Browser software program, based on the 
NCBI human genome assembly v35 (May 2004). Information about exon probe sets 
and gene annotations were obtained from the NetAffx Analysis Center. Potential gene 
truncation events were identified by screening for differential expression of exons 
between the two ends of a gene compared with the control prostate sample. 
Expression changes of at least twofold difference between the cancer sample and the 
normal reference DNA were considered as significantly different. 
 
2.2.12 FISH 
FISH probes (Table 2.16) were labelled and hybridised with prostate cancer cell 
line/CTC slides and/or TMAs. The procedures are different between cell line/CTC 
slides and TMAs.  
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Table 2.16 FISH probes and labelling. 
Fluorophore FISH probes 
Cell line and CTC slide TMA slide 
RP11-476D17 Fluorescein-12-dUTP (Green) Biotine (Red) 
RP11-95I21 Tetramethyl-rhodamine-5-dUTP (Red) DIG (Green) 
Vysis CEP 10  SpectrumGreen (Green) 
Vysis LSI PTEN  SpectrumOrange (Red) 
RP11-79A11 Fluorescein-12-dUTP (Green)  
RP11-98P2 Tetramethyl-rhodamine-5-dUTP (Red)  
RP11-348L18 Fluorescein-12-dUTP (Green)  
RP11-48J22 Fluorescein-12-dUTP (Green)  
RP11-428P16 Fluorescein-12-dUTP (Green)  
RP11-22M5 Tetramethyl-rhodamine-5-dUTP (Red)  
 
2.2.12.1 Cell lines and CTC slides 
 
2.2.12.1.1 Probe labelling 
1 µg of DNA from BAC clones (see sections 2.2.1.2, 2.2.2.1 and 2.2.2.2) was mixed 
with 5 µl of DNase I buffer (Table 2.17), 5 µl of 10XdNTP buffer (Table 2.18), 0.5 
µl of polymerase I, and water to final volume of 50 µl and incubated at 15ºC for 3.5 
hours. The reaction was stopped by adding 3 µl of 0.5 mM EDTA.  
 
Table 2.17 DNAse I buffer preparation. 
Components Volume (µl) 
1 U/µl DNAse I 15 
1 M Tris-HCl (PH7.5) 5 
25 mM Mg(AcO) 20 
0.1 M Beta-mercaptoethanol (BME)  10 
Glycerol 500 
20 µg/µl BSA 5 
Water  220 
Total 1000 
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The labelled probe was purified by passing through Micro-spin G-50 column. Before 
using the column, resin in the column was re-suspended by gentle vortexing. The 
column was placed in a 1.5 ml screw-cap microcentrifuge tube for support and spun at 
750 g for 1 minute, after which the column was washed twice with 200 µl of TE 
buffer at 750 g for 1 minute each. The column was placed in a new 1.5 ml 
microcentrifuge and labelled DNA (maximum volume, 50 µl of probe) was added into 
the centre of the column, followed by spinning at 750 g for 2 minutes. The purified 
sample was collected in the bottom of the support tube.  
 
The probe was then run through 1.2% agarose gel at 120 V for 30 minutes to check 
the size of probes which should be around 400 bp. 20 µl of Cot-1 DNA was then 
mixed with the probe and vacuum dried. Following this, 25 µl of hybridisation buffer 
(Table 2.19) was added to the probe and mixed completely. At least 200 ng of DNA 
was required for each hybridisation.  
 
Table 2.18 10XdNTP buffer preparation. 
Components  Volume (µl) 
10 mM dATP 20 
10 mM dCTP 20 
10 mM dGTP 20 
10 mM dTTP 10 
1 mM Fluoro-dUTP (Fluorescein-12-dUTP for green; 
Tetramethyl-rhodamine-5-dUTP for red) 
100 
1 M MgCl2 50 
1 M BME 100 
1 mg/ml BSA 100 
1 M Tris-HCl (PH 7.5)  500 
Water 80 
Total 1000 
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Table 2.19 Hybridisation buffer preparation. 
Components  Volume (µl) 
20X SSC 100 
dextran sulphate 100 
formamide 500 
Tween 20 10 
Water 290 
Total 1000 
 
2.2.12.1.2 Metaphase slide preparation from cell lines 
Clean slides were treated with 100% acetic acid for 4 hours, following which they 
were washed with water. These slides were then kept in distilled water at 4ºC. 
 
To harvest cells, colcemid at a final concentration at 0.04 µg/ml was added into the 
cultured cells at 80% confluence. The cells were cultured for a further 3 hours and 
then harvested by trypsin digestion. Cells were centrifuged at 700 rpm for 5 minutes 
using ALLEGRATM X-12R centrifuge, and the supernatant discarded. The cells were 
resuspenced in 8 ml of 0.075 mM KCl hypotonic solution and incubated at 37ºC for 
15 minutes (if necessary, incubate longer time). 1 ml of fix solution (methanol: acetic 
acid=3:1) was mixed with the hypotonic solution to prefix cells and then spun at 1000 
rpm for 6 minutes at room temperature. A small pellet could be seen at the bottom of 
the tube. After pouring off the supernatant, 10 ml of fix solution was added to the cell 
pellet, pipetted and incubated at room temperature for 15 minutes. After centrifugal 
spin (1000 rpm for 6 minutes at room temperature) and repeated this fixature process 
once, a 15-20 drops of fixing solution was added if a pellet was visible, or 10 drops or 
less of fixing solution was added if the pellet was not visible. The fix solution and 
cells were mixed completely and two drops of the mixture was placed onto each 
treated slides. The slide was air dried and checked under a microscope for metaphase 
cells. Slide was kept at -20ºC until required.  
 
Before hybridisation, the slide was put on a hot plate at 65ºC for 5 minutes, and 
treated with 70% acetic acid for 10 minutes, shaking vigorously at intervals during the 
incubation. The slide was neutralised by washing in PBS for 5 minutes three times, 
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and then washed with distilled water twice. The slide was dehydrated with a series of 
70%, 95% and 100% ethanol, 3 minutes each, and air dried.  
 
2.2.12.1.3 CTC slide preparation 
CTC cells were dropped onto glass slides and fixed in situ with ethanol. Before 
hybridisation, the CTC slide was pretreated in 70% acetic acid for 10 minutes to 
remove the cytoplasm.  
 
2.2.12.1.4 Hybridisation 
Pre-treated slide was denatured in 70% formamide, 2X SSC at 72ºC for 2 minutes, 
and no more than 2 slides at each time. Immediately after denaturation, the slide was 
dehydrated again in 70%, 95% and 100% ethanol, each for 3 minutes, and air dired.  
In parallel with slide preparation, 10 µl of labelled probes (about 200 ng of each BAC 
DNA) were incubated at 37ºC with shaking for at least 30 minutes and denatured at 
75ºC for at least 5 minutes. Denatured probes were directly applied onto the denatured 
slide for hybridisation. Therefore, time slide and probe preparations to make sure that 
they are ready at the same time. 
 
After the probes were loaded onto the slide, it was carefully covered with a coverslip 
while avoiding trapping air bubbles. After the coverslip was sealed with rubber 
solution, the slide was incubated overnight at 37ºC in a humid box for hybridisation.  
 
2.2.12.1.5 Post-hybridisation wash 
After hybridisation, the rubber seal and coverslip were removed from the slide. The 
slide was then washed in 0.3% Igepal/0.4x SSC at 72ºC for 2 minutes and then in 
0.1% Igepal/2x SSC once at 45ºC and once room temperature, two minutes of each. 
The slide was quickly rinsed and then washed in distilled water for 2 minutes, and 
dehydrated with 70%, 95% and 100% ethanol, 3 minutes for each. When slide was 
dried, added 10 µl of 4,6-diamidino-2-phenylindole dihydrochloride (DAPI) solution 
(0.025% DAPI in antifade solution) and covered with coverslip. The slide was kept at 
4ºC in the dark for 1 hour and then checked under a fluorescence microscopy.  
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2.2.12.1.6 Signal capture and analysis 
The hybridisation signals were observed using a Olympus BX40 fluorescence 
microscope. Images were captured using a cold charge coupled device (CCD) camera 
mounted on the microscope and controlled by MacProbe 4.3 (Applied Imaging, CA, 
USA). DAPI (blue), green and red signals were viewed and captured though 
fluorescence-specific filters under 100X oil objective.  
 
The location of the BAC clone was confirmed by hybridisation on metaphase of 
normal lymphocytes derived from healthy female adult before analysis of the cancer 
cells.  
 
2.2.12.2 TMA slides 
RP11-476D17 and RP11-95I21 were used to check ERG rearrangement and 
commercial Vysis CEP 10 and Vysis LSI PTEN probes were used for PTEN deletion 
detection. There are slightly differences in hybridssation and post-hybridisation wash 
for these two sets of probes.  
 
2.2.12.2.1 TMA slide preparation 
All the tissue used for TMA was embedded in paraffin and checked by a pathologist 
to mark the tumour, PIN and normal tissue areas. Tissue in those areas (diameter is 
0.6 mm or 1 mm in this study) was taken from the FFPE tumour block and inserted 
into a recipient block using Manual Tissue Arrayer (253). Each block contains about 
200 cores. The 5 µm section was cut by Cryotome® E electronic cryostat (Figure 
2.3) from each block and stained by H&E to re-confirm the tumour, PIN and normal 
tissue.  
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Figure 2.3 Cryotome® E electronic cryostat. 
 
2.2.12.2.2 BAC DNA amplification  
DNA from the BAC clone was amplified using the GenomiPhi amplification kit 
(includes sample buffer, reaction buffer and polymerase). BAC DNA was heated to 
55ºC for 5 minutes and spun at 13000 rpm for 10 minutes. 1 µl of BAC DNA (10 ng-
1 µg) was mixed with 9 µl of sample buffer, incubated at 95ºC for 3 minutes and 
cooled on ice for 5 minutes. 1 µl of polymerase and 9 µl of reaction buffer were added 
into the DNA mixture and incubated at 30ºC for 1.5 hours, 65ºC for 10 minutes. The 
amplified product was checked by 1.2% agarose gel at 120V for 30 minutes. 80 µl of 
TE buffer and 100 µl of 1:1 phenol/chloroform were mixed with the amplified 
product, and centrifuged at 13000 rpm for 2 minutes at room temperature to separate 
the two phases. The upper phase containing DNA was transferred into a new tube 
containing 100 µl of chloroform and spun at 13000 rpm for 2 minutes at room 
temperature. The upper phase was transferred into a new tube and mixed with 5 µl of 
4 M NaCl and 250 µl of absolute ethanol and kept in -80ºC for 30 minutes to 
precipitate the DNA. After centrifugation at 13000 rpm for 20 minutes at 4ºC, a DNA 
pellet may be seen at the bottom of the tube. The supernatant was decanted and the 
DNA pellet was washed in 80% ethanol and spun at 13000 rpm at 4ºC for 10 minutes. 
After the supernatant was poured off, DNA pellet was air dried, suspended in 30 µl of 
TE buffer and stored at -20ºC. The concentration was checked by Nanodrop. 
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2.2.12.2.3 Probe labelling  
The BioPrimer® DNA labelling system (includes random primer, 10x dNTP, Klenow 
and stop buffer) was used for probe labelling. 300 ng of amplified BAC DNA was 
mixed with 20 µl of random primer and water to a final volume of 44 µl, incubated at 
95ºC for 5 minutes and kept on ice for 10 minutes. 1 µl of Klenow and 5 µl of 
10XdNTP were added to the sample mixture for a biotinylated probe. 1 µl of Klenow, 
1.75 µl of DIG-11-dUTP and 5 µl of special DIG 10XdNTP (5 µl of 100 mM stock 
GTP, ATP, CTP and 3.25 µl of TTP were diluted with water to a final volume of 500 
µl) were used for a DIG labelled probe.  The mixture was incubated at 37ºC for 3 
hours. The reaction was stopped by adding 3 µl of stop buffer. Then the labelled 
probes were purified by passing through Micro-spin G-50 column (section 
2.2.12.1.1).  
 
The purified labelled probe was mixed with 30 µl of Cot-1 DNA (1 µg/µl), 1 µl of 
salmon sperm (10 µg/µl), 4 µl of 4 M NaCl, 222 µl of absolute ethanol and 
centrifuged at 13000 rpm for 20 minutes. The supernatant was removed and the pellet 
washed with 80% ethanol, followed by spinning at 13000 rpm for 10 minutes, 
removing the supernatant and air drying. 20 µl of water was added to dissolve the 
probe and incubated at 50ºC for 5 minutes. 
 
2.2.12.2.4 TMA slide pre-treatment 
Before hybridisation, TMA slide was treated by SpotLight tissue pre-treatment kit 
(includes pre-treatment buffer and pepsin solution). The TMA slide was incubated in 
three sequential jars of xylene at 55ºC for 7 minutes of each and washed twice in 
absolute ethanol for 3 minutes. The slide was placed on a 98ºC hot plate, after which 
250 µl of absolute ethanol was immediately applied to the slide and covered with a 
coverslip. When the ethanol had evaporated, the slide was washed in water twice for 3 
minutes.  
 
The de-waxed TMA slide was boiled in pre-treatment buffer at 98ºC for 15 minutes 
and washed twice with water for 3 minutes. After removing excess water from the 
slide, it was incubated in pepsin solution at 28ºC for 5 minutes. The pepsin solution 
was added to the slide at 28ºC for 4.5-9 minutes (4.5 minutes for UK TMA slide and 
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9 minutes for Chinese TMA slide). The slide was washed in water twice for 3 
minutes. 
 
2.2.12.2.5 Hybridisation  
RP11-467D17 and RP11-95I21 probes: 1.5 µl each of biotin and DIG probes as 
prepared in section 2.2.12.2.2 were mixed together with 1 µl of concentrated COT-
1/Sperm and 9.6 µl of hybridisation mixture (Table 2.20), and loaded onto the TMA 
slide. Concentrated COT-1/Sperm was prepared by mixing 500 µl of 1 µg/µl COT-1, 
50 µl of 10 µg/µl salmon sperm, 27 µl of 4 M NaCl and 1317 µl of ethanol together. 
The mixture was spun at 13000 rpm for 20 minutes to obtain a pellet. The supernatant 
was removed and pellet was washed with 80% ethanol, spun at 13000 rpm for 10 
minutes and air dried. 50 µl of water was added and the tube was incubated at 55 ºC 
for 15 minutes to resuspend the pellet. 
 
Table 2.20 Hybridisation mixture preparation. 
Components  Volume (µl) 
DI formamide 600 
dextran sulphate 120 
SSC 120 of 20X 
EDTA pH8 0.28 of 500 mM 
Salmon sperm 40 of 10 mg/ml 
Total 1000 
 
Commercial Vysis CEP 10 and Vysis LSI PTEN probes: the mixture of 1 µl of 
commercial probe, 2 µl of water and 7 µl of hybridisation buffer (supplied with 
probe) were added onto the TMA slide.  
 
The slide was carefully covered with a cover slip to avoid trapping air bubbles. After 
being sealed with rubber solution, the slide was denatured at 95ºC for 15 minutes and 
incubated overnight at 37ºC in HYBriteTM hybridisation station. 
 
2.2.12.2.6 Post-hybridisation wash 
RP11-467D17 and RP11-95I21 probes: After the rubber seal and coverslip were 
removed, the slide was quickly washed in 2XSSC at 42ºC for 3 times and washed in 
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50% formamide/2XSSC (25 ml of formamide, 5 ml of 20XSSC and 20 ml of water) 
at 42ºC for 4 minutes twice, 2XSSC at 42ºC for 5 minutes twice, SSCT (100 ml of 20 
XSSC, 1 ml of Igepal and water to final volume of 500 ml) at room temperature for 3 
minutes. The slide was incubated with 200 µl of SSCTM (10 ml of SSCT and 0.5 g of 
skimmed milk powder, prewarmed at 42ºC) at 37ºC for 15 minutes. Meanwhile, 
Streptavidin-Cy3 and anti-DIG-FITC antibody were centrifuged at 13000 rpm for 5 
minutes, and then 1 µl of each antibody was diluted in 200 µl of SSCT. After 
incubation with SSCTM, the slide was washed in SSCT for 3 minutes at room 
temperature. 200 µl of diluted anti-DIG-FITC was added to the slide and incubated at 
37ºC for 10 minutes. Then the slide was washed in SSCT for 2 minutes at room 
temperature for 3 times. 200 µl of diluted Streptavidin-Cy3 was added to the slide and 
incubated at 37ºC for 10 minutes. After the incubation, the slide was washed in SSCT 
for 2 minutes, PBS for 5 minutes twice and 70% ethanol for 20 seconds twice. When 
the slide had air dried, 20 µl of DAPI was added and the slide was covered with a 
coverslip. The slide was kept in the dark for at least an hour at 4ºC until they were 
scanned using Ariol SL-8 System. 
 
Commercial Vysis CEP 10 and Vysis LSI PTEN probes: The cover slip was removed 
in 0.5x SSC at 37ºC. The TMA slide was washed in 0.5XSSC at 37ºC for 5 minutes, 
followed by three PBS washes for 3 minutes at room temperature. When the slide was 
air dried, added 20 µl of DAPI and covered with coverslip. The slide was kept in the 
dark for at least an hour at 4ºC until they were scanned using Ariol SL-8 System. 
 
2.2.12.2.7 FISH signal analysis 
The FISH slide was scanned using a 40X lens on the AriolSL-8 System with seven 
0.5 µm z-stacks. Exposure time was adjusted according to the signal strength. FISH 
results were analysed double-blindly. A minimum of 100 cells with clear 
hybridisation signals were counted per core.   
 
2.2.13 M-FISH 
The metaphase slide was prepared as described in section 2.2.12.1.2. M-FISH was 
carried out as previously described (254) by following the Vysis M-FISH protocol. 
The metaphse slide was incubated with 20 µl of RNase working solution at 37ºC for 
30 minutes with coverslip, and washed twice for 5 minutes each in 2X SSC. The slide 
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was degested with pepsin solution at 37ºC for 5 minutes and washed twice for 5 
minutes in PBS, and then fixed again with formaldehyde fixation solution at room 
temperature for exact 2 minutes, washed twice for 5 minutes each in PBS followed by 
dehydration in 70%, 85% and 100% ethanol for 1 minute each. After air died, the 
metaphase slide was denatured in 70% formamide/2X SSC at 72±1ºC for 1-3 minutes 
and dehydrated in 70%, 85% and 100% ethanol for 1 minute each. The SpectraVysion 
probe was added onto the denatured slide and incubated at 37ºC overnight. After the 
hybridisation, the non-specifically bound probe was washed by 0.4X SSC/0.3% NP-
40 at 72±1ºC for 2 minutes, followed by 2X SSC/0.1% NP-40 wash at room 
temperature for 1 minute. The slide was air dried and mounted with DAPI III 
counterstain. The computer software SpectroVision (Vysis Inc., Downer’g Grove, 
USA) was used to capture and analyse the images. The de novo (non-clonal) 
chromosomal alterations were defined as chromosome changes identified only once at 
a given passage. 
 
2.2.14 IHC  
The Vectastain universal ABC kit (includes hourse serum blocking solution, unversal 
antibody, solution A and solution B) and liquid DBA Concentrated Substrate Pack 
(includes DAB buffer, DAB and DAB substrate) was used for IHC. The slide was 
incubated at 40ºC overnight to melt any excess paraffin covering the tissue. The slide 
was washed in xylene for 5 minutes twice to remove the paraffin and then in absolute 
ethanol for 2 minutes. H2O2/methanol (50 ml of 30% H2O2 and 450 ml of methanol) 
mixture was added twice to the slide and incubated for 5 minutes. The slide was 
washed twice with absolute ethanol for 5 minutes to remove the remaining reagent 
and placed in water. At the same time, 20 ml of Vector antigen unmasking solution 
diluted in 2 liters of distilled water was heated in a pressure cooker. When the 
solution reached the boiling point, the slide was transferred to the pressure cooker and 
heated until a steady stream of steam was produced by the outlet valve for 10 minutes. 
The pressure cooker was cooled down under running water. The slide was removed 
from the pressure cooker washed by running water for additional 5 minutes, and 
placed in phosphate (PB) buffer (pH7.4-7.6) (Table 2.21) until the primary antibody 
was ready. After gently removing excess liquid from the slide, horse serum blocking 
solution (1:50 diluted in phosphate buffer) was incubated on the slide for 20 minutes 
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at room temperature. The blocking solution was removed and the primary antibody 
was added onto the slide to incubate for 40 minutes at room temperature. In this 
study, NCL-PTEN and ERG were the primary antibodies, which were diluted1:150 
and 1:200 respectively in PB buffer with 1% BSA plus azide (Table 2.22). The 
primary antibody was removed and the slide was washed with 0.1% Tween PB buffer 
(1 ml of Tween20 and 1 L of PB buffer). Bridge biotinylated universal antibody was 
diluted 1:200 in PB buffer (1 drop of 2nd antibody was mixed with 2.5 ml of PB 
buffer). The diluted secondary antibody was incubated on the slide for 30 minutes at 
room temperature. Meanwhile, the substrate reagent was prepared by mixing 1 drop 
of solution A, 1 drop of solution B and 2.5 ml of PB buffer and left at room 
temperature for 30 minutes. After 30 minutes incubation, the secondary antibody was 
removed and the slide was washed with 0.1% Tween PB buffer. The third layer 
mixture was added onto the slide and incubated at room temperature for 20 minutes. 
Meanwhile, the DAB mixture was prepared by mixing 2.25 ml of distilled water, 0.25 
ml of DAB buffer, 2 drops of DAB, and 1 drop of DAB substrate and incubated at 
room temperature for 15 minutes. After the incubation, the slide was washed with 
0.1% Tween PB buffer, and then incubated with the activated DAB mixture for 10 
minutes. The slide was washed with running water for 5 minutes, stained in Gill II 
hematoxylin for 5 minutes, and then dipped into acid alcohol (1ml of hydrochloric 
acid and 100 ml of 70% ethanol) 3 times. The slide was rinsed in running water for 5 
minutes, dehydrated in 70%, 90% and absolute ethanol for 2 minutes each, and 
transferred to xylene for 5 minutes twice. The slide was mounted using 20 µl DPX 
mounting medium and covered with a coverslip. 
 
Table 2.21 1X phosphate buffer. 
Reagents  Amount  
Di-sodium hydrogen orthophosphate 72.5 g 
Sodium di-hydrogen orthophosphate 11.5 g 
Distilled water 5 liter 
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Table 2.22 PB with 1% BSA plus azide (pH7.4-7.6). 
Reagents Amount  
PB buffer 200 ml 
BSA 2 g 
Sodium azide 0.2 g 
 
2.2.15 Statistics analysis 
In this study, differences in continuous data were compared using the Student’s t test, 
and differences in categorical data were compared using a Chi-square test. The Kappa 
test was used to analyse the correlation and regression between two groups. All the 
above statistical analyses were performed with SPSS 16.0 for Windows (SPSS, 
Chicago, IL). p values of less than 0.05 were considered statistically significant. 
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CHAPTER III IDENTIFICATION OF GENOME-WIDE 
ALTERATIONS IN PROSTATE CANCER BY SNP 
ARRAY ANALYSIS 
 
3.1 Introduction 
Genome-wide analysis is an efficient method used to identify all the genomic 
alterations in cancer tissues by capturing the overall image and full range of genomic 
changes. Genome-wide studies have been carried out on multiple cancers, including 
lymphoma (255), leukaemia (212, 256), gastric cancer (257), breast cancer (258), 
endometrial cancer (259), ovarian cancer (260, 261), osteosarcoma, and 
hepatocellular carcinoma (262). Many common genomic abnormalities have been 
found and some genomic alterations were shown to be associated with particular 
cancer types. This information can be used to assist diagnosis and treatment 
stratification. From these genome-wide analyses, it has been shown that carcinomas 
have many more genomic alterations compared to haematological malignancies. As 
mentioned in Chapter I, a few powerful genome-wide analysis technologies have 
been developed over the last 50 years, including karyotyping (chromosome binding 
and multi-colour FISH analysis), chromosomal CGH and array technology. With 
technology development, recently SNP array has been widely used in the field of 
cancer research to identify genomic alterations. Comparing with previous 
methodologies, the use of SNP array not only identifies the region with copy number 
changes, but also for copy-neutral AI (a specific type of LOH). The resolution of the 
latest SNP array exceeds that of CGH arrays and, therefore, can provide high-
resolution definition of the regions with gain, loss and LOH. 
 
SNP array was designed for genotype analysis, which includes linkage disequilibrium 
and genome-wide association studies. However, when the signal intensity data of both 
alleles were added up for overall SNP loci signal intensity analysis, SNP array can 
also provide copy number information for both somatic changes and germline status. 
The first paper to describe copy number change detection by SNP array was published 
in 2004 (263), a few years later than its application for LOH study (184). Since then, 
genome-wide genotype and copy number detection have been carried out in many 
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studies. In prostate cancer, common deletions were detected at chromosome 6q, 8p, 
9p, 10q, 13q, 16q and 21q (140, 264-267) and recurrent copy number gains were 
found at chromosomes 1q, 2p, 3q, 7 and 8q (140, 264-267). The LOH regions were 
identified at chromosomes 6p, 8p, 10q, 13, 16 and 21, which were correlated with 
regions of chromosome loss (264, 265, 268). Many important oncogenes and TSGs 
have been found at these regions, such as c-Myc, PTEN, APC, and EIF3S3. Due to 
their ability to provide high-resolution analysis, SNP arrays have also been used to 
define the breakpoints contributing to various TMPRSS2:ERG fusion transcripts (269).  
 112 
3.2 Results 
3.2.1 Demographic information of the samples successfully analysis by 
SNP arrays 
I analysed successfully genome-wide DNA copy number changes in four prostate 
cancer cell lines, PC3, DU145, LNCaP and VCaP, as well as fresh-frozen prostate 
cancer samples from 32 UK and 39 China patients using Affymetrix high-density 
SNP microarrays. The four cell lines and four UK samples (P28, P39, P63 and P127) 
were analysed by the 500K SNP array. Other samples were analysed by SNP array 
6.0. Case-matched adjacent morphologically normal tissues were available for most 
clinical samples, with the exception of four UK (P28, P39, P63 and P127) and six 
China clinical samples (SH7, SH13, SH22, SH31, SH32 and SH39). Good quality 
data were generated from all of the samples with call rates of over 90%. 
 
The clinical information, including patients’ age and Gleason score, was listed in 
Table 3.1 and Table 3.2. There are 25 UK and all 39 Chinese patients with age 
information. The average age at diagnosis of UK and Chinese patients were 64.12 and 
68.3, respectively. Among 30 UK patients with Gleason score, 56.7% (17/30), 26.7% 
(8/30) and 16.7% (5/30) of UK patients have low (<7), medium (=7) and high (>7) 
Gleason score. 7.7% (3/39), 64.1% (25/39) and 28.2% (11/39) of Chinese patients 
were graded with Gleason score <7, =7 and >7 respectively.  
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Table 3.1 Clinical information for UK samples analysed by SNP array. 
Samples  Age  Gleason score 
P9 83 NA 
P28 NA 3+3 
P39 NA NA 
P55 NA 3+3 
P63 NA 4+4 
P68 NA 5+5 
P98 66 4+5 
P107 68 3+3 
P123 64 3+4 
P127 66 3+4 
P130 73 4+4 
WX1 NA 3+2 
WX7 74 3+3 
WX8 63 3+4 
WX9 70 3+4 
WX11 70 3+2 
WX12 68 3+3 
WX21 57 3+3 
WX33 NA 3+3 
WX34 50 3+3 
WX39 67 3+3 
WX47 70 3+4 
WX68 66 3+3 
WX73 67 3+3 
WX76 55 3+4 
WX80 40 3+3 
WX83 60 3+3 
WX85 65 4+4 
WX87 59 3+3 
WX88 52 3+4 
WX92 56 3+3 
WX94 74 3+4 
NA: not available. 
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Table 3.2 Clinical information for Chinese samples analysed by SNP array. 
Samples  Age  Gleason score 
SH1 56 4+3 
SH2 72 3+4 
SH3 65 3+4 
SH4 74 3+4 
SH5 75 3+4 
SH6 75 5+3 
SH7 69 4+3 
SH9 75 4+4 
SH10 63 5+5 
SH11 59 4+3 
SH12 58 4+3 
SH13 75 5+4 
SH14 66 3+4 
SH15 70 3+4 
SH16 69 4+4 
SH17 74 4+3 
SH18 78 5+4 
SH19 65 3+3 
SH20 70 3+4 
SH21 64 5+4 
SH22 75 3+3 
SH23 67 5+3 
SH24 77 4+3 
SH25 60 4+3 
SH26 51 3+3 
SH27 74 5+4 
SH28 75 4+3 
SH29 77 4+3 
SH30 53 3+4 
SH31 75 4+3 
SH32 70 3+4 
SH33 62 3+4 
SH34 66 3+5 
SH35 75 3+4 
SH36 57 4+3 
SH37 65 4+3 
SH38 74 3+4 
SH39 72 4+5 
SH40 67 3+4 
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3.2.2 Demonstration of the high-resolution of SNP array analysis 
As a high-resolution method, SNP array can detect the genomic change around a 
hundred Kb. SNP array identified some small sub-microscopic genomic changes in 
both cell lines and clinical samples, which cannot be detected by other relative low-
resolution array techniques, such as BAC and cDNA arrays (Figure 3.1).  
 
 
        
 
         
 
 
 
 
 
 
 
Figure 3.1 Small regions with copy number changes detected by high-resolution 
SNP array.  
A: Multiple small gains and losses on chromosome 5 in PC3. The arrow indicated the sub-
microscopic chromosome deletion at 5p14.3 in PC3 (111 kb). B: Multiple small gains and 
losses on Chromosome 8 in SH40. The arrow indicated the sub-microscopic chromosome 
amplification at 8p23.2 (263 kb). The SNPs in red, blue and green represent those regions 
statistically with copy number gain, neutral and loss respectively, as visualised in GOLF. 
 
High-resolution SNP array also provided good definition of the boundary for genomic 
copy number gains and losses. For example, using the SNP array, I detected the 
A 
B 
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21q22.2-22.3 deletion with variable breakpoints in different samples (Figure 3.2). 
The range of difference breakpoints at ERG is about 80 kb, while the breakpoints at 
TMPRSS2 are located within only 6 kb genomic region.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Variant breakpoints for TMPRSS2:ERG fusion gene  in prostate 
cancer clinical samples. 
A: Internal deletion between ERG and TMPRSS2 in three clinical samples. B and C: Enlarged 
variant breakpoints for ERG (B) and TMPRSS2 (C) in different clinical samples. The SNPs in 
red, blue and green represent those regions statistically significant for copy number gain, 
neutral and loss, respectively, as visualised in GOLF. Region labelled by read lines are the 
genomic locations of ERG and TMPRSS2 gene. 
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3.2.3 Detection of genomic copy number changes using the SNP array data 
SNP array data were generated from all of the samples with call rates of over 90%. 
SNP array data were analysed using GOLF (version 4.1), a software developed in-
house, and the commercial software, Partek Genomic Suite (version 6.5) for DNA 
copy number changes. Samples with adjacent normal samples were analysed against 
case-matched normal controls. Cell lines and unpaired UK clinical samples were 
analysed against the average signal density of seven normal lymphocyte samples 
generated from HAPMAP. Unpaired Chinese tumor samples were analysed against 
eight normal samples that were representative of the majority germline copy number 
variations 
 
3.2.3.1 Genomic copy number changes in prostate cancer cell lines 
Four prostate cancer cell lines, PC3, DU145, VCaP and LNCaP were analysed by 
500K SNP array. The three prostate cancer cell lines, PC3, DU145 and LNCaP were 
widely used in prostate cancer studies, including genomic studies. LNCaP cells are 
androgen-sensitive, while PC3, DU145 and VCaP cells are hormone-refractory. PC3 
have a high metastatic potential and DU145 cells have a moderate metastatic potential. 
The regions with copy number changes for PC3, DU145, VCaP and LNCaP are 
summarised in Figure 3.3 and Appendix II. Whereas the hormone-refractory PC3, 
DU145 and VCaP cells showed many genomic copy number changes, the androgen-
sensitive LNCaP cells had only a few. The most complex genomic alterations were 
detected in the PC3 cell line, the one with the highest metastatic potential. 
 
3.2.3.2 Genomic copy number changes in UK and Chinese clinical samples 
The regions with copy number changes for all clinical samples are listed in Appendix 
III and Appendix IV. Some samples harboured more genomic alterations than others. 
For example, P98, P130, SH10, SH18 showed genomic changes in almost every 
chromosome, while there was no copy number alteration identified in WX1, WX11, 
SH29 and SH31.  
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Figure 3.3 Genomic copy number changes detected in PC3, DU145, VCaP and 
LNCaP by SNP array analysis. 
The SNPs in red, blue and green represent those regions statistically significant for copy 
number gain, neutral and loss, respectively, as visualised in GOLF. 
 
Many regions were commonly found with copy number changes in these clinical 
samples. The common genomic changes are summarised in Table 3.3. Figure 3.4-3.7 
showed some representative images of some common copy number change regions. 
 
Table 3.3 Summary of common regions with copy number gains or losses. 
Gains  Losses  
7 (21/71, 30%) 5q15-21.3 (23/71, 32%) 
8q (22/71, 31%) 6q14.1-22.1 (40/71, 56%) 
 8p (43/71, 61%) 
 10q23 (15/71, 21%) 
 13q12.3-31.1 (39/71, 55%) 
 16q12.1-24.3 (39/71, 55%) 
 21q22.2-22.3 (21/71, 29.6%) 
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Figure 3.4 The regions with common copy number gain at 8q. 
The SNPs in red, blue and green represent those regions statistically with copy number gain, 
neutral and loss respectively, as visualised in GOLF. 
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Figure 3.5 The regions with common copy number losses at 13q12.3-31.1. 
The SNPs in red, blue and green represent those regions statistically with copy number gain, 
neutral and loss respectively, as visualised in GOLF. 
P130 
W
X
68 
W
X
47 
SH
1 
SH
11 
SH
3 
SH
27 
SH
25 
SH
37 
SH
24 
 121 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 The regions with common copy number losses at 16q12.1-24.3. 
The SNPs in red, blue and green represent those regions statistically with copy number gain, 
neutral and loss respectively, as visualised in GOLF. 
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Figure 3.7 The regions with common copy number losses at 21q22.2-22.3. 
The SNPs in red, blue and green represent those regions statistically with copy number gain, 
neutral and loss respectively, as visualised in GOLF. 
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3.2.4 Recurrent breakpoints analysis 
 
3.2.4.1 Genes at recurrent breakpoints 
Owing to the high resolution of these SNP arrays, the breakpoints can be defined within 
several kb. Together with Prof. Bryan Young, we analysed the breakpoints 
systematically using a specific analysis feature that Prof. Young added to GOLF. 
Generally, if SNP hybridisation signal intensity changed in a running window of 20 
SNPs along the genome of a chromosome, it will be picked up automatically as a break. 
Using this approach, all the breakpoints were searched by GOLF. Many breakpoints 
were recurrently detected in different samples. 38% of breakpoints were located within 
currently known genes. Table 3.4 summarises the genes at recurrent breakpoints found 
in at least 20% of samples.  
 
Some well-known fragile genes were frequently found at the breakpoints in this study, 
such as WWOX and FHIT. The high frequency fusion partners, TMPRSS2 and ERG, 
were also detected at a high frequency using this approach. In order to identify more 
possible breakpoints and associated genes, we set a low criteria/threshold for this 
analysis, which may lead to some false positive results. For examples, breakpoints at 
LRP1B (2q22.1-22.2) and PPP2R2A (8q21.2) were detected in 32% and 25% of my 
prostate cancer samples respectively. After manually checking the SNP array data, I only 
found breakpoints of these two genes each in four samples (Figure 3.8). Overall, the 
frequency of breakpoints occurring at genes identified using manual data analysis was 
much lower than those picked up by automatic GOLF data analysis. I also noticed that 
the auto-analysis can still miss breakpoints, which can be identified by manual analysis. 
For example, tumour cells normally contain the multiple copies of chromosomes. If only 
one copy is lost, the difference of the signal may be strong enough to be detected by 
GOLF. For example, breakpoints at TMPRSS2 were detected only in 14% of samples 
using auto-analysis, but manually SNP array data analysis revealed 28% of samples with 
TMPRSS2:ERG fusion genes (Table 3.3), which have been confirmed by either MCC or 
RT-PCR analysis. As seen in Figure 3.7, the breakpoints at TMPRSS2 in some patients 
are not as obvious as in other samples. While I noticed the difference between auto- and 
manual-analysis in picking-up breakpoints from SNP array data, at the current stage, it is 
difficult to tell which result is more reliable. Further studies are required to confirm these 
breakpoints using other techniques, such as FISH or MCC. Even if the auto-analysis 
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cannot provide accurate results, it is still a rapid approach to identify the possible 
breakpoints, which may be associated with chromosome translocation. Based on the 
auto-analysis results, I have identified rapidly a few genes with recurrent breakpoints by 
manual analysis.  
 
Table 3.4 The common recurrent genes located at breakpoint in prostate cancer. 
Gene names Location  Frequency  Function*  
WWOX 16q23.1 41% Putative oxidoreductase, involve in apoptosis 
FHIT 3p14.2 36% Transcriptional regulator 
ERG 21q22.2 33% Transcriptional regulator 
PPP2R2A 8p21.2 32% B regulatory subunit 
PTPRT 20q12 26% 
May be involved in signal transduction and 
cellular adhesion 
TEC 4p12-11 26% NA 
LRP1B 2q22.1-22.2 25% Potential cell surface proteins 
THSD7B 2q22.1 24% NA 
SMYD3 1q44 23% Histone methyltransferase 
NRG3 10q23.1 22% 
Direct ligand for the ERBB4 tyrosine kinase 
receptor 
PTPN1 20q13.13 20% 
May play an important role in CKII- and 
p60c-src-induced signal transduction 
cascades 
*: The information about function is from www.uniport.org. 
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Figure 3.8 The recurrent breakpoints and associated genes, LRP1B (A) and 
PPP2R2A (B). 
The SNPs in red, blue and green represent those regions statistically with copy number gain, 
neutral and loss respectively, as visualised in GOLF. Regions labelled by red lines are the 
genomic locations of LRP1B and PPP2R2A gene. 
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3.2.4.2 Potential fusion genes  
Cluster analysis was applied to the genes at breakpoints to provide information about 
potential fusion genes (Figure 3.9). The closer the distance between two genes in the 
same group, more likely the fusion gene will be. The known fusion partners, TMPRSS2 
and ERG, were clustered in the same subgroup. RBMS2/GRIA1 and FGF14/PARN were 
clustered in same classes to be potential fusion genes. Considering the possible false 
positive result, I checked the raw SNP array data and found RBMS2 (3p24.1) and GRIA1 
(5q33.2) co-existing at breakpoints in two clinical samples, SH16 and SH17 (Figure 
3.10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 127 
 
Figure 3.9 The cluster analysis for genes located at breakpoints detected by SNP 
array in prostate cancer samples. 
Each row represents the gene, and each column represents the independent sample. Red bar: 
breakpoint at the gene. Green Bar: no breakpoint at the gene. Two genes were clustered closer 
if they break at higher frequency in same samples. 
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Figure 3.10 Breakpoints in RBMS2 (A) and GRIA1 (B) co-existed in samples 
SH16 and SH17.  
The SNPs in red, blue and green represent those regions statistically with copy number gain, 
neutral and loss respectively, as visualised in GOLF. Region labeled by red lines are the 
genomic locations of RBMS3 and GRIA1 gene. 
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3.3 Discussions 
 
3.3.1 The comparison of data from SNP array and CGH array  
SNP array data were analysed along the chromosomes using GOLF and Partek. SNP 
microarray analysis revealed chromosome gain and loss patterns similar to those 
previously reported (270). In addition, many previously undetected small 
chromosomal amplifications and deletions were revealed by SNP array analysis (due 
to lower resolution of these other methodologies) (270, 271). These small 
amplifications and deletions were mainly a few hundred kb in length, represented by 
signal intensity changes of a small number of contiguous SNPs. When our SNP array 
results were compared with the tiling resolution BAC array CGH data on the same 
three cell lines PC3, DU145 and LNCaP (272), there was good correlation in the 
majority of genomic gains and losses (270, 271). However, a few submicroscopic 
amplifications and deletions were detected in our study but not in the array CGH 
analysis, such as the 398 kb homozygous deletion at 2p16.2-21 in LNCaP, 331 kb 
deletion at 4q31.1 in DU145, 530 kb amplification at 6p24.2-24.1 in VCaP and 111 
kb homozygous deletion at 5p14.3 in PC3 cell line (Appendix IV). Overall, I found 
fewer alterations than that reported in the array CGH analysis, 3 gains and 11 losses 
in LNCaP and 48 gains and 43 losses in PC3. As the average ploidy of DU145 cells is 
2.5N (59-63, 273), every chromosome region showed relative copy number changes 
and 40 gains and 29 losses were detected. If chromosome regions with two copies or 
three copies were excluded, only 11 gains and 6 losses occurred in this cell line. As 
my SNP array should not miss these large-scale genomic copy number changes 
detected by the tiling resolution array CGH, these differences in results may be 
caused by both the different capacities of the two array platforms and the variation of 
these cell lines kept in different laboratories. 
 
3.3.2 The common regions with copy number changes 
This study generated a high-resolution genomic alteration map for prostate cancers in 
populations from UK and China, which we hope will facilitate further genetic studies 
of prostate cancer.  
 
In this study, the regions with copy number changes in three cell lines were correlated 
with clinical samples. I found the common region with copy number gains at 7, 8q 
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and losses at 5q15-21.3, 6q14.1-22.1, 8p, 10q23, 13q12.3-31.1, 16q12.1-24.3 and 
21q22.2-22.3. These changes are comparable with the previous publications (274).  
 
3.3.2.1 Copy number gain regions 
As shown in Table3.1, there are a number of recurrent regions of genomic gain, 
including chromosome 7 and 8q.  
 
The gain of chromosome 7 is commonly detected in colon, renal cell, squamous cell 
lung, adrenocortical and prostate carcinoma, as well as lymphoplasmacytic lymphoma 
(275-280). From previous studies, about 50% prostate cancers have gain of 
chromosome 7 as detected by FISH, CGH array and gene expression arrays (277, 280, 
281). The gain of chromosome 7 has been correlated with survival outcomes in 
adrenocortical carcinoma (279). A recent study suggested the gain of chromosome 7 
could help to differentiate clear cell from papillary renal cell carcinoma (RCC) 
because the change was only observed in clear cell RCC (276). Epidermal growth 
factor receptor (EGFR) is located at 7p12. The mutation, or over-activity, of EGFR 
has been associated with cancer development. In prostate cancer, about 50% of 
prostate cancer with EGFR gain is due to chromosome 7 polysomy (280). MCM7 is 
another oncogene potentially associated with gain of chromosome 7. MCM7 is 
required for DNA replication and cell proliferation. Decreased expression of MCM7 
dramatically reduced tumour size in prostate cancer mouse model (282). Another gene 
whose function is potentially affected by gain of chromosome 7 is EZH2, a 
transcription regulator, which represses transcription and affects the target gene. 
EZH2 is frequently over-expressed in many cancers, including prostate and breast 
cancer (283). Over-expression of both MCM7 and EZH2 is associated with high 
Gleason Score and poor survival after prostatectomy treatment (284). 
 
The gain of 8q is one of the most common alterations found in many carcinomas, 
such as gastric carcinoma, prostate cancer, breast cancer and squamous cell carcinoma 
(277, 285-288). The well-known oncogene, C-Myc, located on 8q24, is one of the 
consequences of this genomic event (95, 110). Jalava also reported that the 
amplification and overexpression of TCEB1, a gene located on 8q21.11 is associated 
with invasion of prostate cancer (289).  8q gain was also considered correlated with 
poor survival of prostate cancer (290). 
 131 
 
3.3.2.2 Copy number loss regions 
This study has revealed the presence of genomic losses to be more prevalent than that 
of gains. The high frequency of genomic loss suggests that these regions may harbour 
TSGs. There are well-known TSGs located at these deleted regions, such as NKX3.1 
on 8p21.2, RB on 13q14.2 and BRCA2 on 13q13.1.  
 
Loss of 5q21 was found in multiple cancers, such as hepatoblastoma (291), prostate 
cancer (292), non-small cell lung cancer (293), colon cancer (294) and mantle cell 
lymphoma (295). APC located at 5q21 is a TSG, which is negatively associated with 
Wnt signalling. Both LOH and mutations at APC have been found in human cancers 
(293, 296). Mouse model studies have found that loss of the whole APC gene results 
in more rapid tumour development than the truncated APC gene (297). 
 
The long arm of chromosome 6 is a region commonly deleted in prostate cancers and 
many other tumour types, such as breast cancer, B-cell lymphomas, osteosarcoma, 
pancreatic cancer, ovarian cancer and T-cell leukaemia (298-303). However, the 
candidate TSG(s) on this region has yet to be identified. Using the SNP array 
methodology, I detected the loss of 6q14.3-15 (87.21-90.35 Mb) in 46% (33/71) and 
6q15 (90.88-91.35 Mb) in 49% (35/71) of my informative samples, coinciding with 
the recently reported minimum overlapping regions at this chromosome band (136). 
6q15 deletion has been associated with a subtype of prostate cancer (136, 292, 304). 
The 6q15 chromosome region has been proposed to harbour candidate TSGs in 
prostate cancer, such as the MAP3K7 (136). In our laboratory, we are investigating the 
potential for CNR1 and BACH2 to be TSGs at this region. 6q15 is also involved in a 
novel chromosome translocation t(4;6)(q22;q15) in 11.7% prostate cancer. This 
translocation occurred more frequently in TMPRSS2:ERG fusion-positive prostate 
cancer cases (305).  
 
Loss of 8p, in particular the 8p12-22 region, is commonly found in human cancers 
(306, 307). In this study, the frequency of 8p loss, identified in 43/71 clinical samples 
is consistent with the previously reports. LOH at 8p21 has also been detected in PIN 
lesions although it occurred more frequently in high stage prostate cancer than low 
stage cases (308-310). NKX3.1, located at this region is inactivated in 63%-90% of 
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primary prostate cancer either as LOH, selective CpG methylation or reduced 
expression (311, 312). Loss of NKX3.1 but not its expression level is associated with 
tumour stage (311). LZTS1 is another gene located at 8p21-22, the frequently deleted 
region in human cancers (306, 313-315). Its expression level is frequently down 
regulated in cancers. LZTS1 is frequently methylated in breast cancer, in which the 
expression level is down regulated in 50% of breast cancers (316). LZTS1 deficient 
mice are more susceptible for cancer development (317, 318). Therefore, both of them 
are putative TSGs at this commonly deleted region, and their losses may contribute to 
cancer development.   
 
In this study, loss of 10q22.3-23.33 was identified in 16/71 clinical samples. 10q is 
another frequent region of loss in prostate cancer. The TSG, PTEN, located on 
10q23.31, was initially identified in prostate cancer and is associated with more 
advanced disease. More recently, inactivation of PTEN has been identified in many 
other tumour types and has been shown to occur in the early stage of cancer 
development (319-322). In prostate cancer, PTEN inactivation is associated with 
TMPRSS2:ERG fusion (140, 323, 324) and fusion gene working together with PTEN 
inactivation induces prostate cancer (323, 325). Another putative TSG at this region is 
MXI1, an antagonist of c-Myc, which can repress transcription of many genes and 
reduce cell proliferation (326). In a mouse model, lack of MXI1 induces significant 
prostate hyperplasia (327). 
 
In previous studies, chromosome 13q was demonstrated as one of the most frequently 
deleted regions in cancer, including prostate cancer (110). Besides the well-known 
TSGs, RB and BRCA2, there are a few other putative TSGs on this chromosome 
region, such as FOXO1A, NEK3, KCNRG, CHC1-L and KLF5 (110, 328-331). High 
frequency LOH has been reported at 13q14, 13q21-22 and 13q33 (331, 332) and some 
of these abnormalities are associated with more advanced (i.e. high grade and stage) 
prostate cancer (333, 334). 
 
Chromosome 16q deletion was widely found in different type of cancer, such as 
melanoma, hepatoblastoma and prostate cancer (335-337).  Different deletion patterns 
were found in patients and different foci from one patient (304). In prostate cancer, 
the LOH occurs more frequently in the tumour with higher Gleason score (304). A 
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known TSG, CDH1, is located in 16q22.  There is another potential TSG, ATBF1, 
also located in 16q22. In addition to deletion, frequent somatic mutations were found 
to impair ATBF1 functions (335). WWOX located at 16q23.1 is a TSG involved in cell 
apoptosis. The high expression of WWOX is in hormonally active tissue, such as 
breast, prostate and ovary, and inhibit cell proliferation in breast cancer cell lines, but 
promote cell migration (338). 
 
The loss of genetic material on 21q22.2 has attracted attention after the recent 
publications of the high frequency of fusion gene TMPRSS2:ERG resulting from the 
rearrangements of this chromosome region (40). In this study, 21q22.2 deletion was 
found in 20/79 cases. It is now known that both translocation and internal deletion of 
21q22.2 can lead to TMPRSS2:ERG fusion (40, 141-143, 339). However, only 
internal deletion can be identified by SNP array. In addition to our observation of the 
variation in breakpoints, different sizes of genomic deletion around this chromosome 
region have been described at genomic level (269, 340). All these indicate that 
21q22.2 is an unstable genomic region in prostate cancers.  
3.3.3 Recurrent breakpoints in prostate cancer 
In this study, we used an automatic breakpoint analysis approach identified many 
genes located at high frequency breakpoint regions. As shown in the results part, this 
automatic analysis identified many false breakpoints and can still miss some 
breakpoints. The false positive results were mainly caused by noise SNPs and low 
threshold set up to identify as many breakpoints as possible. Missing breakpoints 
during the auto-analysis are due to gain or loss of a single copy of certain 
chromosome in sub-population cells or in hyperploidy cells. Prostate cancer cells 
frequently contain multiple copies of chromosomes. If only one copy is more or less 
of a chromosome region than its adjacent region, the difference of the SNP signal 
intensity may not be sufficient to be detected by auto-analysis with set criteria. 
Although the automatic analysis cannot provide accurate result, it is still a rapid 
approach to identify the possible breakpoints, which may be associated with 
chromosome translocations. Based on the genes identified using auto-analysis, 
manual analysis can be performed mainly focus on these recurrent genes. 
Identification of the frequent breakpoints occurring at ERG (33%), TMPRSS2 (14%) 
and ETV1 (15%) as expected, proved our analysis approach works. However, the 
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frequency of cases with TMPRSS2 breakpoints was slightly lower than expected due 
to small ratio of copy number changes in TMPRSS2 in some samples, which were 
missed during the auto- analysis. 
 
It is not surprising that genes located on the high frequency breakpoints are those 
located in the chromsome fragile sites, such as WWOX, FHIT and LRP1B genes. The 
most common gene in which breakpoints were detected is WWOX. As described in 
section 3.3.2.2, WWOX was described as a frequently deleted region in my study. 
Because WWOX is located at FRA16D fragile locus, it was reported to be involved in 
the translocation breakpoints in t(14;16) in multiple myelomas(341). In colon cancer 
cell line, exon 6-8 of WWOX was removed resulting in deleted transcript (342). 
 
FHIT, the second most common truncated gene, is a TSG located at FRA3B fragile 
site. It is a common target for DNA damage and checkpoint response (343). FHIT is 
involved in a balanced chromosome translocation t(3;8) in RCC (344, 345), t(3,20) in 
breast cancer cell line (346), and t(3;16) and t(3;4) in esophageal adenocarcinoma 
(347). FHIT is generally inactivated as a result of chromosomal translocation (346, 
347). However, the t(3;8) translocation in RCC maintains the complete coding 
sequence of FHIT with an interrupted 5’ noncoding region and expresses the normal 
RNA sequence (344, 345).  
 
LRP1B belongs to the low-density lipoprotein receptor gene family, locating at 
2q22.1, the FRA2F fragile site (348). Although this gene is located in the fragile site, 
2q22 abnormalities have not been frequently detected in prostate cancer. The down-
regulated LRP1B expression, resulted from genomic deletion or DNA methylation, 
was detected in varies cancers. The internal homozygous deletion was first reported in 
non-small cell lung cancer (349), and then in urothelial cancer (350), liver cancer 
(351) and glioblastoma (352). However, a study of 102 sporadic breast cancer 
samples failed to detect this internal homozygous deletion (353). This internal 
homozygous deletion was also found in 33 out of 770 cancer cell lines (354). In the 
mouse model study, the early embryonic lethality happened to the mice carrying mull 
alleles of LRP1B (355). LRP1B was hypermethylated in esophageal squamous 
carcinoma (356), oral squamous carcinoma (357), acute lymphoblastic leukaemia 
(358), small B cell-lymphoma (359) and gastric cancer (360). According to the 
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studies have been done, LRP1B is a putative TSG, which may be associated with sub-
types of cancers. The internal deletion and methylation of LRP1B have not been 
reported in prostate cancer samples. The identification of LRP1B genomic 
rearrangements, including internal deletions in two cases (SH17 and SH25) in this 
study, indicated that LRP1B may contribute to the development of a proportion of 
prostate cancers. The genomic rearrangements of LRP1B detected by SNP array 
analysis should be confirmed by other techniques and the prevalence of LRP1B 
inactivation in prostate cancer will be determined in the future studies.  
 
PPP2R2A was the forth gene from the top of the commonest breakpoint gene list 
identified by the auto-analysis and it is not located at a fragile site. PPP2R2A is 
located at 8p21.2, which is the most common region deleted in cancers. PPP2R2A 
belongs to B55 subunit of protein phosphatase 2A family, which negatively regulates 
the cell growth and division. The tumour suppressor function of PPP2R2A was 
suggested, as it induces apoptosis through initiating human adenovirus E4orf4 
apoptosis pathway (361) and this TSG role was potentially involved in breast cancer 
development (362). In lung cancer studies, PPP2R2A was found to trigger miR-31 
growth inhibitor effects (363). In prostate cancer, the homozygous deletion in 
PPP2R2A was reported in the VCaP cell line and some clinical samples (264). In my 
study, I confirmed the homozygous deletion in VCaP (Figure 3.5B). Moreover, in 
49.3% (35/71) of the clinical samples, PPP2R2A were located within the 8p deleted 
region, although none of them were homozygous deletions. This suggestes that 
PPP2R2A is a putative TSG and commonly inactivated in prostate cancer. Truncation 
of PPP2R2A in VCaP and three clinical samples indicates that chromosome 
translocation also plays a role in inactivating this putative TSG. Although PPP2R2A 
is generally considered as a TSG, in childhood teratoma, it fuses with CHEK2 to form 
PPP2R2A:CHEK2 fusion gene. In this event, PPP2R2A deregulates the CHEK2 
expression to activate an oncogene-like mechanism (364).  
 
Finally, the cluster analysis provides an easy approach to find more potential fusion 
genes. This approach has been demonstrated by the clustering of TMPRSS2 with ERG. 
There were a number of closer clustered gene pairs than TMPRSS2 and ERG. 
However, I do not think that these pairs of genes will fuse more frequently than 
TMPRSS2 and ERG. Manually checking of a few pairs of these genes revealed the 
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false negative results of TMPRSS2 and false positive results for the other genes such 
as RBMS2, GRIA1, FGF14 and PARN. The FGF14 and PARN pair, which was 
clustered to the closest association, was only individually occurred in a few samples 
and in three samples they co-existed using the auto-analysis. This suggests that 
FGF14 and PARN are unlikely to form a frequent fusion gene in prostate cancer due 
to the small number of the samples with breaks at these genes including potential 
false positive cases caused by the auto-analysis. Although breaks in RBMS2 and 
GRIA1 were not manually identified in as many samples as these picked-up from 
auto-analysis, the identification of the co-existence of breakpoints in these two genes 
in two clinical prostate cancer samples suggests that they may form a novel recurrent 
fusion gene. There are more potential fusion genes suggested by the cluster analysis. 
As the software for this analysis was only developed during my thesis write-up stage, 
similar to the studies for the recurrent potential fusion genes, more studies to confirm 
the fusion events of these clustered gene pairs are required in the future study, 
including manual analysis of SNP array data for these genes and confirmation using 
other techniques such as MCC, FISH and RT-PCR.  
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CHAPTER IV TMPRSS2:ERG FUSION GENE AND ITS 
APPLICATION 
 
4.1 Introduction 
Most fusion genes were identified in haematological malignancies and soft tissue 
sarcomas. Because of the complex karyotype, only a few fusion genes were reported 
in solid tumours until recently. Following the discovery of the recurrent fusions of the 
TMPRSS2 and ETS family transcription factor genes identified in prostate cancer in 
2005 (40, 41), a number of fusion genes have been found in prostate and other cancers 
(40-42, 150, 151, 153-159). TMPRSS2:ERG is the currently most frequent fusion 
gene, occurring in about 50% of prostate cancer (38, 40). At least 14 isoforms of 
TMPRSS2:ERG fusion transcripts were reported (141, 145). TMPRSS2:ERG was 
considered as an early event in the prostate cancer, although it may not initiate 
prostate tumourigenesis (134, 146, 365).  
 
In haematological malignancies and soft tissue sarcomas, fusion genes frequently 
define a tumour subtype and are associated with prognosis. They can be used as 
markers to detect cancer cells in minimum residual disease (366) and also as targets 
for cancer cell specific treatment (40, 135). If the high frequent TMPRSS2:ERG 
fusion gene plays a role in tumour progression and, most importantly, tumour 
metastasis, it will be an invaluable marker for treatment stratification and targets for 
novel forms of therapy. During my study, many other studies have been done for the 
association between TMPRSS2:ERG and prostate cancer progression. However, 
inconsistent results have been generated. Certain isoforms of TMPRSS2:ERG fusion 
products were thought to be associated with worse clinical outcome, higher risk of 
recurrence, higher stage, as well as poorly differentiated and lethal tumour (132, 134, 
367, 368). In contrast, other studies have reported either an absence of or a reverse 
association between the presence of TMPRSS2:ERG and a worse clinical presentation 
(131, 142, 369-371).  
 
Long distance tumour metastasis is caused by tumour cell migration from the primary 
site into the blood stream, culminating in survival and re-establishment at a new site. 
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CTCs were first observed by Thomas Ashworth in 1869 in the blood of patients with 
advanced cancer (372), and they are all early signs of tumour metastasis. Detection of 
the existence of CTCs has potential for monitoring tumour metastasis at early stage. It 
may also be used to study genetic and gene expression alterations in a continual, 
relatively non-invasive fashion. Changes in the number of CTCs have additional 
utility in monitoring tumour progression, response to therapy and have shown 
promise as surrogate biomarkers of survival endpoints (373-375).  
 
The number of CTCs present in the peripheral blood is very small and currently there 
are no reliable methods to distinguish prostate cancer CTCs from other normal 
epithilial cells. The technologies to increase the sensitivity and specificity of CTC 
detection has been developing. Several methods have been developed to enrich CTCs 
prior to further biological studies and density-gradient, filtration and immuno-
magnetic selection are among the best ways used in CTC collection (376).  
 
Many genes associated with prostate carcinogenesis are also expressed in 
hematopoietic cells, and the existence of non-tumour epithelial cells in the peripheral 
blood complicates CTC analysis (377, 378). For prostate cancer, the detection of 
micrometastases is also limited by the lack of specific cancer cell markers (378-380). 
Several prostate-specific markers have been used to confirm that the collected cells 
are prostate originated, including PSA, PSCA, PSMA, CK19, as detected by RT-PCR 
(376). However, these markers still cannot distinguish prostate CTCs and normal 
prostate epithilial cells. The TMPRSS2:ERG fusion gene occurs at a high frequency in 
prostate cancer and is a specific genetic marker of abnormal prostate cells. A few 
studies have attempted to address the role of the fusion gene in advanced metastastic 
prostate cancer (131-134, 142, 149, 365, 368, 370). In this Chapter, I determined the 
frequency of TMPRSS2:ERG fusion transcripts in prostate cancer clinical samples 
from UK and china and attempted to detect its existence in CTCs to monitor tumour 
progression and metastatic potential.  
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4.2 Results 
In this chapter, different isoforms of TMPRSS2:ERG fusion transcripts were detected in 
32 clinical samples. To monitor the metastatic prostate cancer, I also checked the 
TMPRSS2:ERG fusion gene at DNA and RNA levels in fifteen CTC samples. 
 
4.2.1 Confirmation of TMPRSS2:ERG fusion gene in VCaP kept in our 
laboratory 
To investigate TMPRSS2:ERG fusion, I selected a TMPRSS2:ERG fusion positive cell 
line, VCaP, as a positive control. Before using this cell line, I confirmed the fusion 
transcript by RT-PCR and the genomic status relevant to the fusion gene by SNP 
array and FISH analyses.  
 
4.2.1.1 TMPRSS2:ERG fusion transcript in VCaP 
I firstly confirmed the fusion transcript in VCaP by RT-PCR using the primers 
previously described for TMPRSS2:ERG fusion transcript detection (Table 2.4) and 
observed the expected 591 bp band (Figure 4.1), which responses to the fusion transcript 
formed by exon1 of TMPRSS2 and exon4 of ERG. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Gel image for TMPRSS2:ERG fusion transcript in VCaP. 
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4.2.1.2 Confirmation of the genomic rearrangement relevant to TMPRSS2:ERG 
fusion in VCaP cells 
In Chapter III, I have demonstrated the 500K SNP array results of VCaP cells. With a 
close look at chromosome 21, the array results showed copy number gain of whole 
chromosome 21 without internal deletion between TMPRSS2 and ERG (Figure 4.2). The 
result agrees with a previous study of this cell line using Affymetrix 100K SNP array 
(138). To confirm that ERG was rearranged without the commonly associated deletion 
between TMPRSS2 and ERG, FISH was used with two probes, RP11-476D17 (ERG 3’ 
red signal) and RP11-95I21 (ERG 5’ green signal). I found three red and three green 
signals in each VCaP cell, two pairs located next to each others, but in many cells, the 
third pair of red and green signals located far away (Figure 4.3).  
 
 
Figure 4.2 SNP array genomic profile of chromosome 21 in VCaP. 
The top array profile: The SNPs in red represent those regions statistically significant for copy 
number gain, as visualised in GOLF. The bottom array profile: The average intensities of SNPs 
on this chromosome is higher than the controls. For the three horizontal lines in each sample, the 
top line represents log2 ratio (test/control) of 1 compared with normal controls; the middle line 
represents log2 ratio of 0 and the bottom line represents log2 ratio -1. 
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Figure 4.3 FISH signals of ERG rearrangement in VCaP.  
There are three copies of both red and green signals in one VCaP cell. Two pairs of co-
localised ERG 5’ green and ERG 3’ red signals (arrows), one separated ERG 5’ green signal 
and one separated ERG 3’ red signal (arrowheads) were also observed.   
 
4.2.2 Detection of TMPRSS2:ERG fusion transcripts in clinical samples 
As TMPRSS2:ERG is the most common fusion in prostate cancer and deletion of 21q 
regions between TMPRSS2 and ERG were also commonly identified in the SNP array 
analysis I had carried out, I analysed TMPRSS2:ERG fusion gene status in 114 
primary prostate cancer biopsies obstained during radical prostatectomy from UK and 
China using standard RT-PCR. Of the 114 samples, 32 (28.1%) were TMPRSS2:ERG 
fusion-positive and 14 (12.3%) samples were detected with more than one form of 
fusion transcripts. Figure 4.4 are examples of some PCR results showing one band or 
several isoforms. The TMPRSS2:ERG fusion transcript were more frequently detected 
in UK (54.2%, 26/48) than Chinese (9.1%, 6/66) samples. The 14 samples detected 
with multiple isoforms are all from UK. The details about the different frequency of 
TMPRSS2:ERG fusion in UK and Chinese samples will be discussed in Chapter V. 
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Figure 4.4 Gel images for UK TMPRSS2:ERG fusion transcription in positive 
samples.  
 
To confirm the PCR result, some of the PCR products were cloned and analysed by 
DNA sequencing. In sample P39, I verified the presence of the fusion transcription 
TMPRSS2:ERGa between exon1 of TMPRSS2 and exon4 of ERG (the 591 bp 
product) (Figure 4.5A). In this sample, although there was only one obvious band on 
the gel, two different TMPRSS2:ERG fusion transcripts were cloned. In addition to 
TMPRSS2:ERGa, I also detected the TMPRSS2:ERGb transcript (the 779 bp product 
fused  between exon 1 of TMPRSS2 and exon 2 of ERG) (Figure 4.5B). In P9, I also 
verified the presence of one fusion transcription TMPRSS2:ERGa between exon1 of 
TMPRSS2 and exon4 of ERG (591 bp) (Figure 4.5A), but the larger, weaker bands 
seem difficult to be cloned.  
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Figure 4.5 DNA sequence reveals two isoforms of TMPRSS2:ERG in P39.  
A: TMPRSS2:ERGa: exon1 of TMPRSS2 is fused with exon 4 of ERG in P39  and P9. B: 
TMPRSS2:ERGb: exon1 of TMPRSS2 is fused with exon 2 of ERG in P39. 
 
4.2.3 TMPRSS2:ERG fusion in CTCs 
As the TMPRSS2:ERG fusion gene occurs at a very high frequency, we further 
investigated the possibility of detecting the presence of its fusion transcripts in 
peripheral blood. Firstly, fusion transcripts were analysed using RNA extracted from 
Ficoll separated white cells (They should contain CTCs if CTCs exist in the blood) in 
the peripheral blood samples of four patients with advanced prostate cancer (one of 
them, PCB34, taken from a fusion positive case, P127) using standard RT-PCR. Of 
note, 5 ml of blood was taken from each sample. However, no fusion products were 
detected. As the failure to detect the fusion gene may be due to the lack of CTC in the 
small blood volume and a large amount of lymphocyte contamination, I further 
analysed the separated CTCs from 20 ml blood samples (see separation method in 
section 2.1.3) from patients with advanced androgen-independent prostate cancer 
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receiving second line hormone therapy (collected and separated by Dr. Greg Shaw). 
This allowed the enrichment of cancer cells with each sample containing more than 
100 nucleated CD45 negative, cytokeratin/ EpCAM positive cells (Figure 4.6). 
However, of the 15 samples (Table 4.1) analysed using both standard RT-PCR and q-
RT-PCR, including one case (PCB34) in which the primary cancer biopsy was fusion 
positive, no fusion transcripts were detected in any CTC samples (Figure 4.7A, 
4.7B). I confirmed the sensitivity of our RT-PCR protocol in detecting 
TMPRSS2:ERG fusion transcripts by mixing different dilutions of fusion positive 
VCaP cells with fusion negative LNCaP cells. I detected the fusion product in 
approximately 20 (100 pg RNA) but not 10 (50 pg RNA) VCaP cells mixed with 
20,000 LNCaP cells (Figure 4.7C). 
 
                              
Figure 4.6 Representative immunofluorescence of EpCAM positive (green) CTC 
with nuclear counterstain (blue). 
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Table 4.1 Clinical characteristics of patients from whom CTCs were obtained. 
Cases  Age PSA at 
sampling 
(ng/ml) 
PSA slope 
(ng/ml/day) 
Metastasis Gleason Current 
medication  
ERG 
FISH 
results  
PCB20 87 56.3 0.224 0 4 MAB P 
PCB21 90 159 0.23 1 NA MAB NA 
PCB22 53 19.0 NA 1 9 MAB NA 
PCB23 82 199.6 0.599 1 NA MAB P 
PCB24 73 51.8 0 1 7 MAB N 
PCB25 76 471.0 3.73 1 8 DAS N 
PCB26 77 152.5 0.25 1 NA DA NA 
PCB27 55 43.6 0.026 0 7 LHRH P 
PCB28 63 667 26.6 1 7 CLE N 
PCB29 87 164.1 NA 1 8 MAB P 
PCB30 71 153.4 3.86 1 NA MAB P 
PCB31 73 23.2 0.02 1 7 MAB NA 
PCB32 77 11.8 -0.11 1 6 MAB NA 
PCB33 78 64.0 0 NA NA Orchidtectomy N 
PCB34 a 69 63.9 0.156 1 NA LHRH P 
a: TMPRSS2:ERG fusion positive in the primary sample. Abbreviations: MAB, maximum 
androgen blockage; DAS, dexamethasone aspirin stilboestrol; DA, dexamethasone aspirin; 
LHRH, Hormone releasing hormone; CLE, chlorambucil lomustine, etoposide; P, positive; N, 
negative. 
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Figure 4.7 RT-PCR results of the TMPRSS2:ERG fusion transcript and β-actin 
in the isolated CTCs and positive control samples.  
A: A gel image showing the positive RT-PCR results (the bands at approximately 600 bp) 
from VCaP and P127 and lack of PCR products from the 15 CTC samples. B: The β-actin 
RT-PCR product (121 bp band) from the VCaP and 15 CTC samples. C: The RT-PCR result 
of the TMPRSS2:ERG fusion gene from a range of numbers of VCaP cells mixed with 20,000 
LNCaP cells.  
 
As RT-PCR is limited to detecting the fusion transcript in a rare population of cells, I 
applied FISH to analyse the genomic truncation of ERG (which is the result of 
TMPRSS2:ERG fusion) in individual cells. Isolated CTCs from 10 of the 15 blood 
samples were available for this type of analysis, and I found ERG truncation in 6 of 
them, including PCB34, taken from a patient with a fusion positive primary tumour 
sample, P127 (Table 4.1, Figure 4.8). Although the frequency of TMPRSS2:ERG 
fusion was higher than that detected in our UK primary samples, this was not 
statistically significant (p = 0.319).  
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Figure 4.8 FISH signals of truncated ERG gene in CTCs.  
A: One pair of co-localised red (5') and green (3') signals (arrow head), one separated red and 
one green signals (arrow) were detected in a CTC from PCB27. B: One pair of co-localised 
red (5') and green (3') signals (arrowhead) and two isolated red and two isolated green signals 
(arrow) were detected in a CTC cell from PCB29. Some fluorescence background was seen in 
both cells. 
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4.3 Discussions 
 
4.3.1 The prevalence of TMPRSS2:ERG in prostate cancer  
VCaP was reported as a TMPRSS2:ERG positive cell line when this fusion gene was 
initially identified in prostate cancer in 2005 (40). In addition to the fusion transcript, 
Tomlins et al also confirmed the ERG rearrangement in VCaP using FISH. Multiple 
copies of the ERG were found in VCaP and some red and green signals were located 
seperatedly, representing split between ERG 5’ and 3’ probes. No signal loss of ERG 5’ 
was observed indicating that the fusion was not caused by genomic deletion between 
TMPRSS2 and ERG gene. Later, VCaP was analysed by Affymetrix 100K SNP array and 
the result showed a copy number gain of the whole of chromosome 21 without any 
interanal deletion (138).  In this study, I used VCaP as a TMPRSS2:ERG fusion positive 
cell line and confirmed the fusion status in our VCaP cell line as previously published 
both at RNA level using RT-PCR and genomic level by 500K SNP array and FISH 
analyses.  
 
In this study, I investigated the clinical prevalence of the TMPRSS2:ERG fusion gene 
in the UK and Chinese populations. I detected the high frequency of TMPRSS2:ERG 
fusion gene (54.2%) in UK samples, which is comparable to previous studies (40, 
141-145, 339, 381, 382). I also found the co-existence of multiple forms of fusion 
variants of TMPRSS2:ERG which correlated with several previous studies (141-145). 
These different fusion transcript variants correlated with the different genomic 
breakpoints at TMPRSS2 and ERG, which have been observed in my SNP analysis as 
described in Chapter III (Figure 3.2).  
 
4.3.2 Early stage prostate cancer metastasis detection by monitoring CTCs 
As the first described high frequency fusion gene in prostate cancer, TMPRSS2:ERG 
has been detected in urine from patients by RT-PCR for diagnosis (383-385). Its 
fusion transcripts have been identified in metastatic prostate cancer and its presence 
has been reported by some researcher as to be associated with higher likelihood of 
cancer-specific death and metastatic spread (137, 383). In my study, I investigated 
TMPRSS2:ERG fusion in CTCs using both RT-PCR and FISH analyses. While I 
failed to detect fusion transcripts in any CTCs, I detected ERG truncation, generally 
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resulted from the gene fusion, at a high frequency (6/10) in CTC samples prepared 
from the peripheral blood.  
 
The high frequency detection of TMPRSS2:ERG fusion in prostate CTCs suggests 
that cancer cells with TMPRSS2:ERG fusion frequently migrate into the blood vessel 
for long distance seeding. The observation of TMPRSS2:ERG fusion gene positive 
CTCs is consistent with a previous observation where fusion genes were passed on 
from the primary tumours to lymph node metastatic cells (138). The frequency of 
TMPRSS2:ERG fusion was not significantly higher in the CTC samples when 
compared to that detected in our primary samples. The following studies from other 
groups confirmed the similar frequency of TMPRSS2:ERG in CTCs and localised and 
metastatic tumour (386). 
 
As TMPRSS2:ERG fusion can be detected in CTCs from a large proportion of 
prostate cancer cases, detection of ERG truncation in CTCs may be used as a specific 
tool for monitoring tumour metastasis before apparent long distance metastasis 
occurs. In this study, we detected ERG alteration positive CTCs in two cases of 
prostate cancers without detected metastatic tumours. The present study has mainly 
established the principle in detecting TMPRSS2:ERG fusion in CTCs using advanced 
prostate cancers. Further investigation is required to evaluate its applicability in 
monitoring early stage disease.  
 
Although the TMPRSS2:ERG fusion was detected at the genomic level, I did not 
detect the fusion transcript in any of the CTCs isolated from patient blood samples. 
RT-PCR is a sensitive method for detecting fusion gene transcripts in a small amount 
of cells. The protocol we used can detect a sample containing 20 TMPRSS2:ERG 
fusion positive cells in 20,000 fusion negative cells. There are more than 100 prostate 
epithelial cells in each of the selected populations from blood samples determined by 
immunostaining using EpCAM. Although we still cannot absolutely exclude the 
limitation of technical sensitivity as a reason for the failure to detect the fusion 
transcripts in the small number of CTCs, which are a proportion of the EpCAM 
positive cells, it is most likely that the expression of TMPRSS2:ERG is switched 
off/down in the CTCs. Firstly, as all the patients are androgen independent, it is most 
likely that fusion gene expression in CTCs from these patients is switched-off/down 
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as a result of androgen ablation therapy (387). In a previous report, the expression of 
TMPRSS2:ERG was not detectable in androgen-independent cancers, including some 
metastatic samples, although the genomic fusion existed in some cases (142). 
Secondly, most of the CTCs in the blood stream fail to proliferate in culture and 
appear terminally differentiated, which might also affect fusion gene expression. 
 
This is the first study to detect genetic alterations in prostate cancer CTCs using 
FISH. Following my study, genomic alterations of ERG, PTEN and AR has also by 
analysed by FISH in prostate CTCs (386).  
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CHAPTER V THE DIFFERENT GENOMIC 
ALTERATIONS BETWEEN UK AND CHINESE 
PROSTATE CANCERS 
 
5.1 Introduction 
The incidence of many human cancers varies dramatically between different 
geographical regions, such as high hepatocellular carcinoma incidence in Asia and high 
gallbladder cancer incidence in Chile, Poland, India, Japan and Israel (388, 389).  Some 
such cancers are associated with specific oncogenic agents, such as HBV and HCV with 
hepatocellular carcinoma, EBV with Burkitt’s lymphoma and nasopharyngeal cancer and 
aflatoxins in hepatocellular carcinoma (13, 18, 388). However, for many cancers, the 
factors underlying the differential geographical distribution are still not clear. Despite an 
increase in recent years in Asian countries, the prevalence of prostate cancer in Western 
countries is still more than 20 times that in China (65, 111). Numerous studies have been 
carried out in order to understand the factors, such as environmental, dietary or genetic, 
that contribute to this difference with the aim of developing preventative approaches to 
assist prevention. However, each of the currently identified risk-factors is associated with 
only a modest increase in the likelihood of developing prostate cancer and the real 
contributions of such factors are still debatable. Nonetheless, the improved 
understanding of risk factors in prostate cancer development and progression may have 
significant implications in cancer prevention, diagnosis and treatment.  
 
Carcinogenesis is associated with multiple somatic genomic alterations. We 
hypothesised that specific cancer risk factors may underlie particular somatic genomic 
alterations and hence, cellular pathways involved in carcinogenesis. Identifying the 
differences in somatic genomic alterations in populations exposed to different risks may 
indicate specific factors involved in tumourigenesis. Furthermore, investigation of the 
mechanisms leading to these genomic changes may also facilitate the identification of 
the tumour-specific factors, which account for the differences in geographical 
distribution. It is not known if environmental factors and genomic polymorphisms can 
cause different somatic genomic alterations, which may account for the difference in 
prostate cancer incidence between Western and Asian populations. Of note, 
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predominantly all previously published genetic studies using genome-wide analysis 
approach have been carried out on cancers in the Western populations. I therefore sought 
to determine the similarities and/or differences in genomic alterations in prostate cancer 
samples from Western and Chinese populations. 
 
In this chapter, I shall focus on the most significantly differentially presented genomic 
changes identified using SNP array in clinical prostate cancer samples from the UK and 
China, PTEN deletion and TMPRSS2:ERG fusion gene, which later confirmed by MCC 
analysis. I also used RT-PCR to characterise the frequencies of TMPRSS2:ERG fusion 
transcripts in UK and Chinese prostate cancers. In addition, I applied FISH and IHC to 
UK (168 cases) and Chinese TMAs (143 cases) to investigate genomic rearrangements 
and protein level changes respectively for the two alterations in large populations. In 
order to investigate the underlying mechanistic difference, I also examined the CAG 
repeat size in AR to seek its correlation with TMPRSS2:ERG. 
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5.2 Results  
The most common genomic regions with copy number changes in all seventy-one 
prostate cancer samples using SNP array were summarised in Chapter III. When the 
UK and Chinese samples were analysed separately, I found some regions with different 
frequencies of copy number changes between UK and Chinese samples. The frequencies 
of copy number changes in certain genomic regions were different and the genomic 
changes commonly occurring in Western countries but rarely detected in the samples 
from China are deletions of 10q23.31 (involved PTEN) and 21q22.2-22.3 (associated 
with TMPRSS2:ERG fusion). The differences in these two regions between UK and 
Chinese cases were further verified at both the DNA and protein levels in a large number 
of cases.  
 
5.2.1 Frequency of 21q22 and 10q23 deletions detected by SNP array in 
UK and Chinese fresh frozen samples 
In Chapter III, I reported that 21 out of 71 prostate cancers have 21q22.2-22.3 deletion 
and 14 out of 71 cases have PTEN deletion (Table 3.1). While 18/32 (56%) and 11/32 
(34%) of UK samples were identified with 21q22.2-22.3 and 10q23.31 deletions, 
respectively, only 3/39 (8%) and 3/39 (8%) of Chinese samples harboured 21q22.2-22.3 
and 10q23.31 deletions, respectively (Figure 5.1 and 5.2, Table 5.1) (p<0.0001 and 
p=0.0068). Representative SNP intensity plots along chromosome 10 and 21 were shown 
in Figure 5.3. On the other hand, 5q15-21.3 and 6q14.1-22.1 deletions are more 
frequently found in Chinese than UK samples. As PTEN is an important TSG related 
with prostate cancer, TMPRSS2:ERG fusion gene is the most frequent fusion gene found 
in prostate cancer,  21q22.2-22.3 and 10q23.31 deletions were chosen for further studies 
in UK and Chinese prostate cancers in this study. Another reason to select these two 
genomic changes for extensive studies is that these alterations are common in the high 
cancer incidence populations and rare in the low-risk populations, therefore, potential 
reasons contribute to the different frequencies of cancer incidence. 
 
 154 
Table 5.1 The regions with different frequency for copy number changes in UK 
and Chinese prostate cancer samples. 
Frequencies of copy number loss Regions with copy 
number loss UK samples Chinese samples 
p value 
5q15-21.3 5/32 (16%) 17/39 (44%) 0.0107 
6q14.1-22.1 9/32 (28%) 28/39 (72%) 0.0003 
10q23.31 11/32 (34%) 3/39 (8%) 0.0068 
21q22.2-22.3 18/32 (56%) 3/39 (8%) <0.0001 
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Figure 5.1 Summary of the genomic copy number changes detected in UK  
prostate cancer samples by SNP array analysis. 
The red and blue bars on the right side of each chromosome represent regions of copy number 
gain and loss, respectively.  
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Figure 5.2 Summary of the genomic copy number changes detected in Chinese 
prostate cancer samples by SNP array analysis. 
The red and blue bars on the right side of each chromosome represent regions of copy number 
gain and loss, respectively.  
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Figure 5.3 SNP intensity profile of Chromosome 10 and 21 in UK and Chinese 
samples.  
The purple bar indicates the location of PTEN (chr 10), ERG (chr 21, left bar) and TMPRSS2 
(chr 21, right bar) respectively, which mark the regions deleted in UK but not Chinese 
samples. In each SNP intensity plot, the middle horizontal line represents a log2 ratio of 0 
compared with normal controls. The bottom and upper lines represent log2 ratios of -1 and 
+1, respectively. 
 
5.2.2 MCC to confirm 21q22.2-22.3 deletion  
Four UK tumour samples, four Chinese tumour samples and one normal UK control 
were chosen from the samples analysed by SNP array to confirm the deletion of 
21q22.2-22.3. Using two sets of MCC primers ERG(+) and ERG(-), there are a similar 
numbers of ERG(+) and ERG(-) products in the UK normal control with ERG(-
):ERG(+) ratios 1.03. Consistent with the 21q22.2-22.3 deletion detected by the SNP 
microarrays, a reduced number of ERG(-) products were observed in the UK samples 
with ERG(-):ERG(+) ranging from 0.40 to 0.73, and similar numbers of ERG(+) and 
ERG(-) products in the Chinese cases with ERG(-):ERG(+) ratios ranging from 0.90 
to 1.04 (Table 5.2 and Figure 5.4).  
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Table 5.2 MCC results showing more positive PCR products for the ERG 
undeleted than the deleted region in the UK samples. 
 
 
 
 
 
 
Sample ERG(+) No. ERG(-) No. Ratio ERG(-):ERG(+)  
Normal  34 35 1.03 
P9 39 20 0.51 
P55 30 12 0.40 
P68 55 40 0.73 
P98 34 21 0.62 
SH1 31 28 0.90 
SH3 47 48 1.02 
SH5  79 82 1.04 
SH6 65 67 1.03 
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Figure 5.4 MCC confirms a significant copy number loss of ERG in UK samples 
as compared to Chinese samples. 
A: Bar chart illustrating the mean (± SEM) ratio of marker ERG(-) to marker ERG(+) 
products in four UK and four Chinese prostate cancer samples. *** p< 0.001. B-C: 
Representative image showing MCC assays of B one UK sample (P68) and C one Chinese 
sample (SH6) analysing Chromosome 21 markers ERG(+) and ERG(-). Lanes 1-8 show 
negative controls, containing no DNA.   
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5.2.3 RT-PCR analysis of TMPRSS2:ERG fusion transcript 
I analysed the frequencies and types of TMPRSS2:ERG fusion transcripts using RT-
PCR in Chapter IV. Fusion transcripts were detected in 51% (26/49) of UK samples, 
13 samples have at least two fusion isoforms. However, only 9.2% (6/65) of Chinese 
samples expressed the fusion transcript with only one sample having two fusion 
isoforms. The difference in the frequencies of TMPRSS2:ERG fusion transcript 
between the Chinese and UK samples is statistically significant (p<0.0001). 
 
5.2.4 FISH for ERG rearrangements and PTEN deletion in UK and 
Chinese TMA  
To further confirm these genomic differences between Western and Chinese prostate 
cancers, I used TMAs containing separate sets of FFPE samples from Chinese and UK 
patients and used FISH analysis to examine the copy number status of the ERG and 
PTEN regions (Table 5.3 and 5.4). A TMA with BPH samples was used as normal 
controls.  
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Table 5.3 Clinical information, and results of FISH and IHC analyses of TMAs 
from UK patients. 
FISH ERG IHC 
Patient ID Age 
Gleason 
score ERG PTEN Nuclear Cytoplasm 
PTEN 
IHC 
WXFFEP01 63 4+3 Loss G=R + ++ + 
WXFFEP02 58 3+3 NA NA - - NA 
WXFFEP03 66 4+3 G=R G=R - + + 
WXFFEP04 66 4+4 G=R G=R - - + 
WXFFEP05 63 3+4 G=R G=R - ++ ++ 
WXFFEP06 62 4+3 G=R Loss      - - + 
WXFFEP07 57 4+4 G=R G=R - - ++ 
WXFFEP08 64 4+3 G=R G=R - - + 
WXFFEP09 70 4+3 G=R G=R - - ++ 
WXFFEP10 66 4+4 G=R Unstable   - + ++ 
WXFFEP11 57 4+3 G=R Loss - - + 
WXFFEP12 64 4+3 G=R G=R - - - 
WXFFEP13 63 4+4 Loss Loss - ++ - 
WXFFEP14 58 4+3 G=R G=R - ++ +++ 
WXFFEP15 51 4+4 G=R G=R - ++ ++ 
WXFFEP16 58 4+3 G=R G=R ++ - - 
WXFFEP17 58 4+3 G=R Loss - + + 
WXFFEP18 54 3+4 G=R G=R - - - 
WXFFEP19 52 3+3 Loss Loss - +++ + 
WXFFEP20 58 3+4 Gain Loss - + - 
WXFFEP21 64 3+4 Split G=R + ++ +++ 
WXFFEP22 66 3+4 
Loss, 
Split Loss - ++ + 
WXFFEP23 56 4+3 Loss 
Homo 
loss - ++ + 
WXFFEP24 63 3+4 G=R Unstable - - ++ 
WXFFEP25 66 3+3 Loss G=R ++ ++ ++ 
WXFFEP26 55 3+4 Loss Unstable + ++ - 
WXFFEP27 64 4+4 G=R G=R - - + 
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WXFFEP28 69 3+4 G=R G=R + + + 
WXFFEP29 54 3+4 NA NA - + NA 
WXFFEP30 64 4+4 G=R Unstable - - ++ 
WXFFEP31 54 4+4 G=R G=R - ++ +++ 
WXFFEP32 72 4+4 G=R Gain - ++ + 
WXFFEP33 65 4+4 G=R G=R - - - 
WXFFEP34 59 3+4 G=R Loss - ++ +++ 
WXFFEP35 64 3+4 G=R G=R - ++ +++ 
WXFFEP36 69 3+4 G=R G=R - - - 
WXFFEP37 67 3+4 G=R Loss   - - + 
WXFFEP38 69 3+4 Loss Loss - ++ - 
WXFFEP39 66 4+4 Loss Loss - + - 
WXFFEP40 54 3+4 G=R G=R - ++ ++ 
WXFFEP41 64 4+4 G=R G=R - ++ ++ 
WXFFEP42 66 3+4 G=R G=R - - + 
WXFFEP43 68 4+4 G=R G=R - - ++ 
WXFFEP44 62 3+3 G=R G=R - - ++ 
WXFFEP45 62 3+4 G=R G=R - - - 
WXFFEP46 64 4+3 Loss Unstable + ++ + 
WXFFEP47 66 4+4 G=R G=R - + ++ 
WXFFEP48 66 3+4 G=R G=R + + ++ 
WXFFEP49 58 3+3 G=R Loss   - + - 
WXFFEP50 71 3+4 G=R Loss - - + 
WXFFEP51 69 3+3 Split Loss ++ + + 
WXFFEP52 67 3+3 Loss Loss - + + 
WXFFEP53 54 3+3 G=R Loss - - - 
WXFFEP54 64 3+4 G=R G=R - ++ ++ 
WXFFEP55 59 3+4 G=R G=R - ++ ++ 
WXFFEP56 56 3+4 Loss 
Homo 
loss - ++ - 
WXFFEP57 62 3+3 Loss Loss - ++ + 
WXFFEP58 61 3+4 Loss G=R ++ - +++ 
WXFFEP59 60 4+4 G=R G=R - - - 
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WXFFEP60 60 4+4 G=R Unstable - - - 
WXFFEP61 67 3+4 
Loss, 
Split Loss - ++ + 
WXFFEP62 64 4+4 G=R G=R - ++ - 
WXFFEP63 63 4+3 G=R Unstable - - - 
WXFFEP64 54 4+4 G=R G=R - +++ + 
WXFFEP65 56 4+4 Gain 
Homo 
loss - - - 
WXFFEP66 62 3+3 G=R G=R - ++ - 
WXFFEP67 73 4+4 G=R G=R + ++ - 
WXFFEP68 65 4+3 G=R G=R - + ++ 
WXFFEP69 60 3+4 G=R Loss - +++ + 
WXFFEP70 70 3+4 G=R G=R - + - 
WXFFEP71 68 4+4 G=R G=R - - ++ 
WXFFEP72 65 3+4 Split Loss - +++ - 
WXFFEP73 64 3+4 G=R G=R - + ++ 
WXFFEP74 57 3+4 Loss Loss - ++ - 
WXFFEP75 67 3+4 
Loss, 
Split Loss - ++ + 
WXFFEP76 71 3+3 G=R Loss - - - 
WXFFEP77 66 4+4 G=R G=R - + - 
WXFFEP78 66 3+4 G=R G=R - ++ ++ 
WXFFEP79 61 4+3 G=R G=R - - - 
WXFFEP80 58 4+4 G=R G=R - - ++ 
WXFFEP81 71 3+3 Split Loss +++ +++ - 
WXFFEP82 62 3+3 G=R G=R - + ++ 
WXFFEP83 68 3+4 
Gain, 
Split G=R + ++ - 
WXFFEP84 63 4+4 G=R Gain - - - 
WXFFEP85 66 4+4 Split Loss + ++ - 
WXFFEP86 67 4+3 G=R 
Homo 
loss ++ + - 
WXFFEP87 58 5+4 G=R G=R - - +++ 
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WXFFEP88 56 3+3 Split G=R ++ ++ - 
WXFFEP89 55 4+3 Loss 
Homo 
loss + ++ - 
WXFFEP90 62 3+3 NA G=R - - - 
WXFFEP91 66 3+4 G=R G=R - ++ - 
WXFFEP92 54 3+3 G=R G=R + + - 
WXFFEP93 64 4+4 G=R G=R - ++ - 
WXFFEP94 62 4+4 Loss G=R + +++ - 
WXFFEP95 67 3+4 G=R G=R - + + 
WXFFEP96 71 3+3 G=R G=R - + ++ 
WXFFEP97 71 3+4 G=R G=R - - ++ 
WXFFEP98 61 4+3 G=R G=R - - - 
WXFFEP99 68 4+3 G=R G=R - ++ - 
WXFFEP100 54 3+3 Loss G=R - ++ - 
WXFFEP101 63 4+3 G=R G=R - + - 
WXFFEP102 63 3+4 Loss G=R + - - 
WXFFEP103 54 4+4 Loss Loss - + - 
WXFFEP104 64 4+4 G=R G=R - - ++ 
WXFFEP105 66 3+4 G=R G=R - ++ - 
WXFFEP106 66 4+4 Loss NA - ++ ++ 
WXFFEP107 57 3+4 Split Loss + - + 
WXFFEP108 58 3+4 Loss G=R ++ ++ - 
WXFFEP109 62 4+4 G=R G=R + - ++ 
WXFFEP110 63 3+4 Split G=R - ++ ++ 
WXFFEP111 55 3+4 G=R G=R - - - 
WXFFEP112 66 4+4 G=R G=R - - - 
WXFFEP113 73 3+3 Loss G=R - ++ + 
WXFFEP114 70 4+3 G=R Loss - + + 
WXFFEP115 70 4+4 Loss Loss + + - 
WXFFEP116 58 4+3 Split Loss + + - 
WXFFEP117 59 4+3 
Loss, 
Split Loss - ++ + 
BLFFEP01 60 3+3 Unsta Loss +++ + - 
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ble 
BLFFEP02 51 3+3 G=R G=R ++ ++ ++ 
BLFFEP03 70 4+4 Loss 
Homo 
loss ++ ++ - 
BLFFEP04 62 3+4 G=R NA - - ++ 
BLFFEP05 69 4+3 Loss 
Homo 
loss NA NA - 
BLFFEP06 70 3+3 NA NA - + NA 
BLFFEP07 68 3+3 Loss G=R - ++ ++ 
BLFFEP08 69 4+4 G=R G=R - ++ + 
BLFFEP09 58 3+4 Loss Loss +++ +++ + 
BLFFEP10 52 3+3 Loss Loss +++ ++ - 
BLFFEP11 70 4+4 Loss G=R - - +++ 
BLFFEP12 70 3+4 G=R G=R NA NA +++ 
BLFFEP13 76 4+4 
Loss, 
Split Unstable +++ ++ - 
BLFFEP14 80 3+4 G=R G=R ++ - - 
BLFFEP15 73 4+4 G=R Unstable  + + NA 
BLFFEP16 59 3+3 NA NA - ++ NA 
BLFFEP17 83 5+4 Loss Unstable ++ ++ - 
BLFFEP18 68 3+4 G=R Loss + + - 
BLFFEP19 68 4+3 G=R Gain +++ - ++ 
BLFFEP20 58 3+3 G=R Loss - + - 
BLFFEP21 63 4+4 
Loss, 
Split Gain - +++ ++ 
BLFFEP22 65 3+4 NA G=R + + + 
BLFFEP23 60 3+4 NA NA +++ +++ NA 
BLFFEP24 74 4+3 Loss Loss - +++ - 
BLFFEP25 61 3+4 NA NA - ++ NA 
BLFFEP26 58 3+4 Loss Loss - ++ ++ 
BLFFEP27 73 3+4 Loss Loss - +++ + 
BLFFEP28 70 4+3 NA Loss - + - 
BLFFEP29 63 3+3 G=R G=R + + +  
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BLFFEP30 65 3+3 Loss G=R +++ ++ ++ 
BLFFEP31 71 5+4 G=R Gain - ++ +++ 
BLFFEP32 62 3+3 Loss Loss - +++ + 
BLFFEP33 72 3+4 NA NA ++ - NA 
BLFFEP34 63 3+4 G=R Loss + - - 
BLFFEP35 66 4+4 G=R Loss - + - 
BLFFEP36 53 4+4 NA Loss ++ + - 
BLFFEP37 65 3+4 NA G=R ++ + +++ 
BLFFEP38 57 4+5 Loss Loss - - + 
BLFFEP39 58 5+5 G=R Gain - + + 
BLFFEP40 67 3+4 Loss 
Homo 
loss - +++ - 
BLFFEP41 71 4+3 G=R G=R - - - 
BLFFEP42 65 3+4 Split G=R ++ +++ +++  
BLFFEP43 64 3+4 G=R NA - ++ ++ 
BLFFEP44 66 3+3 G=R Gain + ++ + 
BLFFEP45 52 3+4 G=R G=R - - - 
BLFFEP46 68 3+3 G=R NA - ++ + 
BLFFEP47 59 3+4 NA NA - ++ NA 
BLFFEP48 59 3+4 Loss Loss +++ ++ - 
BLFFEP49 67 3+4 G=R G=R - ++ + 
BLFFEP50 68 3+3 Split Unstable - ++ + 
BLFFEP51 39 3+4 Loss Loss ++ ++ - 
-: no stain; +: weak stain; ++; medium stain; +++: strong stain; NA: no data 
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Table 5.4 Clinical information, and results of FISH and IHC analyses of TMAs 
from Chinese patients. 
FISH ERG IHC 
Patient ID Age 
Gleason 
score ERG PTEN Nuclear Cytoplasm 
PTEN 
IHC 
HZ01 NA 4+4 G=R  Loss + - + 
HZ02 75 5+4 G=R  Loss - - + 
HZ03 75 3+4 NA NA + + +++ 
HZ04 71 4+3 G=R G=R ++ - +++ 
HZ05 80 3+3 Split  NA +++ - ++ 
HZ06 72 4+3 NA NA - - NA  
HZ07 73 4+4 G=R G=R + +++ +++ 
HZ08 91 5+4 NA NA - - NA  
HZ09 82 4+4 NA  G=R ++ - +++ 
HZ10 80 5+4 NA NA + - NA  
HZ11 73 3+4 NA  G=R NA NA ++ 
HZ12 73 3+4 NA NA + + NA 
HZ13 74 3+4 NA  G=R - - - 
HZ14 70 3+4 NA NA - - NA 
HZ15 65 4+4 Loss  Loss  - - - 
HZ16 77 5+4 NA NA - - NA 
HZ17 68 5+5 G=R NA + + +++ 
HZ18 76 3+2 G=R  Loss - - - 
HZ19 82 4+4 NA NA - + NA 
HZ20 82 5+4 G=R NA ++ ++ +++ 
HZ21 74 3+3 G=R G=R - - ++ 
HZ22 67 4+3 G=R Loss ++ ++ - 
HZ23 71 3+3 G=R G=R - - +  
HZ24 65 4+4 G=R G=R - ++ +++ 
HZ25 79 4+4 NA NA ++ ++ NA 
HZ26 54 3+4 NA NA +++ ++ NA 
HZ27 83 4+3 NA G=R ++ + +++ 
HZ28 73 3+3 G=R G=R +++ - +++ 
HZ29 74 5+4 NA NA - - NA 
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HZ30 72 4+3 G=R G=R ++ ++ ++ 
HZ31 80 3+4 NA G=R - + - 
HZ32 65 5+4 G=R G=R - + +++ 
HZ33 68 3+3 NA NA + - NA 
HZ34 84 4+4 NA NA - - NA  
HZ35 83 4+4 G=R G=R +++ - ++ 
HZ36 76 5+5 NA NA ++ + NA 
HZ37 76 4+4 NA NA ++ - NA 
HZ38 72 3+4 G=R G=R +++ - - 
HZ39 81 5+5 G=R NA ++ - NA 
HZ40 77 5+5 NA NA - ++ NA 
HZ41 59 5+4 G=R G=R - - - 
HZ42 67 5+4 NA NA + - NA 
HZ43 80 5+4 NA NA - +++ NA 
HZ44 80 5+4 NA NA - ++ NA  
HZ45 74 3+3 G=R G=R + - +++ 
HZ46 80 4+4 G=R G=R +++ - ++ 
HZ47 67 5+5 G=R NA - ++ +++ 
HZ48 78 3+4 G=R NA ++ - ++ 
HZ49 75 3+3 G=R G=R + - ++ 
HZ50 75 3+3 G=R G=R NA NA - 
HZ51 66 5+4 G=R G=R ++ ++ + 
HZ52 66 3+4 NA G=R NA NA ++ 
HZ53 73 4+4 NA G=R - + +++ 
HZ54 58 4+4 NA NA ++ ++ NA  
HZ55 84 4+4 G=R G=R NA NA ++ 
HZ56 69 4+4 NA G=R ++ - - 
HZ57 75 4+4 NA NA - - NA 
HZ58 75 4+4 NA NA - - NA  
HZ59 73 5+4 NA NA ++ - NA 
HZ60 65 3+4 NA NA + - NA 
HZ61 85 3+3 NA NA +++ +++ NA  
HZ62 56 4+4 Loss NA ++ ++ +++ 
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HZ63 68 3+3 NA NA + - NA 
HZ64 55 4+5 G=R G=R NA NA +++ 
HZ65 75 4+4 G=R G=R + + + 
HZ66 66 3+3 G=R G=R ++ - ++ 
HZ67 81 4+3 G=R G=R + + +++ 
HZ68 52 4+4 NA G=R + + - 
HZ69 79 3+4 NA G=R - + ++  
HZ70 77 3+3 NA NA ++ ++ NA 
HZ71 78 3+4 G=R G=R - - - 
HZ72 78 5+5 NA NA ++ ++ NA 
HZ73 69 4+4 NA NA +++ +++ NA 
HZ74 73 3+4 NA G=R - - ++  
HZ75 75 5+4 G=R NA - +++ +++ 
HZ76 55 3+3 G=R G=R ++ - ++ 
HZ77 66 3+4 G=R NA + - - 
HZ78 73 3+4 NA G=R NA NA - 
HZ79 85 4+4 G=R G=R + - ++  
HZ80 47 5+4 G=R Loss + - - 
HZ81 74 4+4 NA NA ++ ++ NA 
HZ82 76 4+4 NA NA ++ ++ NA  
HZ83 69 3+4 G=R G=R + - +++ 
HZ84 48 5+5 NA NA + +++ NA 
HZ85 68 5+4 NA NA +++ +++ NA 
HZ86 80 5+4 G=R G=R - ++ ++ 
HZ87 85 3+3 G=R G=R - - + 
HZ88 58 3+3 G=R G=R - - - 
HZ89 56 4+4 G=R NA ++ + +++  
HZ90 77 4+4 G=R G=R ++ ++ - 
HZ91 66 5+5 NA NA - + NA 
HZ92 70 4+4 G=R NA - + NA 
HZ93 87 4+4 G=R NA ++ - ++ 
HZ94 72 3+3 G=R NA - - NA 
HZ95 76 5+4 G=R NA NA NA ++ 
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HZ96 81 5+5 G=R Loss - ++ + 
HZ97 68 5+5 G=R G=R - - +++ 
HZ98 68 4+3 G=R NA + - - 
HZ99 75 4+4 G=R NA NA NA NA 
HZ100 73 5+4 Loss G=R - - +  
HZ101 83 4+3 G=R G=R ++ - +++ 
HZ102 78 4+4 NA NA + ++ NA 
HZ103 79 4+4 G=R G=R - ++ ++ 
HZ104 74 3+4 G=R G=R ++ - +++ 
HZ105 73 4+4 G=R NA NA NA ++ 
HZ106 75 4+4 G=R G=R ++ ++ ++ 
HZ107 62 3+3 G=R G=R - - NA 
HZ108 75 3+4 G=R G=R ++ - NA 
HZ109 66 5+4 G=R  Loss ++ - - 
HZ110 66 4+3 Split 
Homo 
loss ++ ++ - 
HZ111 66 2+3 G=R G=R + - ++  
HZ112 74 4+4 G=R G=R - - ++ 
HZ113 66 5+4 G=R Loss - - + 
HZ114 72 4+4 G=R G=R - - ++ 
HZ115 70 4+4 NA G=R - - ++ 
HZ116 70 5+4 G=R G=R - - + 
HZ117 74 4+3 G=R G=R - - ++ 
HZ118 76 4+4 G=R G=R - + ++ 
HZ119 60 4+4 G=R Loss - + - 
HZ120 66 3+3 G=R G=R + - - 
HZ121 77 5+4 G=R Unstable - - NA 
HZ122 78 4+4 G=R G=R - - +++ 
HZ123 66 5+4 G=R NA NA NA NA 
HZ124 78 5+4 G=R G=R - - NA 
HZ125 77 4+4 G=R Gain - + + 
HZ126 81 4+4 G=R NA NA NA ++ 
HZ127 76 3+4 G=R G=R - - ++ 
 171 
HZ128 70 3+4 G=R NA NA NA NA 
HZ129 70 4+4 G=R NA NA NA +++ 
HZ130 77 4+3 G=R  NA NA NA ++ 
HZ131 70 5+5 G=R G=R +++ - +++ 
HZ132 78 4+3 G=R G=R - - +++ 
HZ133 81 4+4 G=R G=R ++ ++ NA 
HZ134 63 4+4 Loss G=R ++ ++ NA 
HZ135 70 4+4 G=R G=R - - NA 
HZ136 69 4+3 Loss G=R + - NA 
HZ137 77 4+4 NA NA - - NA 
HZ138 63 5+4 G=R G=R + + +++ 
HZ139 61 4+4 G=R NA NA NA NA 
HZ140 68 4+3 G=R G=R - - NA 
HZ141 69 4+4 G=R G=R ++ + NA 
HZ142 50 5+5 G=R G=R + - +++ 
HZ143 73 3+3 NA G=R - + - 
-: no stain; +: weak stain; ++; medium stain; +++: strong stain; NA: no data 
 
Both 21q22.2-22.3 deletion and translation can result in the formation of the 
TMPRSS2:ERG fusion gene. Using the FISH probes located at ERG, which were 
described in section 2.2.12.2 (390), I found that the 5’ of ERG was deleted in 29.7% 
(46/155) of UK cases (Table 5.3) but only 5.4% (5/93) of Chinese cases (Table 5.4). 
The signals of TMPRSS2 and ERG were separated in 11.6% (18/155) of UK cases 
(Table 5.3) and 2.1% (2/93) of Chinese cases (Table 5.4). No genomic alterations were 
detected in BPH cases. The difference in the frequencies of ERG rearrangements 
between the Chinese and UK samples are statistically significant (p<0.001) (Table 5.5). 
Representative FISH images are shown in Figure 5.5.  
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Figure 5.5 Representative ERG FISH images in UK and Chinese TMAs. 
ERG rearrangement was analysed using a probe for undeleted region at 3’ of ERG (red signal) 
and a probe for deleted region at 5’ of ERG (green signal). A: A UK case with ERG deletion 
(fewer green than red signals). B: A UK case with ERG split (separated green and red signals). 
C: A Chinese cases with no ERG rearrangement (two copies of red and green signals in one 
cell).  
 
Using a FISH probe with the chromosome 10 centromere as a control for PTEN 
deletion analysis, normal copy number of PTEN was found in BPH TMA. The probe 
located at PTEN was deleted in 42.3% (66/156) of UK samples (Table 5.3), but only 
in 14.3% (12/84) of Chinese samples (Table 5.4), which is consistent with our SNP 
array results. The difference in the frequencies of PTEN deletion between the Chinese 
and UK samples is statistically significant (p<0.001) (Table 5.5). Representative 
FISH images are shown in Figure 5.6. Moreover, in the UK samples, I observed 
intra-tumoural heterogeneity for PTEN copy number changes. In addition to the 
frequent co-existence of PTEN neutral and deleted cancer cell colonies, I identified 
cells that showed the co-existence of both PTEN gain and loss populations in 7.1% 
(11/156) of UK cases (Table 5.3, Figure 5.7). In contrast, such events were only 
observed in 1/84 assessable Chinese samples. This indicates that certain factors in the 
UK prostate tissues lead to genomic instability and consequently PTEN deletion in 
many cancer cases. 
 
 
 
 
 
A B C 
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Figure 5.6 Representative PTEN FISH images in UK and Chinese TMAs. 
The PTEN gene status was analysed using a probe for the PTEN locus (red signal) and a 
chromosome 10 centromeric probe (green signal). A: A UK case with homozygous PTEN 
deletion, no red signal. B: A UK case with heterozygous PTEN deletion, less red signals. C: 
A Chinese case without PTEN loss, two copies of red and green signals in one cell. 
 
Table 5.5 Statistical analysis of the difference in ERG and PTEN deletions using 
FISH analysis of Chinese and UK samples in the TMA studies. 
                   ERG                            PTEN  
Normal  Deletion* Split * Total p value Normal Deletion Total p value 
UK 97 (62.6%) 46 (29.7%) 18 (11.6%) 155 90 (57.7%) 66 (42.3%) 156 
Chinese 86 (92.5%) 5 (5.4%) 2 (2.1%) 93 72 (85.7%) 12 (14.3%) 84 
Total 183 51 20 248 
 
<0.001 
162 78 240 
 
<0.001 
*: There are six UK prostate cancer cases have both ERG deletion and split. 
 
A B C 
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Figure 5.7 FISH analysis of one UK prostate cancer case exhibiting both PTEN 
copy number gain and loss cancer cells. 
The PTEN gene status was analysed using a probe for the PTEN locus (red signal) and a 
chromosome 10 centromeric probe (green signal). A: A FISH image of whole core, where the 
area with PTEN loss (within the upper large square) and gain (within the lower large square). 
B: An enlarged image of the area showing PTEN loss, with more green signals. C: An 
enlarged image of the PTEN gained region with more red than green signals.  
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5.2.5 IHC for ERG and PTEN expression 
To determine if the differences in genomic alterations lead to differential translational 
expression of ERG and PTEN between the two populations, we analysed protein 
expression levels by IHC using the same Chinese and UK TMAs. Consistent with 
previous reports (391), ERG was highly expressed in the nucleus of basal and 
endothelial cells of normal prostate tissue, and staining was negative in secretory 
epithelial cells. In cancer lesions in the UK samples, ERG was detected predominantly 
in the cytoplasm (46.4% in cytoplasm and 15% in nuclear), while it was detected more 
frequently in the nucleus in the Chinese samples (25% in cytoplasm and 34.4% in 
nuclear) (Table 5.3, 5.4, 5.6). Representative IHC images are shown in Figure 5.8. 
 
 
 
 
 
 
Figure 5.8 Differential expression of ERG between UK and Chinese prostate 
cancers detected by IHC in TMAs. 
A: In adjacent normal prostate glands, positive signal can be seen in the basal cells and the 
secretary cells are negative. B: Endothelium of vessels is positively stained. C: Cytoplasmic 
localisation of positive signal in one UK prostate cancer sample. D: Nuclear localisation of 
positive signal in one Chinese prostate cancer sample. 
 
Table 5.6 Statistical analysis of differences in ERG expression between UK and 
Chinese samples in IHC TMA analysis. 
Cytoplasmic ERG (cancer (%))   Nuclear ERG (cancer (%))    
Negative or 
equivocal  
Weakly 
positive 
Strongly 
positive 
Total p 
value 
Negative or 
equivocal 
Weakly 
positive 
Strongly 
positive 
Total p 
value 
UK 89 (53.6 %) 63 (38.0 %) 14 (8.4%) 166  141 (84.9 %) 16 (9.6 %) 9 (5.4 %) 166  
Chinese 96 (75.0 %) 25 (19.5 %) 7 (5.5 %) 128 0.001 84 (65.6 %) 34 (26.6 %) 10 (7.8 %) 128 <0.001 
Total 185 88 21 294  225 50 19 194   
 
PTEN can also be inactivated by mutation and DNA methylation. I determined the 
frequency of PTEN inactivation using IHC on the same TMA samples to determine 
the impact of genomic defects on protein expression in the UK and Chinese groups. 
A C D B 
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Low level (- and +) protein expression of PTEN was detected in 76.1% (111/159) of 
UK samples (Table 5.3), but only in 36.3% (33/91) of Chinese samples (Table 5.4). 
This difference is statistically significant (p<0.001) (Table 5.7). Representative 
images are shown in Figure 5.9.  
 
 
 
 
 
 
 
Figure 5.9 Differential expression of PTEN between UK and Chinese prostate 
cancers detected by IHC in TMAs. 
A: Loss of PTEN expression in cancer cells and positive stroma cells in a UK PTEN 
homozygous deletion case. B: Lack of PTEN expression in a proportion of cancer cells from 
a UK partial PTEN deletion case. C: Strong PTEN expression in a Chinese sample without 
PTEN deletion. 
 
Table 5.7 Statistical analysis of the difference in PTEN expression between UK 
and Chinese samples in the TMA IHC analysis. 
PTEN UK  (%) Chinese  (%) p value 
- 70 (47.2%) 22 (24.2%) 
+ 41 (28.9%) 11 (12.1%) 
++ 36 (16.4%) 30 (33%) 
+++ 12 (7.5%) 28 (30.7%) 
Total  159 91 
<0.001 
-: no stain; +: weak stain; ++; medium stain; +++: strong stain 
 
5.2.6 CAG repeat polymorphism in AR 
As an initial study into the mechanistic factors associated with the genomic alterations 
differently represented in UK and Chinese prostate cancers, I investigated the repeat 
size and prevalence of AR CAG repeat polymorphism in 37 UK and 24 Chinese 
prostate cancers. As illustrated in Figure 5.10, the CAG repeat lengths in the UK 
A B C 
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samples (mean=20.65) were statistically shorter (p=0.0347) than the Chinese samples 
(mean=22.13). Due to the limited TMPRSS2:ERG fusion-positive case from Chinese 
samples, I only examined the difference in CAG repeat size in UK fusion positive and 
negative populations. The average CAG repeat size in UK fusion-positive cases is 1 
repeat shorter than fusion-negative cases, although it is not statistically significance 
(p=0.1765). This should be investigated in larger series to find out the difference.  
 
Figure 5.10 Shortened AR CAG repeat lengths are found in UK samples as 
compared to Chinese samples. 
A histogram illustrates the number of AR Exon1 CAG repeats observed in 37 UK and 24 
Chinese clinical samples as detected by microsatellite analysis.  
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5.3 Discussion 
Many of the common genomic alterations observed in the Chinese samples have been 
reported in prostate cancer from the Western countries previously (139, 392). These 
genomic alterations common to both populations suggest that the genetic pathways 
involved in the development of prostate cancer are common to both Chinese and 
Western populations. 
 
5.3.1 Different frequencies of genetic alterations and protein expression 
changes in ERG and PTEN in UK and Chinese prostate cancers 
Here, I detected the different frequencies of ERG and PTEN alterations in UK and 
Chinese samples. This difference was detected at different level with variant 
techniques, including genomic, RNA and protein expression. From the SNP array 
result, the frequencies of 21q22.2-22.3 and 10q23.31 deletions in the UK samples are 
similar to those previously published for Western samples (133, 137-139, 292, 393). 
However, it is the first time that the deletion events are observed much less frequently 
in the Chinese samples. In addition, the frequency of TMPRSS2:ERG fusion transcript 
is much less in Chinese than UK cases. FISH and IHC also verified the statistically 
significant difference between UK and Chinese prostate cancers. These data indicated 
that TMPRSS2:ERG fusion  and inactivation of PTEN are the key genetic differences 
between Western and Chinese prostate cancers. Recently, the low frequency of 
TMPRSS2:ERG fusion in Japanese and Korean populations comparing to Western 
countries has also been reported (394-396).  
 
5.3.2 Correlation of age and ERG rearrangement and PTEN deletion 
The risk of prostate cancer increases with age. Most patients are diagnosed over the 
age 65 years; very few patients are diagnosed younger than 50 years. The association 
between age and ERG rearrangements and PTEN deletion has not been reported. In 
this study, I noticed that the patient ages were higher in the Chinese (range from 47-
91, mean 72.1) than the UK (range from 39-83, mean 63.3) cases (p<0.001). 
However, age at diagnosis was not significantly associated with ERG rearrangements 
or PTEN deletion in UK and Chinese samples (Table 5.8).  
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Table 5.8 Correlation of age with FISH results of ERG rearrangements and 
PTEN deletion in UK and Chinese samples. 
ERG rearrangement PTEN deletion 
 Age 
Negative Positive Total p value Negative Positive Total p value 
≤65 55 (60.4%) 36 (40%) 91 55 (59%) 38 (41%) 93 
65-70 30 (62.5%) 18 (37.5%) 48 27 (57%) 20 (43%) 47 
71-73 9 (73.3%) 3 (26.7%) 12 7 (58%) 5 (42%) 12 
≥74 1 (25%) 3 (75%) 4 
0.561 
1 (25%) 3 (75%) 4 
0.406 UK 
TMA 
Total 95 60 155  90 66 156  
≤65 13 (81.3%) 3 (18.7%) 16  11 (78.6%) 3 (21.4%) 14  
65-70 22 (91.7%) 2 (8.3%) 24  15 (78.9%) 4 (21.1%) 19  
71-73 9 (90%) 1 (10%) 10 0.221 13 (100%) 0 13 0.071 
≥74 41 (97.6%) 1 (2.4%) 42  33 (86.5%) 4 (13.5%) 37  
Chinese 
TMA 
Total 85 7 92  72 11 83  
 
5.3.3 Gleason score and ERG rearrangements and PTEN deletion 
There is conflicting evidence regarding to the association between Gleason score and 
the frequency of TMPRSS2:ERG (397-399). High Gleason score is generally 
associated with an increased frequency of PTEN inactivation (400-402). In this study, 
as the average Gleason score was higher for the Chinese cases than for the UK ones 
(p<0.001), the difference in Gleason score between the two populations cannot 
account for the difference in the frequency of these genomic alterations. Gleason 
score was not significantly correlated with ERG rearrangement or PTEN deletion in 
either the UK (p=0.463 and 0.546 respectively) (Table 5.9) or the Chinese sample 
groups (p=0.731 and 0.272 respectively). 
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Table 5.9 Impact of Gleason scores with FISH results of ERG rearrangements 
and PTEN deletion by FISH in UK and Chinese samples. 
ERG rearrangement PTEN deletion 
 
Gleason 
Score Negative Positive Total p value Negative Positive Total p value 
<7 13(46.4%) 15 (53.6%) 28 15 (53.6%) 13 (46.4%) 28 
=7 51(62.2%) 31 (37.8%) 82 46 (55.4%) 37 (44.6%) 83 
>7 31 (68.9%) 14 (31.1%) 45 29 (64.4%) 16 (35.6%) 45 
UK 
TMA 
Total 95 60 155 
0.463 
90 66 156 
0.546 
<7 15 (93.8%) 1 (6.2%) 16 14(93.3%) 1 (6.7%) 15 
=7 19 (90.5%) 2 (9.5%) 21 23 (91.7%) 2 (8.3%) 25 
>7 52 (92.9%) 4 (7.1%) 56 35 (77.8%) 9 (22.2%) 44 
Chinese 
TMA 
Total 86 7 93 
0.731 
72 12 84 
0.272 
 
5.3.4 ERG rearrangements and overexpression 
In this study, ERG deletion and split events occurred in majority of the ERG 
expression-positive cases in the UK samples (Table 5.10). While TMPRSS2:ERG 
fusion can lead to ERG overexpression, ERG can also be activated in the absence of 
gene fusion by other transcription regulation mechnisms. The Kappa value of 0.472 
(moderate agreement) in the cytoplasm expression correlation and Kappa value of 
0.221 (fair agrrement) in the nuclear expression correlation suggest that ERG 
rearrangements mainly correspond with ERG cytoplasmic expression (Table 5.10). 
There were a small number of cases with ERG rearrangements, but without 
cytoplasmic over-expression of ERG (Table 5.3, 5.4 and 5.10). It is possible that 
such cases may result from an underlying genomic instability that leads to ERG 
rearrangements without fusion to genes, such as TMPRSS2, which are highly 
expressed in the prostate. Alternatively, the TMPRSS2:ERG fusion may be 
transcriptionally inactive due to reasons such as inactivation of the AR in patients 
receiving hormone therapy. In many of the ERG deletion cases, ERG protein was not 
detected by IHC in the nucleus (Table 5.3 and 5.10), suggesting that ERG 
rearrangements are not directly associated with ERG nuclear expression. Due to the 
small number of cases exhibiting ERG genomic alterations in the Chinese samples, it 
is impossible to statistically concordance the FISH and IHC results for the Chinese 
samples. 
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Table 5.10 Statistical analysis showing the concordance between ERG FISH and 
IHC status in UK samples.  
  IHC-cytoplasm IHC-nuclear 
  - / + ++/ +++ 
Total Kappa 
- / + ++/ +++ 
Total Kappa 
Negative 68 28 96  91 5 96  
FISH 
Positive 12 45 57 0.472  41 16 57 0.221 
Total  80 73 153  132 21 153  
 
5.3.5 PTEN deletion and underexpression 
The occurrence of PTEN deletion and inactivation is common in cancers (140, 403, 
404); the common mechanisms include PTEN deletion, mutation and methylation. As 
expected, in this study, there were more cases of PTEN protein underexpression than 
PTEN genomic deletion in both UK and Chinese prostate cancers (Table 5.3 and 5.4). 
However, PTEN deletion accounted for the majority (60/110, 54.5%) of PTEN loss of 
expression cases in UK and 38.7% (12/31) of Chinese cases with PTEN loss of 
expression were detected with PTEN deletion (Table 5.11). The kappa showed slight 
and moderate agreement between PTEN deletion and expression in UK and Chinese 
cases respectively. In the cases with PTEN underexpression without PTEN deletion, 
the low expression level may be caused by PTEN mutation and/or methylation. In the 
cases (n=5) where PTEN deletion was accompanied with high expression by IHC, 
unknown mechanisms may be induced the overexpression of the remaining PTEN 
gene.  
 
Table 5.11 Statistical analysis showing the concordance between PTEN FISH and 
IHC status in UK and Chinese samples. 
   PTEN  IHC 
   -/ +  ++/+++ 
Total  Kappa 
Deletion  60 5 65  
PTEN  
Undeletion  50 40 90 0.148 UK TMA 
Total   110 45 155  
Deletion  12 0 12  
PTEN  
Undeletion  19 43 62 0.423 Chinese TMA 
Total   31 43 74  
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5.3.6 Relationship between PTEN status and ERG rearrangements  
It has recently been reported that the TMPRSS2:ERG fusion event co-exists with 
PTEN deletion in prostate cancer specimens and that ERG over-expression cooperates 
with PTEN inactivation in driving prostate cancer development (323-325). From my 
FISH analysis, the co-existence of ERG rearrangements with PTEN deletion was 
observed in the UK samples (kappa=0.436) but only slight agreement with PTEN 
underexpression (kappa=0.154) (Table 5.3, 5.12). The number of Chinese cases with 
these deletions is too small for statistical analysis (Table 5.4). It is, therefore, 
interesting to find that the predominant genomic differences between Western and 
Chinese samples are the 21q22.2-22.3 deletion, which causes the TMPRSS2:ERG 
fusion, and the 10q23.31 deletion, which causes inactivation of PTEN. This not only 
further supports the co-function of ERG over-expression and PTEN inactivation in 
prostate cancer development, but, more importantly, it suggests that a currently 
unknown causative/selective factor(s) for these two deletions may exist in the 
Western population.  
 
Table 5.12 Statistical analysis of the concordance between ERG and PTEN 
alterations in UK samples. 
ERG rearrangement  
Negative Positive 
Total Kappa 
Negative 70 17 87  
Positive 24 40 64 0.436 PTEN deletion 
Total 94 57 151  
++/+++ 37 12 49  
-/+ 59 46 105 0.154 PTEN IHC 
Total 96 58 154  
 
5.3.7 CAG repeat polymorphism and TMPRSS2:ERG  
As I mentioned in section 1.3.1, shorter CAG repeat size is associated with a higher 
prostate cancer risk (405). The CAG repeat length at AR Exon 1 varies among Chinese, 
white and black populations, resulting in different levels of AR activity (406-409). 
Although this polymorphism has been previously been associated with prostate cancer 
development, the relationship between the CAG repeat length difference and 
TMPRSS2:ERG in cancer patients from different populations has not been studied. Here, 
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I identified the difference of CAG repeat length in UK and Chinese cancer patients, 
indicating that it may be one of the factors contributing to the different frequencies of 
TMPRSS2:ERG fusion in thee two populations. AR induces transcription of androgen-
responsive genes, such as TMPRSS2. Transcriptional activity can lead to the co-
localisation of genes located far away on chromosomes by spatial genome organization, 
which consequently increases the risk of gene translocations (410-412). Therefore, AR 
CAG repeat length may be associated with TMPRSS2:ERG fusion by affecting AR 
activity and subsequently TMPRSS2 transcription, which was now confirmed by our and 
the other studies (413-415). 
 
In summary, I have used a high-resolution SNP array approach to reveal the global 
genomic alterations in UK and Chinese prostate cancers. In doing so, I have identified 
key differences in the somatic genomic alterations found in prostate cancer cases from 
two populations with different cancer risk. Deletions of 10q23.31 and 21q22.2-22.3, 
which lead to PTEN inactivation and TMPRSS2:ERG gene fusion events, 
respectively, are commonly observed in prostate cancers from Western populations 
but not in my Chinese samples  examined. This suggests that these deletions may be 
key genomic alterations underlying the regional/ethnic difference in clinical incidence 
and they may be induced by specific environmental and/or genetic risk factors to 
which Western men are exposed. This supports our hypothesis that certain cancer risk 
factors cause specific somatic genomic alterations. Identification of these factors and 
further understanding of the mechanisms inducing these deletions should lead to the 
development of better prevention and, consequently, dramatically reduce the burden 
of prostate cancer in Western men. 
 
Based on the nature of these genomic alterations and the potential risk factors 
associated with different geographic populations, specific studies can be designed to 
accelerate the identification of such factors and, thus, the mechanisms underlying 
these genomic alterations and the development of the disease. We have demonstrated 
this in our AR CAG repeat polymorphism study. The genome-wide approach used in 
this study can also be applied to other cancers with an apparent regional or ethnic 
differences in incidence to identify specific cancer-related genomic changes in the 
populations with high-incidence.  
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 CHAPTER VI HIGH-RESOLUTION KARYOTYPING 
(HRK) FOR CHROMOSOME TRANSLOCATION AND 
FUSION GENE IDENTIFICATION 
 
6.1 Introduction  
Genetic abnormalities, including deletion, amplification and chromosome 
translocation, are associated with cancer initiation, development, diagnosis and 
treatment (38). Full understanding of the genetic impact in human tumours requires 
identification of all of the genetic alterations in individual cancers, but currently the 
majority of genetic abnormalities in most cancers remain unknown. In addition, 
chromosome translocations and fusion genes are the hallmark of hematologic and soft 
tissue malignancies, but their importance in solid tumours is still not well defined. 
Due to the technical difficulty in the analysis of solid tumour and the complex 
karyotype, only a few fusion genes have been identified in solid tumour so far (416). 
In recent years, some high frequency chromosome rearrangements were revealed and 
fusion genes found in carcinomas, including the TMPRSS2:ERG in prostate cancer 
(40) and EML4:ALK in lung cancer (45, 46). This highlights the critical role of 
chromosome rearrangements in prostate and other solid cancers, and the potential for 
discovering critical genetic alterations in solid tumours using new approaches. In fact, 
TMPRSS2:ERG is the first fusion gene frequently found in epithelial originated 
cancers. Together with PTEN inactivation or overactivity of the PI3K pathway, it can 
accelerate prostate cancer development (417). According to the result of this study, 
these two alterations may be a crucial factor that accounts for the different prostate 
cancer incidence between Western and Chinese populations.  
 
The recent discovery of these high frequency fusion genes indicates the presence of 
many recurrent chromosome rearrangements and fusion genes that remain hidden in 
the complex genomic alterations of carcinomas. More chromosome rearrangements, 
especially for those inducing fusion genes, will be found using new technologies. 
Karyotyping is the initial technique that has been used to identify chromosome 
rearrangements and fusions. However, the resolution of chromosomal rearrangements, 
detected by traditional G-banding and the more recently developed 24-color 
karyotyping methods, including M-FISH and SKY (173, 174), is very low at 
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chromosome band level. Moreover, the further identification of DNA sequences and 
genes involved at the breakpoints is very time consuming. The application of CGH on 
microarrays has achieved higher resolution (175, 418). However, these CGH and 
microarray based methods detect genomic copy number changes, not chromosome 
rearrangements. Through the combination of M-FISH and high-density SNP array 
technology, I have developed an approach for HRK with precise definition of 
chromosome breakpoints. 
 
My approach is based on the observation that many chromosome rearrangements lead 
to DNA copy number changes at the breakpoints. In human malignancies, particularly 
solid tumors, translocations are frequently unbalanced leading to relative chromosome 
copy number changes (419). Even in the case of cytogenetically balanced 
translocations, small chromosome deletions frequently occur at these breakpoints 
(272, 420). Therefore, the boundaries of DNA copy number changes can define not 
only the breakpoints of chromosome deletions and amplifications, but also of other 
rearrangements including translocations. I developed a novel HRK approach, which 
combines the Affymetrix 500K SNP array with the M-FISH analysis to get the 
chromosome rearrangements with high-resolution. I used this approach to map 
genome-wide chromosome rearrangements at a previously unprecedented resolution.  
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6.2 Results  
 
6.2.1 HRK  
I applied HRK in the analysis of three prostate cancer cell lines, PC3, DU145 and 
LNCaP, which have been previously studied using M-FISH (Figure 6.1, Figure 6.2 
and Figure 6.3) by Dr. John Strefford from our group (421). The degrees of 
chromosome alterations were simple, complex and very complex in LNCaP, DU145 
and PC3 respectively.  
 
 
 
 
Figure 6.1 M-FISH image for PC3. 
(Adapted from Dr. John Strefford’s paper with permission) 
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Figure 6.2 M-FISH image for DU145. 
(Adapted from Dr. John Strefford’s paper with permission) 
 
 
 
Figure 6.3 M-FISH image for LNCaP. 
(Adapted from Dr. John Strefford’s paper with permission) 
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Using HRK, I karyotyped the three cell lines and defined most of the chromosome 
breakpoints (Table 6.1, 6.2 and 6.3). Figure 6.4 shows an example of the HRK 
analysis of chromosome 9 in DU145.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4 HRK for chromosome 9 in DU145.  
A: 500K SNP profile of chromosome 9. Low SNP intensity at the beginning, intermedium 
SNP intensity at the end, and high SNP intensity in the middle. The big gap in the middle is 
the centromeric area without SNP. B: M-FISH image reveals four fragments for chromosome 
9. Two fragments are whole chromosomes. The third fragment lost one small region and the 
fourth shortest fragment contains a translocation with other chromosome. C: The four 
fragments were represented with the four lines according to the copy number changes shown 
in SNP array. Each line was defined with precise boundary. 
 
 
 
A B 
C 
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Table 6.1 High-Resolution Karyotypes of Prostate Cell Lines LNCaP. 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
LNCaP 
del(1)[p36.11(26,723 kb)-36.21(26,723 b)]x2 
der(1)t(1;15)(p?::q?)x2 
del(2)[2p13.1(74,801 kb)-2p22.2(38,360 kb)] 
del(2)[2p16.3(47,940 kb)-2p21(47,564 kb)]x2 
der(4)t(4;6;10)[q22.3(96,668 kb)::q15(91,744 kb)q25.3(158,266 kb)::q23.33(96,232 kb)]x2 
amp(5)[q11.2(57,180 kb-58,439 kb)] 
der(6)t(4;6)[q22.3(98,325 kb)::q15(87,631 kb)]  
der(6)t(6;16)[p21.1(41,967 kb)::q22.2(71,256 kb)]x1.5 
der(10)t(6;10)[q25.3(160,264 kb)::q23.33(95,380 kb)]x2  
del(10)[q23.1(86,170 kb)-q23.31(90,839 kb); q24.2(101,240 kb)-q24.32(103,208 kb)]x2 
del(12)(in  rare population) 
del(13)[q12.11(19,554 kb)-q12.3(28,837 kb);q21.32(67,037 kb)-q22.2(7 4,905 kb);q31.1(83,290 
kb)-q33.2(105,146 kb)] 
del(13)[ q21.32(67,037 kb)-q22.2(74,905 kb)]x2 
der(15)t(1:15) (p?::q?)x2 
add(15)[q11.2(18,361 kb-19,609 kb)] 
der(16)t(6;16)[ p21.1(41,967 kb)::q22.2(71,256 kb)]x2 
amp(17)[q21.31(41,370 kb-42,071 kb)] 
del(19)[q13.2(46,015 kb)-q13.33(54,409 kb)]x2 
del: deletion; der: derivative chromosome; t: translocation; amp: amplification; add: additon. 
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Table 6.2 High-Resolution Karyotypes of Prostate Cell Lines DU145. 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
DU145 
-X  
add(X)[p22.33(2,692 kb)-pter] 
der(Y)t(20;Y)[p10::q?]del(20)[p12.1(14,657 kb-15,982 kb)] 
der(1)t(1;4)(q10;p10) 
amp(1)[q10-23.3(158,418 kb)] 
del(2)[p12(80,558 kb-80,426 kb)] 
der(4)t(4;16)[q31.22(14,7635 kb)::p11.2(33,629 kb)]del(4)[q31.1(141,021 kb-141,352 
kb)]amp(4)[q31.21 (142,874 kb)-q31.22(147,629 kb)], chr 16 component missing in many cells 
der(5)t(5;21)(p10::q10) 
i(5)(p10) 
del(6)[ q24.3(148,158 kb-148,343 kb)]x2 
der(9)del(9) [p21.1(33,224 kb)-ter]t(9;15)[q13.1(80,185 kb)::q?)]  
del(9)[p21.1(33,224 kb)-ter] 
der(10)t(10;21)(p11.21(36,198 kb)::q10] 
der(11)t(11;12)[p11.2(48,477 kb)::q10] 
amp(12)[p12.1(23,490 kb-25,303 kb)] 
der(13)t(1;13)[:q23.3(158,418 kb)q10::qter] 
der(13)t(2;10;13)[p12(80,816 kb)::p12.33(17,407 kb)pter::qter]del(2)[p12(80,432 kb-80,335 kb)]  
der(14)t(3;14)[q22.2(136,200 kb)::q22.1(51,534 kb)] 
del(14)[q11.2(21,669 kb)-q12(27,058 kb)] 
der(15)t(15;20)(p10::q10)x2 
+del(15)[q11.2(21,118 kb)-qter] 
der(16)t(6;16)[pterq12(68,076 kb)::p11.2(33,629 kb)] del(6)[q12(62,771 kb-66,039 kb)] 
del(17)[p11.2(17,944 kb)-p12(15,698 kb)]x2 
der(18)t(14;18)[q12(26,929 kb)::q12.2(34,870 kb)]amp(18)[q12.2(31,850 kb-34,872 
kb)]del(14)[q13.3 (36,258 kb)-q21.3(46,683 kb)] 
del(19)[p13.2(10,972 kb)-p13.12(14,005 kb); P13.12(15,234 kb)-p10; q13.31(49,743 kb)-ter] 
add(20)[p13(1,363 Kb)-pter] 
amp(22)[q10-q11.21(20,323 kb)] 
add: addition; der: derivative chromosome; del: deletion; amp: amplification; t:translocation; i: 
isochromosome. 
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Table 6.3 High-Resolution Karyotypes of Prostate Cell Lines PC3. 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
PC3 
+X 
Chr1 complex rearrangement leads to gain of p36.31(6,881 kb)-pter, q10-q24.2(166,551 kb), 
q24.2(166,967 kb-167,314 kb), q32.1(199,454 kb)-q42.2(230,771 kb), q43(235,415 kb-240,059 
kb), q44(243,612 kb)-qter; amp of q24.2(167,555 kb)-q24.3(170,564 kb), q31.1(186,688 kb-
187,744 kb), q31.3(196,462 kb)-q32.1(198,178 kb); del of p32.3(50,777 kb)-p33(50,274 
kb)(homo), q24.2(166,551 kb-166,967 kb), q24.2(167,314 kb-167,555 kb), q24.3(170,564 kb)-
q31.1(186,688 kb), q31.1(187,744 kb)-q31.3(196,462 kb), q32.1(198,178 kb-199,454 kb), 
q42.2(230,771 kb)-q43(235,415 kb). Chr1 material in the der(10)i(3;10;1;10) most like the amp 
regions  
der(2)t(2;4)[pter::p14-pterorq31.21(142,118 kb)-q31.22(147,887 kb)(amp)]add(2)[q24.3(165,851 
kb- 167,433 kb)] 
der(2)t(2;8)(pter::q12.3(62,508 kb)]x2 
del(3)(p13(70,746 kb)-p14.2(63,569 kb);q21.2(125,682 kb)-qter]x2 
der(4)t(4;6)(q10::p10) 
der(4)t(4;20)(q10::?) 
der(4)del(4)(p14-pter)t(3;4)[q24(147,342 kb);q13.3(75,623 kb)]del(3)[q25.32(159,340 kb-160,106 
kb)] 
der(4)t(4;10)(p10::?) 
i(5)(p10)del(5)[p14.3(19,885 kb-19,996 kb)]x2  
der(5)t(14;10;5)[q11.2?(?)::p?q?::q10(5q complex rearrangement leading to amp of: q14.3(84,331 
kb-87,432 kb), q15(96,078 kb)-q21.3(104,070 kb), q21.3(106,935 kb-108,819 kb), q23.2(126,023 
kb)-q23.3(128,907 kb), q32(146,902 kb)-q33.1(150,059 kb), q33.3(156,029 kb-157,775 kb); del 
of:q11.2(58,468 kb-58,728 kb), q12.3(64,630 kb-66,225 kb), q13.1(67,080 kb-67,949 kb), 
q31.2(138,153 kb-138,343 kb)(homo)]x2 
del(6)(q21), in a small population 
+7 
amp(7)[q22.3(104,645 kb-105,980 kb)] 
del(8)(q11.21(50,010 kb)-q12.3(62,488 kb),q22.2(99,279 kb-100,438 kb)] 
del(8)[p22(17,334 kb-pter)] 
-9 
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Chr10: complex rearrangement including der(10)t(3,10,1,10,1,10,3) 
(p10::??::q?q?::??::q?q?::??::q10)x2. Leads to amp of p11.22(32,640 kb)-p11.21(38,278 kb), 
q11.21(41,935 kb-45,316 kb), q11.22(49,238 kb)-q21.1(60,308 kb), q21.1(60,560 kb)-
q21.3(65,161 kb), q21.3(65,821 kb)-q22.1(72,499 kb), q22.1(74,155 kb)-q22.3(81,980 kb) and del 
of q22.3(81,980 kb-82,316 kb), q23.31(89,630 kb-90,504 kb) 
del(11)[q14.2(85,328 kb-86,283 kb)] 
der(12)t(8;12)[q13.2(70,623 kb)::qter]del(12)[q24.33(129,203 kb-129,744 kb)]x2 
del(12)(p10-pter) 
add(12)[p12.1(25,763 kb)-p11.22(30,029 kb)]amp[p11.22(28,679 kb-30,029 kb)] 
+del(13)[q12.11(20,549 kb)-qter] 
del(14)[q24.3(73,151 kb)-q32.11(89,833 kb);q32.12(90,834 kb)-qter]amp[q24.3(72,186 kb-73,151 
kb)]x2 
der(14)t(14;15)(p10::q10)del(14)[q12 (30,033 kb)-q21.3(49,965 kb)] 
der(15)t(8;15;1;10)(:p22(17,334 kb)q11.21(50,010 kb)::p10q21.1(43,562 kb)::??::?] 
der(15)t(4;15)[ :p14-pterorq31.21(142,118 kb)-q31.22(147,887 kb)(amp)::p10] 
der(15)t(13;15)(q10::p10)x0.5 
-16 
del(17)[q21.2(37,507 kb-37,921 kb)]x2 
add(17)[q21.31(38,927 kb)-qter] 
add(17)[ q21.31(38,927 kb)-q25.3(76,215 kb)] 
del(18)[q12.1(26,931 kb)-q21.1(47,789 kb)]x2 
+del(18)(q10-qter) 
del(19)[p13.3(4,350 kb)-pter;q10-q13.33(54,323 kb)] 
+del(19)[p13.3(4,349 kb)-pter;p10-p13.12(14,811 kb);q10-q13.33(54,323 kb)] 
+20 
+21 
-22 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
chr: chromosome; amp: amplification; der: derivative chromosome; del: deletion; homo: homozygous 
deletion; t: translocation; add: addition; i: isochromosome. 
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6.2.2 Chromosome translocations and fusion genes  
The SNP array shows that LNCaP has the fewest number of genomic alterations. 
Using the HRK approach, six chromosomes were identified to be involved in 
chromosome translocations with eight breakpoint sites, three of them on Chromosome 
6 (422). Four breakpoints (4q22.3, 6q15, 6q25.3, and 10q23.33) are cytogenetically 
balanced. The t(6;16) is slightly unbalanced as one of the two copies of der(6)t(6;16) 
only exists in half of the cell population. With the exception of the t(1;15), where the 
associated deletions are too small (several hundred bp) (422) for detection at the 
resolution of the 500K SNP array, I precisely defined all breakpoints in LNCaP 
(Table 6.1). 
 
In DU145, all of the chromosome translocations, involving 18 chromosomes and 
resulting in 13 different derivative chromosomes, are unbalanced (421). I found two 
small amplicons at chromosome breakpoints, one (4q31.22) in the der(4)t(4;16) and 
another one (18q12.2) in the der(18)t(14;18) (Table 6.2). I mapped all breakpoints 
using chromosome gain/loss boundaries except for Chromosome Y in the 
der(Y)t(Y;20) due to lack of SNPs, and Chromosome 15 in the der(9)t(9;15) due to its 
presence in only a small population of cells which prevented detection as a copy 
number change.  
 
Chromosome alterations in PC3 were extremely complex, particularly for 
Chromosomes 1, 5, and 10. As these three chromosomes are severely fragmented and 
many regions involved in different derivative chromosomes, it was not possible to 
correlate each chromosome fragment with copy number gains and losses. Therefore, I 
karyotyped PC3 partially at high resolution with a general description of the gain/loss 
regions for Chromosomes 1, 5, and 10 (Table 6.3). Twelve internal deletions were 
found. Fragments of these three chromosomes can be further identified by FISH using 
BACs located at the defined breakpoints of chromosome gains or losses.  
 
The resolution of our approach also allowed direct identification of genes at the 
breakpoints. Searching Ensembl.org (http://www.ensembl.org/index.html) for the 170 
noncentromeric breakpoints (from translocations, internal deletions, and 
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amplifications) identified in the three cell lines, I found 96 genes/putative genes 
potentially split by chromosome rearrangements (Table 6.4).  
 
Table 6.4 Summary of Breakpoints Identified in the Prostate Cancer Cell Lines. 
Cell line Copy 
number 
change 
BPs Intragenic 
BPs 
BP genes up-
regulated in 
cancer 
BP genes 
down-
regulated in 
cancer 
BP genes 
translocated 
in cancer 
LNCaP Loss  26 10 0 1 (UNC5C) 0 
 Gain  5 3 2 (PDE4D, 
MAPT) 
0 0 
 Neutral  2 2 0 1 (ATBF1) 0 
DU145 Loss  12 8 0 1 (DRG2) 0 
 Gain  12 8 0 0 0 
 Neutral  21 6 0 1 (SMARCA4) 1 (BRD4) 
PC3 Loss  29 16 1 (PDE4D) 4 (FAF1, 
CDH18, 
CTNNA1, 
PTEN) 
0 
 Gain  42 22 1 (CAST) 3 (CAMTA1, 
SULF1, 
EFNA5) 
0 
 Neutral  36 22 3 (MAPK8, 
SLIT3, 
ADAMTS19) 
3 (LATS2, 
DPT, 
SLC30A4) 
1 (RANBP17) 
Bold: genes with 5’ and 3’ exons expressed at different levels; Underlined: genes reported in 
the literature as over-expressed in cancer, but not over-expressed in the prostate cancer cell 
lines according to exon array analyses; BP: breakpoint. 
 
I identified 27 translocations with both breakpoints precisely defined in the three cell 
lines. Nine of these translocations have a potentially split gene located at one of the 
breakpoints. Two translocations may carry truncated genes at both breakpoints, and in 
one case, the genes are in the same orientation (Table 6.5), which may lead to fusion 
transcripts. I characterised twenty-nine internal deletions with precise boundaries, 
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nine in LNCaP, eight in DU145, and twelve in PC3 (Table 6.1, 6.2 and 6.3). 
Interestingly, there were more genes located across the breakpoints of internal 
deletions than of translocations. 18 internal deletions carry a gene potentially split by 
one of the breakpoints. Five internal deletions led to potential gene truncations at both 
breakpoints, with both genes having the same orientation in three cases (Table 6.5). 
 
Table 6.5 Paired gene cross the breakpoints in LNCaP, DU145 and PC3. 
Cell lines Gene pairs associated with 
translocations 
Gene pairs associated with 
deletions 
LNCaP SNX9/TBC1D12 [t(6;10)] 
USP49/ATBF1 [t(6;16)] 
ZN198_human/NP-056048.1 
[del(13q12)] 
DU145 P54762-4/C14orf166 [t(3;14)] SLC25A21/MAMDC1 [del(14q)] 
SMARCA4/IL27RA [del(19p)] 
PC3 None Npal2/vp13B_human [del(8q)] 
LGP2_human/ATP6V0A1 
[del(17q)] 
Five pairs of genes in bold have the same orientations.  
 
6.2.3 Expression level analysis by Exon array  
Downstream of HRK, we used Affymetrix Exon 1.0ST arrays performed by Dr. 
Sharon James to monitor exon expression changes at many breakpoint genes 
simultaneously. The Affymetrix Human Exon 1.0 ST array contains 1.4 million 
exons/putative exons. Exon arrays can detect genome-wide expression changes in 
individual exons, and they include probes for 83 of the genes located at breakpoints in 
the three cell lines. Comparing gene expression in the cancer cell lines with that of a 
control prostate sample, there were twenty-nine down-regulated and sixteen up-
regulated genes across all of the exons. Twenty-eight genes showed differential 
expression of some exons (at least two fold and in many cases, ten or greater fold 
difference comparing the exons at both ends of a gene) in the relevant cell lines but 
not in those cell lines without truncation in those genes (Table 6.4). This suggests the 
expression of truncated or fusion genes. Many genes found to be potentially truncated 
in this study have been previously reported as differentially expressed in human 
cancers, including BRD4 and RANBP17, which have been previously identified in 
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chromosome translocations (423, 424). PTEN, the tumor suppressor deleted or 
mutated in advanced prostate cancer (425) is truncated in PC3 according to the HRK, 
and exon array data showed loss of expression of 3’ exons in this cell line (Figure 
6.5A). This correlates with a previous report of absence of normal PTEN transcripts 
(426) and, therefore, validated the application of this HRK approach for identifying 
altered genes at the chromosome breakpoints. Figures 6.5B and 6.5C show over-
expression of 3’ exons in SLC25A21 and IL27RA, both of which were 3’ fusion 
partners in separate fusion events as a result of deletions in the DU145 cell line.  
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Figure 6.5 Altered exon expression patterns of genes located at breakpoints.  
A: In the cell line, PC3, we detected down-regulation to background levels of PTEN exons 
from exon 3 to the 3’ end. PTEN is shown in the 5’-3’ orientation. B: In the cell line, DU145, 
we detected relative (>10-fold) over-expression of the last four exons of SLC25A21 compared 
to the control prostate sample. SLC25A21 is shown in the 3’-5’ orientation. C: In cell line, 
DU145, we detected relative (several fold) over-expression of all exons of IL27RA except for 
the first one. IL27RA is shown in the 5’-3’ orientation. There are four parts to the exon array 
plots: one shows genes as horizontal green lines linking green vertical bars that denote 
individual exons; the second part shows probes arrayed as single, vertical white bars; finally, 
the two yellow bars represent the expression levels of exons or exploratory probes for other 
sequences in the control prostate sample and the relevant cell line. 
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6.2.4 Cloning of MAMDC1:SLC25A21 fusion gene using MCC 
From Table 6.5, MAMDC1:SLC25A21 is a putative fusion gene identified by HRK, 
which was caused by a 14q internal deletion in DU145 cell line (Figure 6.6). To 
confirm this new finding and elucidate the breakpoints in MAMDC1 and SLC25A21, 
MCC was applied with help from Dr. Qian An, University of Southampton to define 
the breakpoint from 100kb to 527 bp so that the breakpoint sequence can be 
determined by inverse PCR. We selected the region between 36,277,603-36,240,748 
crossing the breakpoint of SLC25A21 and designed eight sets of primers (Table 2.5) 
for first round semi-nested PCR. Based on the first round results, the region between 
36,251,340-36,247,344 was selected from the results of the first-round of semi-nested 
PCR for the second round with four sets of primers (Table 2.5), which defined the 
breakpoint to a 527 bp region (Figure 6.7).  
 
The genomic DNA surrounding this breakpoint was cloned using inverse PCR and 
sequenced by Dr. An. The breakpoint of MAMDC1 is located in intron 3 and 
SLC25A21 is located in intron 7 (Figure 6.8). Following the cloning of this genomic 
breakpoint, I tried to identify the corresponding fusion transcript using RT-PCR. 
However,no fusion transcript was obtained after several pairs of primers have been 
tried (Table 2.4).  
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Figure 6.6 14q 13.3-21.3 deletion in DU 145.  
A: A 500K SNP array result showing the deletion region between 14q13.3 (SLC25A21) and 
14q21.3 (MAMDC1). B: The breakpoints at SLC25A21 and MAMDC1.  
 
 
 
 
 
 
 
        14q13.3 (SCL25A21)                               14q21.3 (MAMDC1) 
A 
B 
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Figure 6.7 Breakpoint mapping for SLC25A21 in DU145 using MCC.  
A: The results of the first round of PCR revealed DNA copy numbers at the region containing 
SLC25A21 breakpoint between the sixth and seventh probes. B: The second round PCR result 
narrowed the breakpoint into about 500 bp interval. Horizontal: probes along the genome; 
Vertical: DNA copy number (genomes/aliquot). 
527bp 
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5’-GTGTTAATAAATAAAAAGAAGGCCTGCAAGGCTGAGGTGGAAAGAT-3’ 
 
Figure 6.8 The genomic sequence of the MAMDC1:SLC25A21 fusion breakpoint 
region.  
Sequence in red and blue represents MAMDC1 and SLC25A21, respectively. The breakpoint 
of MAMDC1 is located in intron 3 and that of SLC25A21 is located in intron 7. 
 
MAMDC1 SLC25A21 
Exon 3 Intron 3 Intron 7 Exon 8 
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6.3 Discussion  
HRK is a novel and powerful approach that allows karyotyping to be carried out with 
high resolution and accuracy. Combining the 500K SNP array and M-FISH, I can 
define the breakpoints at the boundaries of most chromosome amplifications, 
deletions and translocations. Some chromosome aberrations detected by HRK were 
reported previously, such as der(6)t(4;6) in LNCaP (422). My FISH mapping data on 
the t(4;6) confirmed the HRK results of the 4q22.3 and 6q15 breakpoints and the 
associated chromosome deletion regions (427). Due to the high resolution of this 
technique, HRK also enabled the detection of small deletions and defined the 
breakpoints for cytogenetically ‘balanced translocations’, such as 4q22.3, 6q15, 
6q25.3 and 10q23.33 in LNCaP, 4q31.22 and 18q12.2 in DU145. In two situations, 
HRK cannot detect the chromosome aberrations. Firstly, 500K SNP array cannot 
detect very small deletion fragments, although it can provide results with high 
resolution (average one SNP per 5 kb). For example, the deletion at breakpoint of 
t(1;15) in LNCaP was confirmed of only several hundred bp by sequencing analysis 
(422). HRK cannot define this breakpoint. Secondly, the aberrations only happened in 
a few of the cells. For example, der(9)t(9;15) in DU145 is present in only a small 
population of cells. The normal karyotype in the majority of cells masked the copy 
number changes, so 500K SNP array cannot find the alteration. Currently, the 
approach was only used to karyotype cell lines because it is difficult to get metaphase 
cells from clinical samples. The protocol for metaphase preparation needs to be 
optimised for clinical samples. 
 
As a powerful and rapid approach in the definition of chromosome breakpoints and 
identification of the associated genes, HRK makes feasible the systematic analysis of 
truncated genes in large numbers of cancer samples. In this study, 96 gene/putative 
genes were located at breakpoints, 22 have been previously reported as having altered 
expression in cancer or being involved in translocations. Notably, PDE4D is the only 
recurrent breakpoint gene, potentially truncated in LNCaP and PC3 (Table 6.4). 
PDE4D over-expression leads to apoptosis resistance in leukemic cells (428). It is 
also found related with lung cancer (429). Knockdown of PDE4D reduced the growth 
and proliferation rate in prostate cancer xenografts in vivo (430). Of note, breakpoints 
in intergenic regions may also lead to gene deregulation as in the case of MYC 
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oncogenic activation (431). The HRK allowed us to characterize rapidly all of the 
chromosome breakpoints regardless of their effect on gene expression. Table 6.5 lists 
the potential fusion genes identified in this process. There were more potential fusion 
genes caused by internal deletion than translocation, and these data are comparable 
with those of previous studies. For example, TMPRSS2:ERG in prostate cancers (40) 
and STIL:TAL1 in leukemia (432) are both associated with internal deletion. Hence, 
HRK is a useful tool to identify chromosome alterations and the genes involved in 
breakpoints or potential fusion genes.  
 
After the detection of the potential fusion genes using HRK, I applied MCC to 
validate the presence of one fusion gene, MAMAD1:SLC25A21. The 
MAMDC1:SLC25A21 fusion was determined by HRK in the prostate cancer cell line 
DU145, resulting from an internal deletion of 14q13.3-21.3. As experiments are much 
easier to be performed on cell lines than clinical samples, we originally planned to 
clone the fusion gene using the cell line and then use RT-PCR to screen a large series 
of samples for the presence of the fusion transcripts. Although I could confirm the 
presence of the fusion gene at the DNA level, I failed to detect the corresponding 
fusion transcript. A possible explanation is that formation of the 
MAMDC1:SLC25A21 fusion may lead to gene inactivation rather than gain of 
function fusion product. We hypothesize that one or both genes in the deleted region 
may be candidate TSGs in prostate cancer. I note with interest that SLC25A21 is a 
mitochondrial 2-oxodicarboxylate carrier gene (433) and no association has been 
reported between SLC25A21 and cancer yet. In additional, MAMDC1 has been 
reported as potentially being important in cell-cell interactions and may also play 
regulatory functions in neuronal migration (434). 
 
Based on this HRK technical development, I focused my investigation on fusion 
genes, which recently progressively gained importance in our understanding of 
prostate cancer development and progression. As the 500K SNP arrays can define 
genomic breakpoints to a 50 kb region, PCR-based MCC method can subsequently be 
used to confirm the breakpoints and clone the genomic fusion sequence. This has 
been demonstrated through the cloning of the MAMDC1 (intron 3):SLC25A21 (intron 
7), the potential fusion gene caused by internal deletion on 14q in DU145 using MCC. 
In conclusion, the combined M-FISH/SNP HRK analysis rapidly identified most 
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chromosome rearrangements in the three studied prostate cancer cell lines, with the 
breakpoints defined at a resolution that can be further analysed directly by sequence-
based methods. This approach provides a unique opportunity to identify the 
fusion/truncated genes potentially important in prostate cancer development and 
progression.   
 
However, the application of M-FISH to clinical samples is limited by the difficulty in 
obtaining of adequate quality and quantity metaphase cells. In cases where M-FISH 
analysis has failed, SNP array data can be combined with MCC to clone and analyse 
the fusion genomic sequence. Prof Bryan Young has designed the new function of 
GOLF to define the breakpoint automatically. Using SNP array 6.0, I have identified 
many genes frequently truncated in prostate cancer clinical samples (Table 3.4). 
These frequently broken genes may be potentially fused with other genes in prostate 
cancer. As these genomic breakpoints are defined at a resolution of a few kb, MCC 
can be used to rapidly clone the fusion sequence and reveal its partner gene(s).  
 
Although I illustrated the use of the 500K SNP array in combination with M-FISH in 
this case, this HRK approach is applicable to the combination of any high-density 
genomic arrays with M-FISH analysis. The application of this HRK approach should 
lead to a better understanding of the roles of complex genetic alterations in human 
malignancies. With the recent development of next-generation sequencing 
technology, it is now possible to sequence the whole genome for systematic detection 
of all the genomic rearrangements, especially fusion genes, at the DNA sequence 
level. However, the new sequencing technology is very expensive and time 
consuming for whole genomic analysis. On the other hand, HRK provides high-
resolution karyotype using much less time and it is less expense. 
 
In this chapter, I have demonstrated an approach capable of quickly and precisely 
identifying most chromosome rearrangements in individual tumours. This should 
facilitate the identification of critical genes and genetic markers in tumourigenesis, 
which is particularly relevant in the complex chromosome rearrangements found in 
solid tumours. Although many researchers have attempted to combine CGH with 
cytogenetic karyotype data for better understanding of the genomic alterations in 
cancer cells, including the array CGH study of the same three prostate cancer cell 
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lines we used here (272), this is the first time a systematic approach was used in 
generating high-resolution karyotypes of complex cancer cells. In this study, I 
revealed the breakpoints of the three cell lines in unprecedented detail. Candidate 
genes thus identified can be further investigated in detail using focused molecular 
biological analyses. 
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CHAPTER VII SUBTLE GENOMIC ALTERATIONS 
AND GENOMIC INSTABILITY REVEALED IN DIPLOID 
CANCER CELL LINES 
 
 7.1 Introduction 
As described in Chapter IV, during my FISH analysis of PTEN copy numbers in 
TMA samples, I observed a high degree of intra-tumour heterogeneity of PTEN status 
and even gain and loss of PTEN copy numbers occurring within a same TMA core in 
different tumour glands. The intra-tumour heterogeneity of PTEN status has similarly 
been reported by other researchers (386, 435). Other genetic alterations have also 
been reported to occur in a proportion of cancer cells in prostate cancer as well, 
representing widely existing genomic heterogeneity. Prostate cancer frequently 
presented morphologically as multiple foci lesions and different genomic alterations, 
including multiple forms of TMPRSS2:ETS fusions, frequently occur in different foci 
within a same case of prostate cancer (436-439). Both forms of intra-tumour genomic 
heterogeneities generally reflect genomic instability, particularly chromosomal 
instability. Together with the identification of genetic alterations in the normal 
prostate epithelia cells adjacent to cancer lesions, this suggests that there is underlying 
mechanism leading to genomic instability in the prostate cells before the development 
of cancer (436). Genomic instability is an important mechanism in carcinogenesis 
(440). Linked with my observation of genomic instability in prostate cancer and the 
general interest in genomic instability in the laboratory, I investigated the important of 
genomic instability in tumourgenesis. 
 
It is clear that the accumulation of multiple genetic alterations leads to cancer 
development (441-443). There is strong evidence that genetic instability is required 
for the generation of multiple genetic alterations in human cancers, and many cancers 
are associated with genomic instability (441, 442, 444, 445). However, it is not clear 
if genomic instability is essential for tumour development (446). Two levels of 
genomic instability are described. The first is MIN, occurs at the DNA sequence level 
and shows an increased mutation rate of DNA base pairs. The second is CIN and 
includes alterated chromosome rearrangements and copy number changes (441, 444). 
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Whereas MIN is mainly found in hereditary non-polyposis colorectal cancer (444), 
which accounts for a small proportion of human tumours, the majority of human 
tumours, especially solid tumours, are associated with multiple chromosome changes, 
which have been linked to CIN (444, 446, 447). Of interest, CIN is reflected in the 
commonly observed heterogeneity within a single tumour due to persistent generation 
of new chromosomal alterations (448). 
 
Both hematological malignancies and solid cancers have been occasionally reported 
with cytogenetically normal karyotypes (449-453). Tumourigenic non-colorectal solid 
cancer cell lines with normal karyotypes are rare. However, a few have been 
established, including SK-UT-1B (leiomyosarcoma), CAL51 (breast cancer) and 
A204 (rhabdomyosarcoma), which have been described with normal karyotypes (454-
456). Notably, an ovarian cancer cell line, CH1, with only one chromosome 
aberration, i.e. a balanced translocation t(15;20), is also available. I investigated the 
genomic alterations in these cell lines using 500K SNP array analysis, aiming to 
detect small copy number gains and losses that would be missed by karyotype and 
chromosomal CGH analysis (43). The CIN status was determined by assessing the de 
novo chromosome rearrangement rates using multiplex FISH (M-FISH) analysis of a 
large number of metaphase cells, and the MIN status was assessed using the 
microsatellite marker BAT-26. Interestingly, multiple subtle chromosome alterations 
were detected in MIN negative cell lines, A204 and CH1; while other two cell lines, 
CAL51 and SK-UT-1B, containing few chromosome alterations, were MIN positive. 
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7.2 Results 
7.2.1 Karyotype of the cell lines by M-FISH 
M-FISH analysis, which was carried out by Dr. Yong-Jie Lu, confirmed the stable 
normal diploid karyotype of the three cancer cell lines, A204, CAL51 and SK-UT-1B, 
used in this study. No clonal chromosome alterations were detected during a long 
period of passaging. In the cell line, CH1, M-FISH analysis detected a balanced 
translocation t(15;20) existing in all metaphases analysed (Figure 7.1). No other 
clonal chromosome alteration was detected. We did not detect any genomic gains or 
losses in any of the four cancer cell lines using chromosomal CGH analysis.  
 
7.2.2 Genomic copy number alteration detection and confirmation  
In 500K SNP array analysis, genomic copy number changes were detected in all four 
cancer cell lines (Table 7.1, Figure 7.2)). As shown in Table 7.1, there were many 
small chromosomal changes in the cell lines CH1 and A204, but only few in SK-UT-
1B and CAL51 cells. Most of those chromosome copy number changes were subtle 
(<0.6 Mb). I searched Ensembl (www.ensembl.org) for genes located at these gained 
and lost genomic regions and found that most of these regions contain known genes 
(Table 7.1). The relatively large 2q22.1-31.1 gain was missed in the chromosomal 
CGH analysis, even when CGH profiles were checked in individual metaphases. 
Based on the SNP array results, I identified the slightly larger chromosome 2 (with 
duplication of 2q22.1-31.1) in some M-FISH karyotyped CH1 metaphases (Figure 
7.1). The existence of an additional copy of 2q22.1-31.1 (151,030-151,196 kb) was 
confirmed by FISH analysis in 71% of CH1 cells (Figure 7.3A). A number of the 
small genomic gains and losses were also confirmed by FISH analysis using BAC 
probes, including gain of 6q26-27 (161,408–168,064 kb), losses of 8p21.2 (25,937–
26,222 kb) and 11p15.4-15.2 (9,328–12,890 kb) in CH1 cells; and gain of 10q22.3 
(78,979–79,402 kb) and loss of 22q11.21-11.23 (19,894–23,041 kb) in A204 cells 
(Table 2.1 and Figure 7.3).  
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Figure 7.1 M-FISH images from CH1 cells.  
Representative karyotype of the CH1 cell line showing the balanced t(15;20) chromosome 
translocation (arrows). The size of one of the chromosome 2 (arrowhead) is slightly bigger 
than normal, which contains the duplication of 2q22.1-31.1.  
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Figure 7.2 Representative images of genomic gains and losses detected by 500K 
SNP array analysis.  
A: Array profile along chromosome 3 of SK-UT-1B cells showed deletion of 3p14.2 (60,265–
60,815 kb). B: Array profile along chromosome 8 of CAL51 cells showed deletion of 8q24.23 
(137,746–137,910 kb). C: Array profile along chromosome 2 of CH1 cells showed gain of 
2q22.1-31.1 (135,996–174,788 kb). D: Array profile along chromosome 9 of A204 cells 
showed loss of 9p21.2 (28,189– 28,291 kb). For the three horizontal lines in each sample, the 
top line represents log2 ratio (test/control) of 1 compared with normal controls; the middle 
line represents log2 ratio of 0 and the bottom line represents log2 ratio -1. 
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Figure 7.3 Representative FISH images using BAC clones to confirm the gained 
and lost chromosome regions detected by SNP array analysis.  
A: Three copies of RP11-79A11 (red) with a pair of them located close to each other on the 
duplicated 2q22.1-31.1 region (arrow) in a CH1 cell. B: A single copy of RP11-98P2 (8p21.2, 
green) and three copies of RP11-348L18 (6q26-27, red) in one metaphase and one interphase 
CH1 cells. A pair of red signals was located close to each other (mixed together in the 
metaphase on 6q) (arrow), indicating a local duplication of the 6q26-27 (161,408–168,064 kb) 
fragment. C: A single copy of RP11-48J22 (11p15.2-15.4, red) in a CH1 cell. D: Three 
copies of RP11-428P16 (10q22.3, red) with a pair of them located close to each other (arrow) 
in one metaphase and one interphase A204 cell, indicating a local duplication of the 10q22.3 
(78,979–79,402 kb) fragment. 
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Table 7.1 Summary of the gained and lost chromosome regions and genes located 
within them. 
Cell lines  MIN 
status 
Gained regions Genes in gained 
regions 
Lost regions Genes in lost regions 
CH1 _ 2q22.1-31.1    
(135,996–174,788 kb) 
Many genes 6p21.33     
(31,247–31,421 kb) 
HLA-C, HCG27, HLA-
B, Q6H1K9_HUMAN 
  6q26-27          
(161,408–168,064 kb) 
Many genes 8p21.2       
(25,937–26,222 kb) 
PPP2R2A 
    11p15.4-15.2 
(9,328–12,890 kb) 
Many genes including 
Wee1, XLKD1 and 
DKK3 
    11p14.3     
(21,567–21,691 kb) 
No gene 
    13q14.2     
(46,926–46,999 kb) 
No gene 
    13q31.1     
(82,993–83,072 kb) 
No gene 
    15q22.2     
(58,670–59,082 kb) 
RORA 
    22q13.2     
(39,554–40,152 kb) 
Many genes 
A204 _ 10q22.3             
(78,979–79,402 kb) 
KCNMA1, DLG5 5q11.2       
(58,465–58,744 kb) 
PDE4D 
  21q22.3            
(44,107–44,214 kb) 
AGPAT3, 
Q8TEB0_HUMAN 
9p21.2       
(28,189–28,291 kb) 
LRRN6C (LINGO2) 
    16q23.1     
(77,236–77,368 kb) 
WWOX 
    22q11.21-11.23 
(19,894–23,041 kb) 
Many genes 
    Xp21.3-21.2 
(29,196–29,553 kb) 
IL1RAPL1 
SK-UT-1B + 15cen-q11.2 
(centromere-20,815 kb) 
Many genes 3p14.2       
(60,265–60,815 kb) 
FHIT 
    5q11.2-12.1 
(58,808–59,049 kb) 
PDE4D 
CAL51 +   8q24.23  (137,746–
137,910 kb) 
No genes 
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7.2.3 de novo chromosome alterations 
The de novo (non-clonal) chromosome changes in three cell lines, CAL51, SK-UT-1B 
and CH1, were detected using M-FISH analysis of a large number of metaphases 
(Table 7.2). These cell lines had similar rates of proliferation whereas A204 grew 
more slowly and was excluded from this analysis. Only translocations and deletions 
were scored (Table 7.2), as other chromosome alterations were difficult to interpret 
and/or were prone to artifacts during metaphase preparation. Interestingly, a 
significantly higher frequency of de novo chromosome changes was detected in CH1 
(25%) than in CAL51 (6.9%) (p<0.0001) and SK-UT-1B (6.4%) (p=0.0001) 
(Table7.2). Although the frequency of chromosome alterations of CAL51 and SK-
UT-1B were slightly higher than that of the normal lymphocyte sample, they were not 
statistically significant (p=0.0539 and 0.1709, respectively). An image of a de novo 
chromosome translocation t(X;1) in addition to the existing t(15;20) in cell line CH1 
is shown in Figure 7.4. 
 
Table 7.2 de novo (non-clonal) chromosome aberrations and clonal chromosome 
rearrangements in three tumour cell lines and a normal lymphocyte control 
sample detected by M-FISH karyotyping. 
de novo aberrations Cell types 
Translocation Deletion Total 
Clonal 
changes 
p value* 
Lymphocyte 0/302 (0%) 10/302 
(3.3%) 
10/302 (3.3%) None  
CAL51 4/260 (1.5%) 14/260 
(5.4%) 
18/260 (6.9%) None 0.0539 
SK-UT-1B 2/110 (1.8%) 5/110 (4.5%) 7/110 (6.4%) None 0.1709 
CH1 6/64 (9.4%) 10/64 
(15.6%) 
16/64 (25%) t(15;20) <0.0001 
*: The percentage of de novo aberrations of the three cell lines was compared with normal 
lymphocyte sample.  
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Figure 7.4 Detection of the de novo chromosome translocation t(X;1) in CH1 cells.  
A painted CH1 metaphase with the de novo chromosome translocation t(X;1) (arrowheads) in 
addition to the clonal t(15;20) (arrows) was shown. 
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7.2.4 MIN analysis 
Microsatellite analysis using BAT-26 was carried out by Dr. Yong-Jie Lu. Figure 7.5 
showed that both CAL51 and SK-UT-1B lines were MIN positive, while A204, CH1 
and the normal lymphocyte control were negative. The MIN results were summarised 
in Table 7.1.  
 
 
Figure 7.5 The microsatellite analysis for the normal control and four cell lines. 
SK-UT-1B and CAL51 are MIN positive and CH1 and A204 are MIN negative. 
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7.3 Discussion 
In this study, I analysed three cancer cell lines, SK-UT-1B, CAL51 and A204, which 
were identified as containing normal karyotype by both M-FISH and chromosomal 
level CGH analyses; and an ovarian cancer cell line, CH1, which contained a simple 
reciprocal translocation. Interestingly, with the application of high-resolution 500K 
SNP array analysis, I found genetic alterations in all four cell lines, indicating that 
subtle clonal chromosome abnormalities may occur in most tumours previously 
reported as bearing normal karyotypes. Of significance, many of these changes are too 
small to be identified by traditional cytogenetic and low-resolution CGH analyses. 
Some of the subtle alterations are encompassed by regions frequently involved in 
human tumours such as loss of 3p, 8p, 9p, 11p and 13q. Some of the implicated genes, 
such as FHIT, Wee1 and PDE4D, may contribute to the development of cancers. It is 
also interesting to note that in these cells with simple chromosome aberrations, three 
chromosomal gain analysed by FISH, 2q22.1-31.1, 6q26-27 and 10q22.3, were 
caused by in situ chromosome fragment duplication (Figure 7.3). This may be the 
initiating event for chromosome amplification. 
 
It is striking that all four diploid cell lines are associated with certain levels of 
genomic instability. The A204 and CH1 lines showed the phenotype associated with 
CIN, while CAL51 and SK-UT-1B were MIN positive. There were many more clonal 
chromosome alterations detected by SNP array analysis in the A204 and CH1 cells 
than in the CAL51 and SK-UT-1B cells (p<0.001). This is in agreement with the 
significantly higher frequency of de novo, non-clonal chromosome rearrangements 
detected by M-FISH in CH1 compared to the cell lines CAL51 and SK-UT-1B and 
normal lymphocytes. Although these de novo chromosome alterations were not 
passed on to daughter cells, we propose that the high rate in generating these non-
clonal changes represents CIN that is subject to further checkpoint control (457). 
 
The MIN status of CAL51 cells has been previously reported, resulted from the 
mutation of the DNA mismatch repair gene, MLH1 (458). Although positive MIN 
was detected in non-colorectal cancers, it occurs at a relatively low rate (459). 
Therefore, it is unlikely that by chance two of the four cytogenetically stable cell lines 
studied here, with few chromosome alterations are MIN positive. In these two cell 
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lines, MIN may be important in permitting the cells to accumulate enough DNA 
mutations for tumour development, such as the activation mutation of the RRAS2 gene 
in CAL51 (460). The identification of genomic instability in the four cell lines 
suggests that genomic instability may also exist in other cytogenetic normal cancer 
cell lines. Therefore, genomic instability may be essential in cancer development. The 
characterisation of the genomic alterations in these tumour cell lines with minimum 
genetic alterations also make these cell lines a useful model system to study genes 
associated with genomic instability. 
 218 
CHAPTER VIII FINAL DISCUSSION AND FUTURE 
PLANS 
 
8.1 Final discussion 
In this PhD study, I have combined a range of genetic technologies to investigate 
systematically the genomic changes in prostate cancer as well as the consequence of 
the genomic changes, although the latter was less extensive compared to the genomic 
studies. Here I will discuss the meaning and potential scientific importance of these 
findings and the advantages and limitations of these techniques used as well as my 
research approach. 
 
8.1.1 Genomic copy number changes in prostate cancer revealed by 
genome-wide analysis 
In this study, I analysed seventy-one prostate cancer fresh frozen samples using high-
resolution SNP arrays and revealed the regions with high-frequency gains at 7 and 8q 
and losses at 5q15-21.3, 6q14.1-22.1, 8p, 10q23, 13q12.3-31.1, 16q12.1-24.3 and 
21q22.2-22.3. Array technology has previously been used to analyse genomic copy 
number changes, but the majority are at low resolution (265, 270, 274, 277, 281, 319, 
393, 461-473).  At least twenty peer-reviewed publications have previously 
investigated genomic copy number changes using array technology. Perhaps not 
unsurprisingly, fourteen of them failed to detect the 21q22.2-22.3 deletion, which 
causes the TMPRSS2:ERG fusion, due to low resolution  (270, 281, 319, 461-466). In 
total, there are slightly more than a hundred prostate cancer cases that have been 
previously analysed with adequate sensitivity to detect the 21q22.2-22.3 deletion (265, 
277, 393, 472, 473). This study detecting genomic alterations comparable to previous 
array results, increased significantly the total number of prostate cancers analysed by 
high-resolution analysis and defined the breakpoints more accurately.  
 
The Affymetrix array 6.0 contains much more probes than previous arrays used for 
prostate cancer analysis. Therefore, it has the potential to discover smaller genomic 
amplicons and deletions. Indeed, I found many deletions and amplification smaller 
than 1 Mb in size. However, none of them occurred at a high frequency. The recent 
genome-wide transcriptome sequencing using next-generation sequencing did not 
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reveal any additional frequently occurring fusion genes in addition to ETS genes 
either, although many non-recurrent fusion transcripts were identified (150, 152, 154). 
Therefore, this study indicates that further increase in array density may not reveal 
many more recurrent genomic rearrangements in prostate cancer. 
 
Based on the data from this study and previous array analysis, it is clear that prostate 
cancer contains many more genomic deletions than amplifications. Genomic 
amplification is one of the main mechanisms leading to oncogene up-regulation and it 
is frequently detected in many human tumours including NMYC amplification in 
neuroblastoma and c-erbB-2 and CCND1 amplification in breast cancer (474-476). 
However, in prostate cancer, oncogenes are mainly de-regulated using genomic 
fusions as a mechanism. In addition, there are many commonly deleted regions in 
prostate cancer, indicating that the inactivation of TSGs may play important roles in 
prostate cancer development and progression. As previous discussed, many known 
TSGs have been identified in these regions. Therefore, the search for additional TSGs 
should be a key direction to be taken in prostate cancer genomic study. 
 
8.1.2 Different genomic changes between UK and Chinese prostate cancers 
One of the unique points of this study is that it is the first high-resolution genome-wide 
analysis of prostate cancer samples from Chinese patients in China, a population with 
low prostate cancer incidence. Indeed, the incidence of this cancer in China is less than 
10% compared to that in Western countries 
(http://globocan.iarc.fr/factsheets/cancers/Prostate.pdf). While genetic, environmental, 
dietary and lifestyle factors may contribute to these differences, it is not clear if cancers 
caused by different factors take on different development pathways. Genomic alterations 
play an important role in carcinogenesis. Comparing the UK and Chinese prostate 
cancers should reveal the differences or similarities of genomic changes between these 
two populations. My study revealed that these two groups shared genomic changes 
including gains at 7 and 8q, and losses at 8p, 13q12.3-31.1 and 16q12.1-24.3. Most 
importantly, this genome-wide study identified some important changes with different 
frequency in UK and Chinese samples. The losses at 21q22.2-22.3 (TMPRSS2:ERG) and 
10q23.31 (PTEN) are commonly found in Western prostate cancers (140, 323, 469, 477). 
However, they are much less frequently detected in Chinese samples. Significantly, these 
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differences were additionally confirmed in TMAs using FISH and IHC. These genomic 
alterations may be the key genomic events underlying the regional/ethnic difference in 
clinical incidence and they may be induced by specific environmental and/or genetic risk 
factors that Western and Chinese men are differentially exposed to. This also supports 
the hypothesis that certain cancer risk factors cause specific somatic genomic alterations.  
 
Based on the nature of these genomic alterations and the potential risk factors associated 
with different geographic populations, specific studies can be designed to accelerate the 
identification of such factors and, thus, the mechanisms underlying these genomic 
alterations and the development of the disease. We have demonstrated the utility of this 
approach in our AR CAG repeat polymorphism study. Identification of the environmental 
and genetic risk factor(s), as well as improved understanding of the mechanisms 
underlying these genomic changes should lead to better prevention and treatment of 
prostate cancer. The genome-wide approach used in this study to compare somatic 
genomic changes between high- and low-risk cancer populations, can be applied to other 
cancers with an apparent regional or ethnic difference in incidence to identify specific 
cancer-related genomic changes in the high incidence populations. 
 
In the comparison study between UK and Chinese prostate cancers, TMPRSS2:ERG 
and PTEN deletion were the two main genomic alterations commonly existing in UK 
but rarely occurring in Chinese samples. TMPRSS2:ERG and PTEN deletion co-act to 
contribute to prostate cancer development and progression and recent genomic 
analysis also showed that prostate cancer cases with PTEN inactivation are more 
likely to own TMPRSS2:ERG fusion gene (323, 325), which is the same result as 
observed in this study. All these data indicate that these two genomic alterations may 
share similar aetiological factors. 
 
8.1.3 Prostate cancer cell lines and clinical samples 
There are three prostate cancer cell lines, PC3, DU145 and LNCaP, analysed by SNP 
arrays in this study. I karyotyped these three cell lines using the HRK approach and 
some potential fusion genes identified may be critical for prostate cancer study. 
However, the genomic changes in cell lines may be induced during cell culture 
instead of original changes in primary clinical samples. In this study, the common 
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regions with copy number changes detected in primary samples, including the gains at 
7, 8q and losses at 6q, 8p, 13q and 16q, were also detected in cell lines. Moreover, it 
is known that VCaP and DuCaP carry the TMPRSS2:ERG fusion gene (40). These 
data indicate that the genomic alterations detected in cell lines recapitulate these 
common changes in clinical samples.  
 
8.1.4 Gene(s) potentially affected by chromosome rearrangements 
Since the identification of the high-frequency fusion gene, TMPRSS2:ERG, in 
prostate cancer, many studies have been carried out to determine chromosome 
translocations and fusion genes in carcinomas. Interestingly, apart from the ETS 
family of genes, none of the other genes are frequently involved in fusions in prostate 
cancer (150, 151). Recently, it was reported that genomic fusion might not only result 
in deregulation of oncogenes but also inactivation of TSGs (478, 479). In contrast to 
gene outliner and transcriptome sequencing analysis (where only genomic fusions 
with fusion expression products are detected), the high-resolution arrays used in my 
study can map genes located on the chromosome breakpoints, and can therefore be 
used to identify genomic translocation leading to both activation of oncogenes and 
inactivation of TSGs. 
 
As described in Chapter VI, I introduced a novel approach, HRK, to define the 
karyotype with high-resolution. Using this approach, I detected five potential fusion 
genes in three prostate cancer cell lines. MAMDC1:SLC25A21 was confirmed by 
MCC and the fusion gene was cloned and sequenced. Although HRK is a rapid 
approach for karyotype detection, it is difficult to get metaphase cells from solid 
tumour tissue samples. Therefore, it is difficult to apply HRK for karyotyping prostate 
cancer clinical samples.  
 
Another approach to identify fusion genes without M-FISH analysis involves the use 
of high-resolution arrays to detect genes frequently located at breakpoints, followed 
by the use of inverse PCR to clone the fusion partners. In this study, many genes were 
identified expressing at high frequencies at breakpoints in prostate cancer samples. 
Interestingly, the two most frequent genes identified using this approach, WWOX and 
FHIT, are located at fragile regions and are known to play tumour suppressor roles. 
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This strongly supported our previous hypothesis that chromosome rearrangement in 
prostate cancer may be largely associated with TSG inactivation. In this study, ERG is 
the third most frequent gene located at the breakpoints and TMPRSS2 and ETV1 are 
on the common (14% and 15%) truncated gene list. Together with the detection of 
high-frequency breakpoints at BCR and ABL in CMLs (Unpublished data from Prof. 
Bryan Young), our findings validated the efficiency of identifying genes at common 
breakpoints using this approach and indicated that the genes located at breakpoints 
may be involved in fusion genes. This approach can also determine the frequencies of 
two genes at breakpoints occurring in the same samples, which suggests these genes 
are potential fusion partners. TMPRSS2 and ERG have been clustered together in 
prostate cancer and BCR and ABL have been clustered together in CMLs 
(Unpublished data from Bryan Young). I also found that RBMS2 and GRIA1 are 
clustered much closer than that of TMPRSS2 and ERG, therefore they have very high 
potential to be fused together. Finally, according the breakpoint location from SNP 
array, I can design PCR (including inverse PCR) primers to find the fusion genes. 
Due to time limitation, the involvement of the genes at the high frequency breakpoints 
has not been confirmed and fusion genes have not been cloned, but these will be done 
in the future. 
 
8.1.5 High-resolution genomic analysis 
500K SNP array and SNP 6.0 provide the high-resolution for detectable genomic 
changes. As previously discussed, many small deletions and amplifications (several 
hundred Kb) were identified in cell lines and clinical samples, although no frequent 
small changes were detected in either cell lines or clinical samples. Most importantly, 
I identified numerous genes located at high frequency chromosome breakpoints. All 
of these demonstrated the advantage of using 500K and in particularly, Array 6.0, in 
high-resolution analysis of genomic changes in prostate cancer. 
 
High-resolution arrays are particularly useful in detecting small genomic changes in 
normal karyotype samples defined by low-resolution analyses. As shown in Chapter 
VII, I analysed four 2N cancer cell lines using 500K SNP arrays and discovered many 
small regions with copy number changes, mainly in CH1 and A204, which are MIN 
negative. 67% of these regions with genomic alterations are less than 500 Kb. In 
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combination with M-FISH de novo chromosome rearrangement detection and MIN 
data, these allowed me to detect the general existence of genomic instability in normal 
karyotype cell lines. The genes identified at the regions with genomic alterations may 
be associated with CIN. As these regions are small in size, the candidate genes in 
these regions are easier to identify. 
 
8.1.6 Microdissection 
Although the SNP arrays are sensitive in detecting small regions of copy number 
changes and allow chromosome breakpoints to be mapped at a high degree of 
accuracy, the purity of cancer cell population is essential to enable the reliable 
detection of these genomic changes.  In prostate cancer samples, tumour cells are 
typically mixed with normal glands, and stromal cells and the majority of prostate 
samples contain only less than half of cancer cells. The DNA from non-malignant 
cells significantly reduces the sensitivity of SNP arrays to detect the aforementioned 
changes. The copy number gain and loss ratio of tumour versus normal cells can be 
decreased to close to the background noise level. In this study, I firstly analysed 
undissected prostate cancer specimens and found that no genomic alterations were 
detected in a sample containing 30% of cancer cells and that limited genomic 
alterations were detected in samples with less than 50% cancer cells. Consequently, 
all the clinical prostate cancer samples were checked by pathologists and 
microdissected to achieve a cancer cell purity of > 80%. Indeed, many genomic 
changes were detected in the majority of those cases. Overall, it is unlikely that failure 
to detect copy number changes in the microdissected samples is due to analytical 
reasons. Therefore, in cases where no genomic copy number changes were detected, it 
is most likely that no large-scale genomic copy number changes were present in these 
samples rather than the failure to detect these alterations. In previous cytogenetic 
studies, prostate cancer with normal karyotype is frequently reported and it is not 
clear if it is truly from the cancer cells or the selective over-growth of normal 
(fibroblast) cells (441, 442, 444, 445, 480). It is debatable if normal karyotype 
prostate cancer samples exist. My data suggest that normal karyotype prostate cancer 
do exist, although it is at low frequency. 
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8.1.7 Heterogeneity of prostate cancer  
It is known that prostate cancer is a heterogeneous disease, at both inter-tumour 
(population level) and intra-tumour (including intra- and inter-foci) levels. At the 
population level, each cancer contains different combinations of genomic changes and 
these changes rarely occur in all cancer samples. For example, AR amplification was 
present in 30% of hormone-refractory patients, while point mutations in AR exist in 
10-30% of prostate cancer treated by anti-androgens (481). TMPRSS2:ERG fusion 
gene has been reported to be associated with androgen-dependent cases, but not in 
late-stage androgen receptor-negative cases (142). The frequency of the 
TMPRSS2:ERG fusion gene also differs in histological variants of prostate cancer 
(482, 483) and in distinct glandular location from which the cancer arose. For 
example, prostate cancer with a transition zone origin lacks the TMPRSS2:ERG 
fusion gene (484). In this study, I demonstrated that prostate cancer arising in 
different geographic populations has distinct genomic profiles by comparing prostate 
cancer samples from the UK and China. I also detected many small regions with 
alterations of very low frequency in this study. However, they may be only associated 
with specific cases. Based on the genomic changes, prostate cancer can potentially be 
divided into distinct subgroups and allows for a more individualised approach for 
management (136, 292, 304).  
 
The intra-tumoural heterogeneity was found in this study at two levels. Firstly, 
different foci within a case were identified with different genomic alterations by SNP 
arrays. More importantly, in the FISH study, I identified some samples that contained 
heterogeneous PTEN alterations (existing of two cell populations with different PTEN 
status, such as PTEN loss and normal status, PTEN loss and gain status, and PTEN 
gain and normal status) within individual cancer foci and even within small 
tumoureous gland with a few cells. Intra-tumoural heterogeneity usually reflects 
genomic instability. The presence of widespread intra-tumoural genomic 
heterogeneity strongly indicates that genomic instability in prostate epithelial cells 
leads to the generation of many genomic sub-clones. 
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8.1.8 Advantages and disadvantages of the study  
In this study, I used SNP arrays to map genome-wide genomic alterations, followed 
by the use of FISH, IHC and PCR to confirm the significant findings. The overall 
genomic alteration patterns both in UK and Chinese prostate cancer samples were 
generated and some interesting genes and potential gene fusions were identified. As 
discussed above, the 500K SNP array and array 6.0 provided high-resolution 
detection of genomic alterations. Using SNP arrays, I detected numerous small 
genomic changes, which are undetectable using traditional low-resolution techniques. 
The boundary of the copy number changes may be the breakpoints of potential fusion 
genes. Karyotyping chromosomal CGH and low-resolution array CGH cannot 
accurately define the genes at these breakpoints. Further extensive breakpoint 
mapping, usually using FISH, is required. All these clearly show the advantage in the 
use of high-resolution microarrays. 
 
However, the use of hybridisation signal intensity on microarray platform to 
determine genomic copy numbers can generate falsely positive and negative results. 
Therefore these array-based genomic results have to be confirmed by other genetic 
technologies such as PCR and FISH, which are established methods to determine the 
presence of specific genomic targets. Involving multiple steps, SNP array experiments 
are particularly time-consuming and expensive in the analysis of large number of 
samples. Therefore, upon the detection of abnormalities in specific genomic regions, 
it is followed by the use of PCR or FISH to determine the prevalence of these specific 
genomic alterations in a large cohort of samples. Finally, normal tissue contamination 
also affected the results from array analysis. FISH and IHC technologies not only can 
be used to evaluate efficiently the SNP array results in a large cohort of samples, but 
also detect the signals in individual either cancer or normal cells. However, FISH and 
IHC analysis requires to select a specific genes or specific regions from previous 
information and it also need pathologist to differentiate the tumour and normal tissue 
in each core.  
 
In this study, I also developed an HRK approach to efficiently identify novel fusion 
genes. In HRK, not only the genomic breakpoints, but also the potential partner genes 
were identified. This enables the use of RT-PCR in the detection of fusion transcripts. 
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In this study, however, I failed to detect the fusion transcript for 
MAMDC1:SLC25A21 using RT-PCR. RT-PCR detects fusion genes based on the 
expression of fusion transcripts, which are the results of the fusion of oncogenes. 
Either MAMDC1 or SLC25A21 may play a TSG role and the expression level was 
down-regulated after the fusion.  Therefore, a fusion transcript cannot be detected by 
RT-PCR analysis. A major limitation of HRK is the requirement of metaphase 
preparations from tumour cells, which are difficult to be obtained from solid tumour 
samples.  
 
Next generation sequencing allows the detection of all genomic changes in individual 
cells with detailed sequence information. It has been successfully applied in prostate 
cancer in the search of novel fusion genes (150-152). Although the price per base pair 
sequenced is cheaper than the traditional method, the cumulative costs are still very 
high for each run of samples. In the future, when the cost is further reduced, next 
generation sequencing will be the main platform in the conduct of genome-wide 
studies. 
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8.2 Future plans 
In this study, I applied the Affymetrix SNP arrays in the study of genomic alterations 
in prostate cancer, particularly in the comparative analysis of genomic differences 
between cancer cases from the UK and China. Many of these genomic changes 
require validation using other techniques and many genes identified have to be further 
investigated to examine their prevalence and roles in prostate cancer. The genomic 
differences between Western and Chinese cancers indicate that distinct aetiologies 
and genetic mechanisms operating in prostate carcinogenesis in different populations 
resulting in the vastly different epidemiological and clinical patterns observed 
between Western countries and China. Further studies to identify these prostate 
cancer causative or protective factors by comparing these populations will help us to 
understand the aetiology better and hopefully reduce the incidence of prostate cancer. 
 
8.2.1 Confirmation of the different genomic changes found in the UK and 
Chinese samples 
In this study, I compared genomic changes detected by SNP array analysis between 
32 UK and 39 Chinese prostate cancer samples and identified four major changes 
with different frequencies between them. The deletions between TMPRSS2 and ERG 
(21q22.2-22.3), and at the PTEN region (10q23.31) are significantly more frequently 
found in the UK than Chinese samples. On the other hand, deletions in 5q and 6q are 
significantly more frequent in the Chinese than UK samples. Due to limitation of time, 
I had focused on the former two alterations in this study and confirmed the different 
frequencies in UK and Chinese TMAs both at genomic and expression levels using 
FISH and IHC. Although it is important to identify genomic changes commonly 
occurred in Western but not Chinese samples to associated them with the higher 
incidence of prostate cancer in Western countries, those genomic alterations occurred 
more frequently in Chinese samples than Western ones may also play important roles 
in alternative genetic pathways/mechanisms in prostate cancer development and 
progression. Therefore, I will use the same genomic approaches as I did for the 
analyses of TMPRSS2:ERG and PTEN to confirm that 5q and 6q deletion are more 
common in Chinese samples than the UK ones. FISH will be used to determine the 
frequencies of these genetic changes in both UK and Chinese TMA samples. As the 
candidate genes in these two regions are not known, I will identify the putative TSGs 
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in these deleted regions before further investigations into their specific contributions 
to prostate carcinogenesis. Of note, two candidate TSGs located at 6q15, CNR1 and 
BACH2, are currently under investigation in our laboratory. 
 
8.2.2 Identification of prostate cancer causative or protective factors 
differentially presented in Western and Chinese populations  
The most interesting finding of this study is the identification of the differences in 
genomic alterations between Western and Chinese prostate cancer samples. This leads 
to the hypothesis that differentially presented aetiological factors in Western and 
Chinese populations lead to the differences in genomic changes and prostate cancer 
incidence in these two populations. This opens a new research area in prostate cancer 
aetiology and prevention through the study of this disease in distinct human 
populations with different genomic alterations. The following studies should be 
performed in the future to identify and confirm the genetic, environmental and dietary 
factors associated with prostate cancer development and progression. 
 
8.2.2.1 Genes in AR pathway 
Androgens play a major role in normal prostate development and cancer evolution. 
Recently, we and others researchers have shown that exposure to high concentration 
of an androgen can induce the formation of the TMPRSS2:ERG fusion gene (413-
415). AR CAG repeat polymorphism has been investigated in a limited number of the 
UK and Chinese samples. The significant differences in CAG repeat in this study are 
comparable with previous reports (112, 408). The significance of CAG repeats length 
difference will be further confirmed in a larger series of UK and Chinese samples. At 
the same time, I will investigate the difference between Western and Chinese cancer 
patients for AR gene GGN repeat length polymorphisms and AR, SRD5A1 and 
SRD5A2 activity. Genetic polymorphism will be identified by PCR-based 
microsatellite analysis and AR, SRD5A1 and SRD5A2 activity will be analysed by 
measuring their serum levels and down-stream testosterone metabolic products. 
 
8.2.2.2 Large Scale prostate cancer susceptibility gene study 
In association with an international consortium, PRACTICAL led by Prof. Ros Eeles, 
for a prostate cancer predisposition gene study, my supervisor, Dr. Yong-Jie Lu, has 
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established a Chinese prostate cancer collaborative study group that includes a 
number of Chinese researchers from different cities in China to collect blood samples 
from at least 1000 prostate cancer patients and 1000 normal controls. GWAS will be 
applied to these samples to investigate the similarities and/or differences in 
susceptible loci between the Western and Chinese populations. As epidemiological 
data will be collected from individuals who provide the blood samples, we will also 
investigate the interaction between genomic and epidemiological factors contributing 
to prostate carcinogenesis. 
 
8.2.2.3 Association between prostate Dihydrotestosterone (DHT) concentration 
and TMPRSS2:ERG fusion in prostate cancer 
DHT is formed by the reduction of the 4,5 double bond of testosterone by 5?-
reductase. It stimulates prostate epithelial cell proliferation and differentiation with 3 
and 15-30 times greater affinity for AR compared with testosterone and the adrenal 
androgens, respectively. In mouse models, high DHT level promotes prostate cancer 
(485). Androgen level is higher in Black and Caucasian people than in Asian people. 
It has been reported that high DHT level can induce the formation of the 
TMPRSS2:ERG fusion gene (413-415). Therefore it is of interest to determine if intra-
tumoural DHT level is associated with the formation of the TMPRSS2:ERG fusion. 
Many studies have investigated the relationship between circulating level of DHT and 
prostate cancer. However, no consistent association has been found between the 
circulating level of DHT and the risk of prostate cancer (486). Previous studies have 
only analysed circulating androgen levels, neglecting androgen levels within the 
prostate gland. Therefore, the concentration of DHT will be measured in prostate 
cancer samples using IHC and it will be correlated with TMPRSS2:ERG status as 
determined by FISH on the same samples used for DHT analysis.  
 
8.2.2.4 HPV and prostate cancer 
Infectious agents are known carcinogens, notable association including EBV with 
Burkitt’s lymphoma and nasopharyngeal cancer, HBV with hepatocellular carcinoma 
and HPV 16 and 18 with cervical carcinomas (13, 18, 487). Hence, the natural 
distributions of these infectious agents can lead to unequal geographic spread of 
incidence of certain neoplasms in human populations. A recent study revealed that the 
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risk of prostate cancer was increased in patients infected with HPV (488). Therefore, 
it would be of interest to determine if there is difference in the presence of HPV 
infection of the prostate gland in UK and China. HPV DNA in prostate cancer 
samples will be checked using two methods: PCR with primers, which can detect 
multiple HPV subtypes, and in situ hybridisation, which also can detect multiple 
subtypes of HPV. The HPV infection result will be correlated with status of 
TMPRSS2:ERG fusion, PTEN deletion and CAG polymorphism in AR. I expect to 
find that certain subtypes of HPV infection may be associated with the inactivation of 
PTEN and the formation of the TMPRSS2:ERG fusion gene. Comparing the HPV 
infection status with CAG repeat size may enable us to find out whether HPV 
infections are more frequent in susceptible populations with shorter CAG repeat size 
in AR.  
 
8.2.3 Confirmation of frequent involvement of genes at genomic 
breakpoints identified by SNP array analysis and cloning of the potential 
fusion genes.  
In this study, I identified numerous genes frequently truncated by genomic breakages. 
Due to limited time, these genes have not been studied further. In the future, these 
genomic breaks can be confirmed by MCC analysis, followed by inverse PCR. 
Subsequent DNA sequencing can be used to define the breakpoint DNA sequence and 
the fusion partner genes. Once these genomic fusions are cloned, FISH can be used to 
investigate the frequency of the potential fusion genes and RT-PCR can be applied to 
detect the presence of the fusion transcripts. As a large number of recurrent truncated 
genes were identified, I plan to select the top 10 candidate TSGs and two oncogenes 
(EGFR and PIK3CA) for further studies. There are a number of reasons to select more 
TSGs than oncogenes. Firstly, from recent transcriptome sequencing studies, there are 
not many recurrent fusion transcripts except those involved in ETS family genes (150, 
151). Secondly, as previously discussed , it looks that chromosome rearrangements in 
prostate cancer are more likely to affect TSGs than oncogenes and previous studies 
have mainly focused on oncogenes. Finally, the top two most frequently truncated 
genes, WWOX and FHIT, are TSGs. These two genes were harboured at FRA16D and 
FRA3B fragile sites and involved in recurrent chromosome translocations in myeloma, 
breast cancer, esophageal adenocarcinoma (341, 346, 347). Therefore, inactivation of 
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these two genes may play important roles in prostate cancer. In addition to these high-
frequency truncated genes, the potential fusion between RBMS2 and GRIA1, which 
are much more closely correlated than TMPRSS2 and ERG, will also be further 
investigated. Once these fusion genes are cloned or common disruption of TSGs are 
confirmed, functional studies will be carried out to demonstrate their roles in 
carcinogenesis, including the application of siRNA gene knock-down and gene 
activation by transfection approaches.  
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APPENDIX I REAGENTS AND EQUIPMENTS  
 
30% H2O2 (Fisher Scientific, UK) 
Acetic acid (Fisher Scientific, UK) 
Agarose gel (Invitrogen, Paisley, UK) 
AmpliTaq® DNA polymerase (Applied Biosystems, USA) 
AmpliTaq Gold® DNA Polymerase (Applied Biosystems, USA) 
Anti-DIG-FITC (Roche, Germany) 
ApaLI (New England Biolabs, USA)  
BioPrimer® DNA labeling system (Invitrogen, USA) 
Biotinylated antibody (Vector Laboratories, Ltd., USA) 
BME  (Sigma, USA) 
BSA (New England Biolabs, USA) 
Chloroform (Fisher Scientific, UK) 
Chloramphenicol (Sigma, USA) 
Colcemid (Invitrogen, UK) 
Cot-1 DNA (Roche, Germany) 
DAPI (Sigma, Israel) 
Deep well plate (Povair plc, Norfolk, UK) 
DEME growth medium (Invitrogen, UK) 
Denhardt’s (Invitrogen, UK) 
Dextran sulphate (Sigma, UK) 
Di-sodium hydrogen orthophosphate (BDH Laboratory supplies, Poole, UK) 
DI formamide (Qbiogene, UK) 
DIG-11-dUTP (Roche, Germany) 
DMSO (Sigma, UK) 
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DNA polymerase I (New England Biolabs, USA) 
DNAse I (Promega, UK) 
Di-n-butyle phthalate in xylene mounting medium (Fisher Scientific, UK) 
10X dNTP mix (NEN Life Science, USA)  
EB buffer (Qiagen, UK) 
EcoRI (New England Biolabs, USA) 
EDTA (Invitrogen, UK) 
EndoFree plasmid mini kit (Qiagen, Germany) 
ERG antibody (sc-353) (santa cruz, USA) 
FISH probes for ERG (Sanger Centre, UK) 
EpCAM microbeads (Miltenyi Biotec, Germany) 
Ethidium bromide (Sigma, USA) 
Ethanol (Fisher Scientific, UK) 
Expand Long Template buffer 2 (Roche, Germany) 
Expand Long Template enzyme (Roche, Germany) 
Fluorescein-12-dUTP (Roche, Germany) 
Filter plate (Porvair plc, Norfolk, UK) 
Foetal Calf Serum (PAA, Pasching) 
Formamide (Fluka Chemika, Germany) 
Frozen solution (Clarehall, UK) 
G-C melt (Sigma, USA) 
G-50 column (GE Healthcare, UK)  
Genechip IVT cRNA Cleanup kit (Affymetrix, USA) 
Genechip Whole Transcript Sense Target Labeling Assay (Affymetrix, USA) 
Genome-Wide Human SNP array 6.0 (Affymetrix, USA) 
Genome-Wide Human SNP Nsp/Sty Assay Kit 5.0/6.0 (Affymetrix, USA) 
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GenomiPhi amplification kit (GE Healthcare, UK) 
Gill II Hematoxylin (Merck, Germany) 
Glycerol (Clarehall, UK) 
Green GoTaq® Flexi DNA Polymerase (Promega, UK) 
HotStarTaq DNA Polymerase kit (Qiagen, Germany) 
HSDNA (Sigma, USA) 
Human Exon 1.0 ST arrays (Affymetrix, USA) 
Human Mapping 500K Assay set (Affymetrix, USA) 
Hydrochloric acid (Fisher Scientific, UK) 
Igepal (Sigma, USA) 
Isopropanol (Fisher Scientific, UK) 
Kanamycin (Invitrogen, UK)  
KCl (VWR International, UK) 
LB agar (Clarehall, UK) 
LB Broth (Clarehall, UK) 
Liquid DAB Concentrated Substrate Pack (BioGeneX, San Ramen, USA) 
Loading buffer (New England Biolabs, USA) 
M-FISH probe (Vysis Incl., Downer’s Grove, USA) 
MACS running buffer (Miltenyi Biotec GmbH, Germany) 
MACS CD45RO microbeads (Miltenyi Biotec GmbH, Germany) 
MACS EpCAM microbeads (Miltenyi Biotec GmbH, Germany)  
Manual Tissue Arrayer (Beecher Instruments Inc, Sun Prairie, USA) 
Meganic beads (Beckman Coulter, UK) 
Membrane slide (Beckman Coulter, UK) 
MessageAmp™ II RNA amplification kit (Ambion, USA) 
MES hydrate (Sigma, USA) 
 235 
MES Sodium Salt (Sigma, USA) 
Methanol (Fisher Scientific, UK) 
MgCl2 (Applied Biosystems, USA)  
MicroAmp Clear Adhesive Film (Applied Biosystems, USA) 
NaCl (Sigma, USA) 
NCL-PTEN (Novocastra, USA) 
NE buffer 2 (New England Biolabs, USA) 
NE buffer 3 (New England Biolabs, USA) 
Nsp I (New England Biolabs, USA) 
Oncoquick kit (Hexal AG, Germany) 
PBS (Clarehall, UK) 
Penicillin (Invitrogen, UK) 
Phenol (USB, USA) 
Phenol:chloroform (25:24) (USB, USA) 
Proteinase K (Roach, Germany) 
QIAquick Gel Extraction Kit (Qiagen, UK) 
QIAquick PCR Purification Kit (Qiagen, UK) 
Random primer (invitrogen, UK) 
RiboMinus Human/ Mouse Transcriptome Isolation kit (Invitrogen, Paisley, United 
Kingdom) 
RNaseA (Invitrogen, UK) 
RNase free water (Applied Biosystems, USA) 
RNeasy Mini kit (Qiagen, UK) 
RPMI1640 growth medium (Invitrogen, UK) 
Rubber solution (Weldtite, UK) 
Salmon sperm (invitrogen, UK) 
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SAPE (Invitrogen, UK)  
Shandon Eosin Y (Anatomical Pathology international, Runcorn, UK) 
Sodium di-hydrogen orthophosphate (BDH Laboratory supplies, Poole, UK) 
Sty I (New England Biolabs, USA) 
20% SDS (National diagnostics, UK) 
Skimmed Marvel milk powder (Marvel, Premier International Foods, UK) 
Sodium acetate (3M) (Sigma, USA) 
Sodium azide (BDH Laboratory supplies, Poole, UK) 
SNP array 6.0 (Affymetrix, USA) 
SNP array kit (Affymetrix, USA) 
Spot light tissue pre-treatment kit (Invitrogen, UK) 
20XSSC (Vysis, IL, USA) 
SSPE (Invirogen , UK) 
Sterile Scalpel (Swann-moston, UK) 
Streptavidin-Cy3 (Sigma, USA) 
Streptavidin Phycoerythrin (Sigma, USA) 
Superscript II reverse transcriptase (Invitrogen, UK) 
T4 DNA ligase (New England Biolabs, USA) 
T4 DNA ligase buffer (New England Biolabs, USA) 
TBE buffer (Clarehall, UK) 
Terminator Reaction Kit (Applied Biosystems, USA) 
Tetramethyl-rhodamine-5-dUTP (Red) (Roche, Germany) 
TITANIUMTM Taq PCR buffer (10x) (Clontech Laboratories, Inc., USA) 
TITANIUMTM Taq DNA Polymerase (50x) (Clontech Laboratories, Inc., USA) 
TMACL (Sigma, Germany) 
TOPO TA cloning Kit (Invitrogen, UK) 
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Tris-HCl (Sigma, USA) 
TRIzol (Invitrogen, UK) 
Tween 20 (Sigma, USA) 
Trypsin (Invitrogen, UK) 
Vectastain universal ABC kit (Vector Laboratory, UK) 
Vysis PTEN / CEP 10 FISH Probe Kit (Abbott Molecular, UK) 
Water (Molecular biology reagent) (Sigma, USA) 
X-gal (Sigma, USA) 
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ALLEGRATM X-12R Centrifuge (Beckman, USA) 
Ariol SL-8 (Applied Imaging, USA) 
AutoMACS™ machine (Miltenyi Biotec, Germany) 
2100 bioanalyzer (Agilent, Germany) 
ABI 9700 thermal cycler (PE Applied Biosystems, USA) 
ABI Prism® 3700 DNA Analyzer (Applied Biosystem, USA)  
ABI Prism® 3730xl DNA Sequencer (Applied Biosystems, USA) 
ABI Prism® 377 DNA Sequencer (Applied Biosystems, USA) 
Centrifuge 5417R (Eppendorf, Germany) 
Slide (H.V. Skan Ltd, Germany) 
Cryotome® E electronic cryostat (Life Sciences International (Europe) Limited, 
England) 
DNA Engine Tetrad® Thermal cycler TPC225 (MJ Research Inc., USA) 
Dri-block DB.2D (TECHNE, Cambridge, UK) 
Olympus BX40 fluorescence microscope (Olympus Optical Co. Ltd, Japan) 
Hot plate (Science services (U.K.) Ltd, London, UK) 
HYBriteTM hybridization station (Vysis, USA) 
Leica RM 2125 (Leica CE, Germany) 
MixMate® (Eppendorf, Hamburg, Germany) 
Spectrophotometer ND-1000 (Nanodrop, USA) 
PALM MicroBeam (Zeiss, Germany) 
LABOPORT® Mini Diaphragm Vacuum Pump N816.3 KT.18 (KNF Neuberger 
GmbH, Freiburg, Germany) 
Water bath (Grant, Cambridge, UK) 
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APPENDIX II GENOMIC CHANGES IN THREE 
PROSTATE CANCER CELL LINES REVEALED BY SNP 
ARRAY ANALYSIS 
 
PatientID Chromosome Type Start (bp) End (bp) 
PC3 1 Gain 1 6771078 
 1 Gain 141394913 168046701 
 1 Gain 168456959 172032515 
 1 Gain 188099395 189205952 
 1 Gain 197911167 199694274 
 1 Gain 200967459 232455937 
 1 Gain 237164552 247249719 
 2 Gain 165742847 167224967 
 3 Gain 1 63569000 
 3 Gain 70746000 125862000 
 3 Gain 147342000 159340000 
 3 Gain 160106000 199501827 
 4 Gain 48399997 75624995 
 5 Gain 84331000 87432000 
 5 Gain 96078000 104070000 
 5 Gain 106935000 1088190 
 5 Gain 126923000 128907000 
 5 Gain 146902000 150059000 
 5 Gain 156029000 157775000 
 7 Gain 1 158821424 
 8 Gain 62508000 99276567 
 8 Gain 100410510 146274826 
 10 Gain 32536882 45161937 
 10 Gain 49238079 72506038 
 10 Gain 74144519 81970273 
 11 Gain 54575390 85328005 
 11 Gain 86269355 134452384 
 12 Gain 25761444 30013948 
 12 Gain 98058675 128923878 
 12 Gain 129783250 132349534 
 13 Gain 17774000 20549000 
 14 Gain 24900631 72963758 
 14 Gain 89833000 90834000 
 15 Gain 18394000 43562000 
 17 Gain 38927000 76215000 
 18 Gain 1 15099537 
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 19 Gain 4457573 14295112 
 19 Gain 54314664 63811651 
 20 Gain 1 62435964 
 21 Gain 9822900 46944323 
 X Gain 2705840 154913754 
 1 Loss 168046702 168456959 
 1 Loss 172032516 188099394 
 1 Loss 189205953 197911166 
 1 Loss 199694275 200967458 
 1 Loss 232455938 237164551 
 3 Loss 63569000 70746000 
 3 Loss 125862000 147342000 
 3 Loss 159340000 160106000 
 4 Loss 1 48399996 
 4 Loss 75623000 142118000 
 4 Loss 147887000 191411000 
 5 Loss 19885000 19996000 
 5 Loss 58468000 58728000 
 5 Loss 64630000 66225000 
 5 Loss 67080000 67949000 
 5 Loss 115380000 116575000 
 5 Loss 138153000 138343000 
 5 Loss 157775000 159087000 
 5 Loss 164297000 165422000 
 5 Loss 167254000 168029000 
 5 Loss 169255000 170524000 
 5 Loss 173760000 175238000 
 6 Loss 62023219 170899992 
 8 Loss 1 17334000 
 8 Loss 50010000 62488000 
 8 Loss 99276568 10041059 
 9 Loss 1 140273252 
 10 Loss 1 32536881 
 10 Loss 45161938 49238078 
 10 Loss 72506039 74144518 
 10 Loss 81970274 135374737 
 11 Loss 85328006 86269354 
 12 Loss 1 25761443 
 12 Loss 30013949 34025821 
 12 Loss 128923879 129783249 
 15 Loss 43586000 100339000 
 16 Loss 1 88827254 
 17 Loss 1 38927000 
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 18 Loss 26931000 47789000 
 19 Loss 1 4457572 
 19 Loss 32646331 54314663 
 22 Loss 14387544 49691432 
DU145 1 Gain 141290000 247249719 
 2 Gain 1 80816000 
 3 Gain 136200000 199501827 
 4 Gain 1 48769701 
 4 Gain 142613199 147448216 
 5 Gain 1 46460454 
 6 Gain 1 62779223 
 6 Gain 66193393 68097559 
 7 Gain 1 158821424 
 8 Gain 47334677 146274826 
 9 Gain 33279824 140273252 
 10 Gain 1 17407000 
 10 Gain 36198001 135374737 
 11 Gain 48477000 134452000 
 12 Gain 23269939 25310172 
 12 Gain 33679122 132349534 
 14 Gain 19151522 21676000 
 14 Gain 26929000 33773967 
 15 Gain 18310022 100338915 
 16 Gain 33630000 88827254 
 17 Gain 1 15698000 
 17 Gain 17944001 78774742 
 18 Gain 1 34874356 
 19 Gain 1 11480515 
 19 Gain 13579541 15189932 
 19 Gain 32649825 49738285 
 20 Gain 1 1300681 
 20 Gain 28103318 62435964 
 21 Gain 9822900 46944323 
 22 Gain 14426000 20323000 
 X Gain 1 2717942 
 1 Loss 1 120969707 
 2 Loss 80816000 242951149 
 3 Loss 1 136160000 
 4 Loss 52393133 142613198 
 4 Loss 147448217 191273063 
 6 Loss 62779224 66183392 
 6 Loss 68097560 170899992 
 9 Loss 1 33279823 
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 10 Loss 17407000 36198000 
 11 Loss 1 48477000 
 12 Loss 1 23489000 
 12 Loss 25303000 34709000 
 13 Loss 17953493 114142980 
 14 Loss 21676000 26929000 
 16 Loss 1 33630000 
 17 Loss 15698000 17944000 
 18 Loss 34874357 76117153 
 19 Loss 11480516 13579540 
 19 Loss 15189933 24299622 
 19 Loss 49738286 63811651 
 20 Loss 1300682 25455479 
 22 Loss 20304000 49555000 
 X Loss 2717943 154913754 
LNCaP 3 Gain 176487000 177389000 
 5 Gain 57177000 58437000 
 17 Gain 41423000 41773000 
 1 Loss 14796000 26723000 
 2 Loss 38891000 74799000 
 4 Loss 96668000 98325000 
 6 Loss 87631000 91744000 
 6 Loss 158266000 160264000 
 10 Loss 86170000 90839000 
 10 Loss 95380000 96232000 
 10 Loss 101240000 103208000 
 13 Loss 19403000 28749000 
 13 Loss 46855000 49713000 
 13 Loss 50168000 52533000 
 13 Loss 67030000 74903000 
 13 Loss 83265000 105481000 
 19 Loss 45890000 54369000 
 22 Loss 9822900 46944323 
VCaP 1 Gain 1 8607000 
 1 Gain 152833000 153505000 
 4 Gain 62591000 75148000 
 4 Gain 75747000 81501000 
 5 Gain 42215000 16047000 
 5 Gain 34319000 39543000 
 5 Gain 58555000 60444000 
 5 Gain 94277000 96969000 
 5 Gain 97993000 99719000 
 5 Gain 120744000 121309000 
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 5 Gain 123652000 124453000 
 5 Gain 125122000 126849000 
 5 Gain 136113000 138388000 
 5 Gain 152616000 153008000 
 5 Gain 159886000 161017000 
 5 Gain 164496000 165481000 
 5 Gain 170900000 171998000 
 5 Gain 173287000 174206000 
 5 Gain 175051000 177690000 
 5 Gain 178482000 180858000 
 6 Gain 11074000 11590000 
 6 Gain 19937000 20955000 
 6 Gain 21647000 30173000 
 6 Gain 33208000 34916000 
 6 Gain 43290000 48197000 
 6 Gain 49419000 50193000 
 7 Gain 39090000 158628000 
 8 Gain 35791000 39153000 
 8 Gain 41551000 146275000 
 9 Gain 1 1092000 
 9 Gain 108238000 114391000 
 9 Gain 114391000 138429000 
 11 Gain 43863000 46094000 
 11 Gain 47917000 57494000 
 11 Gain 62768000 67846000 
 12 Gain 1 19645000 
 12 Gain 20366000 90129000 
 12 Gain 93061000 103809000 
 12 Gain 105174000 113471000 
 12 Gain 114606000 132350000 
 13 Gain 107371000 111804000 
 15 Gain 58614000 100339000 
 17 Gain 22137000 35937000 
 17 Gain 71683000 78775000 
 18 Gain 1 76117153 
 19 Gain 1 3270000 
 19 Gain 11399000 19017000 
 20 Gain 1 62435964 
 21 Gain 1 46944323 
 X Gain 65901000 67010000 
 X Gain 125343000 132916000 
 1 Loss 225165000 226768000 
 4 Loss 12197000 12326000 
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 4 Loss 75148000 75747000 
 5 Loss 2541000 4221000 
 5 Loss 49572000 52546000 
 5 Loss 52714000 53089000 
 5 Loss 54888000 58555000 
 5 Loss 60444000 61452000 
 5 Loss 62865000 65452000 
 5 Loss 79868000 94347000 
 5 Loss 99721000 102122000 
 5 Loss 108905000 110814000 
 5 Loss 124453000 125122000 
 5 Loss 126849000 136113000 
 5 Loss 143890000 148101000 
 5 Loss 159015000 159886000 
 5 Loss 170213000 170900000 
 5 Loss 171998000 182539000 
 5 Loss 174206000 175051000 
 5 Loss 177690000 178482000 
 6 Loss 1 1284000 
 6 Loss 6216000 11074000 
 6 Loss 11590000 19937000 
 6 Loss 46012000 49419000 
 6 Loss 50193000 52545000 
 6 Loss 135466000 135900000 
 8 Loss 2061000 35791000 
 8 Loss 39153000 41551000 
 9 Loss 1092000 2846000 
 10 Loss 115839000 135375000 
 12 Loss 103809000 105174000 
 12 Loss 90129000 93061000 
 12 Loss 103809000 105174000 
 12 Loss 113471000 114606000 
 13 Loss 66851000 73511000 
 13 Loss 94592000 96013000 
 13 Loss 111804000 114143000 
 15 Loss 56227000 58614000 
 16 Loss 83296000 88827000 
 17 Loss 4441000 8269000 
 19 Loss 3270000 11399000 
 19 Loss 19017000 23797000 
 22 Loss 44121000 49555000 
 X Loss 48616000 54382000 
 X Loss 93733000 125343000 
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APPENDIX III GENOMIC CHANGES IN UK PROSTATE 
CANCER CLINICAL SAMPLES REVEALED BY SNP 
ARRAY ANALYSIS 
 
PatientID Chromosome Type Start (bp) End (bp) 
P9 1 Loss 72539000 72581000 
 2 Loss 20217000 20626000 
 2 Loss 34533000 34594000 
 3 Loss 70048000 86040000 
 4 Loss 9819000 9840000 
 4 Loss 69018000 69176000 
 4 Loss 104874000 106858000 
 5 Loss 52526000 58035000 
 5 Loss 54774000 55553000 
 5 Loss 140755000 141028000 
 7 Loss 97617000 129206000 
 8 Loss 13140000 34078000 
 10 Loss 1 15519000 
 10 Loss 47634000 49615000 
 11 Loss 24545000 25897000 
 12 Loss 1 18192000 
 12 Loss 29502000 33003000 
 12 Loss 49510000 52348000 
 12 Loss 61443000 63147000 
 14 Loss 90332000 91830000 
 15 Loss 82836000 83525000 
 16 Loss 32011000 33551000 
 16 Loss 48365000 61700000 
 16 Loss 62386000 88827000 
 17 Loss 5040000 15422000 
 17 Loss 18228000 18388000 
 19 Loss 20385000 20508000 
 20 Loss 20302000 20446000 
 20 Loss 20530000 20633000 
 21 Loss 38771000 41797000 
 22 Loss 14422698 49691432 
P28 7 Gain 1 158821423 
 14 Gain 24249826 49058693 
 1 Loss 152507326 185361543 
 1 Loss 202976444 205224688 
 1 Loss 216490057 222098591 
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 1 Loss 228740721 234779976 
 2 Loss 42926462 47459116 
 2 Loss 68350821 71553811 
 2 Loss 85116537 86002861 
 5 Loss 87128607 128932737 
 6 Loss 66322504 115596589 
 8 Loss 4050956 31683148 
 10 Loss 12606158 16824372 
 10 Loss 118669375 135374737 
 12 Loss 1 14519816 
 13 Loss 94831951 95148882 
 14 Loss 19240309 24249826 
 16 Loss 1 4889723 
 16 Loss 65063790 69274804 
 16 Loss 79993748 80253782 
 18 Loss 25557585 42132974 
 20 Loss 3502301 3927359 
 21 Loss 41434261 42206704 
 X Loss 1 154913754 
P39 4 Gain 77177977 81006358 
 4 Gain 113585662 114985660 
 8 Gain 26517136 36807824 
 11 Gain 1 134452384 
 12 Gain 1 11811649 
 12 Gain 12877209 132349534 
 14 Gain 22163665 39277180 
 19 Gain 53773709 63811651 
 20 Gain 1 62435964 
 22 Gain 16910900 41553162 
 1 Loss 1 66259884 
 1 Loss 69959387 77354732 
 1 Loss 209618978 210409521 
 2 Loss 1 242951149 
 3 Loss 30065936 32936740 
 4 Loss 59304830 77177976 
 4 Loss 81006359 113585661 
 6 Loss 1 28412007 
 8 Loss 19253662 26517135 
 8 Loss 36807825 38825554 
 9 Loss 1 22719945 
 10 Loss 126975575 135374737 
 12 Loss 11811650 12877208 
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 13 Loss 30098682 114142980 
 14 Loss 39301109 98996439 
 15 Loss 24177124 40524102 
 15 Loss 68633325 100338915 
 16 Loss 44953939 88827254 
 20 Loss 1 62435964 
 21 Loss 13249493 15876548 
 21 Loss 38765503 41855152 
 22 Loss 41512045 49691432 
P55 1 Loss 76057000 88978000 
 1 Loss 91715000 91940000 
 1 Loss 104086000 107781000 
 1 Loss 115257000 120368000 
 3 Loss 21060000 25276000 
 3 Loss 44228000 44854000 
 3 Loss 65907000 76820000 
 3 Loss 79375000 84323000 
 3 Loss 117124000 122836000 
 3 Loss 154001000 161876000 
 3 Loss 186047000 186786000 
 3 Loss 196329000 198984000 
 8 Loss 19390000 26202000 
 8 Loss 38137000 39777000 
 8 Loss 91753000 96615000 
 9 Loss 94993000 98909000 
 10 Loss 45011000 48793000 
 10 Loss 77604000 94640000 
 16 Loss 21263000 23545000 
 16 Loss 69752000 72822000 
 16 Loss 88472000 88827000 
 21 Loss 38813000 41799000 
 22 Loss 19540000 31043000 
 22 Loss 42781000 48534000 
P63 5 Gain 35930602 45349998 
 7 Gain 1 158821423 
 16 Gain 28493230 48620434 
 17 Gain 16372757 19890132 
 1 Loss 230044288 231319903 
 2 Loss 149875320 157924503 
 4 Loss 25021782 42771504 
 4 Loss 185490574 186387374 
 5 Loss 6600653 35930602 
 248 
 6 Loss 50937093 51910869 
 8 Loss 6203569 27743734 
 9 Loss 70126246 88177771 
 10 Loss 88186999 90642916 
 10 Loss 93857366 106277596 
 13 Loss 17948933 114142980 
 14 Loss 67488586 80513654 
 16 Loss 48620434 88827254 
 17 Loss 1 16372757 
 18 Loss 53985757 76117153 
 19 Loss 13149271 14883947 
 19 Loss 40645122 44017766 
 21 Loss 38794285 41818329 
 X Loss 1 154913754 
P68 1 Loss 16569000 23429000 
 2 Loss 38393000 49620000 
 3 Loss 54434000 56178000 
 12 Loss 11596000 14644000 
 12 Loss 83437000 84431000 
 17 Loss 38417000 40511000 
 21 Loss 38764000 41796000 
P98 1 Gain 1 67739000 
 1 Gain 110654000 112125000 
 1 Gain 113221000 116094000 
 1 Gain 116863000 118317000 
 1 Gain 118479000 120424000 
 1 Gain 148518000 149417000 
 1 Gain 152114000 154446000 
 1 Gain 157809000 158041000 
 1 Gain 158353000 158961000 
 1 Gain 159458000 161885000 
 1 Gain 163124000 165390000 
 1 Gain 170616000 171071000 
 1 Gain 171569000 171729000 
 1 Gain 172736000 173071000 
 1 Gain 176156000 176596000 
 1 Gain 180230000 181045000 
 1 Gain 181991000 185506000 
 1 Gain 198609000 199141000 
 1 Gain 201481000 202497000 
 1 Gain 204820000 207608000 
 1 Gain 209684000 210250000 
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 1 Gain 210507000 211166000 
 1 Gain 212477000 215544000 
 1 Gain 218194000 220717000 
 1 Gain 225450000 225775000 
 1 Gain 226178000 226755000 
 1 Gain 229882000 230419000 
 1 Gain 120713000 231156000 
 1 Gain 231927000 232858000 
 1 Gain 233893000 234851000 
 1 Gain 236858000 237529000 
 1 Gain 240884000 241376000 
 1 Gain 241718000 242885000 
 1 Gain 245766000 247250000 
 2 Gain 33292000 39472000 
 2 Gain 52032000 53165000 
 5 Gain 14961000 52490000 
 7 Gain 142126000 142183000 
 8 Gain 1 10427000 
 8 Gain 99262000 107401000 
 9 Gain 6485000 27986000 
 9 Gain 88369000 140273000 
 10 Gain 56272000 66976000 
 10 Gain 66989000 89510000 
 11 Gain 70834000 134452000 
 12 Gain 12468000 30283000 
 12 Gain 36143000 129349000 
 13 Gain 17923000 31739000 
 13 Gain 93605000 96638000 
 20 Gain 10828000 10894000 
 20 Gain 46568000 47563000 
 20 Gain 47715000 49057000 
 20 Gain 50530000 51081000 
 20 Gain 54598000 54866000 
 20 Gain 55009000 57137000 
 20 Gain 59170000 61375000 
 20 Gain 61642000 62436000 
 2 Loss 131909000 134505000 
 2 Loss 220658000 223602000 
 3 Loss 45701000 48945000 
 3 Loss 68955000 80217000 
 3 Loss 80802000 90598000 
 5 Loss 13209000 13334000 
 9 Loss 85921000 88369000 
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 10 Loss 41753000 54089000 
 10 Loss 46476000 46481000 
 10 Loss 54089000 56272000 
 10 Loss 66976000 66989000 
 10 Loss 89510000 89627000 
 10 Loss 89717000 135375000 
 11 Loss 1 48999000 
 11 Loss 70474000 70834000 
 12 Loss 30283000 34745000 
 12 Loss 129349000 132349000 
 13 Loss 40075000 42281000 
 13 Loss 98154000 99480000 
 13 Loss 99940000 100817000 
 15 Loss 46412000 100339000 
 17 Loss 1 16619000 
 17 Loss 19522000 22067000 
 18 Loss 17286000 76117000 
 19 Loss 32726000 47758000 
 20 Loss 1 1862000 
 20 Loss 4697000 5341000 
 20 Loss 6171000 6463000 
 20 Loss 12858000 16330000 
 20 Loss 19075000 19800000 
 20 Loss 29263000 42620000 
 20 Loss 44443000 46228000 
 21 Loss 38853000 41793000 
P107 1 Gain 193191973 195389719 
 2 Gain 206053485 207409758 
 3 Loss 149548126 168238025 
 4 Loss 184912241 186231963 
 6 Loss 80267484 84644165 
 6 Loss 91357909 92420211 
 6 Loss 91332616 92287676 
 6 Loss 112939318 118116772 
 6 Loss 128305000 128953762 
 6 Loss 146455175 168009015 
 8 Loss 1 28956045 
 8 Loss 59523163 70134345 
 10 Loss 41709710 60392690 
 10 Loss 84647578 135374737 
 12 Loss 9814509 10107537 
 12 Loss 10287351 11566022 
 12 Loss 61640263 62323083 
 15 Loss 39661763 41436484 
 15 Loss 56926197 57739382 
 16 Loss 23639495 24714465 
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 16 Loss 71047447 72680214 
P123 1 Loss 23171852 24125546 
 1 Loss 70974829 71328312 
 2 Loss 126692119 132020846 
 4 Loss 12922694 13485179 
 4 Loss 15689786 15755028 
 4 Loss 169124027 171070400 
 6 Loss 1 756621 
 6 Loss 4519781 6174579 
 6 Loss 79710942 107652835 
 6 Loss 139640918 139825441 
 6 Loss 143862087 150613720 
 6 Loss 164360291 170892931 
 7 Loss 156957618 157164857 
 7 Loss 157627142 157677673 
 9 Loss 73108654 76554430 
 11 Loss 73437711 73701859 
 12 Loss 120141934 120941561 
 12 Loss 123135673 123257341 
 12 Loss 123388661 123978982 
 16 Loss 64297100 88827254 
 21 Loss 38856721 41793166 
 22 Loss 17288827 18699636 
 22 Loss 22481610 31028060 
 X Loss 134278978 134431504 
P127 8 Gain 36012127 87569541 
 20 Gain 10026214 14759059 
 1 Loss 1 53239904 
 2 Loss 1 15960295 
 2 Loss 38431705 49906057 
 2 Loss 60656011 74846856 
 3 Loss 1 90374677 
 4 Loss 86771012 90420643 
 5 Loss 59696555 60269361 
 5 Loss 70743180 71339773 
 5 Loss 129248587 132457395 
 5 Loss 154882989 156844180 
 5 Loss 170680121 175917013 
 6 Loss 106065723 106665856 
 6 Loss 113708981 114314328 
 8 Loss 1 36012127 
 8 Loss 87569541 146274826 
 9 Loss 4397800 6839679 
 11 Loss 1 89168497 
 11 Loss 111763081 114415978 
 11 Loss 123605598 134452384 
 12 Loss 10775275 13513802 
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 13 Loss 17774090 114142980 
 16 Loss 1 1848367 
 16 Loss 70643988 88827254 
 17 Loss 1 19166605 
 18 Loss 31391382 76117153 
 19 Loss 1 63811651 
 21 Loss 38275919 41919070 
 21 Loss 45193509 46944323 
 22 Loss 14327092 49691432 
P130 3 Gain 8248000 17234000 
 3 Gain 36258000 76003000 
 3 Gain 118924000 145136000 
 3 Gain 185182000 191978000 
 3 Gain 194851000 199502000 
 4 Gain 1 9806000 
 4 Gain 55088000 56437000 
 5 Gain 1 46425000 
 6 Gain 1 17750000 
 6 Gain 29403000 44929000 
 6 Gain 105825000 112686000 
 7 Gain 1 5402000 
 7 Gain 57097000 124379000 
 7 Gain 125682000 144468000 
 7 Gain 146021000 158821000 
 8 Gain 47028931 146274826 
 10 Gain 1 39082293 
 11 Gain 3367000 8095000 
 11 Gain 13275000 24122000 
 11 Gain 24398000 31381000 
 16 Gain 26693000 31817000 
 16 Gain 21846000 35014000 
 16 Gain 45111000 47530000 
 17 Gain 33073000 47216000 
 17 Gain 50642000 54095000 
 17 Gain 58822000 64095000 
 17 Gain 67214000 74023000 
 18 Gain 16774000 17649000 
 18 Gain 72343000 76117000 
 21 Gain 13508000 18724000 
 21 Gain 19945000 46944000 
 22 Gain 31340000 31595000 
 22 Gain 31993000 42588000 
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 1 Loss 1 12732000 
 1 Loss 102294000 106641000 
 1 Loss 193926000 199121000 
 2 Loss 99247000 100308000 
 2 Loss 120226000 178963000 
 2 Loss 239231000 239244000 
 3 Loss 50852000 51009000 
 3 Loss 76003000 90603000 
 3 Loss 117509000 118508000 
 3 Loss 161883000 167708000 
 4 Loss 58104000 191273000 
 5 Loss 77411000 166885000 
 7 Loss 9035000 19807000 
 7 Loss 51921000 54467000 
 8 Loss 1 43832614 
 9 Loss 28147000 32144000 
 9 Loss 103573000 106455000 
 10 Loss 51699000 135375000 
 11 Loss 24122000 24398000 
 11 Loss 36957000 45106000 
 11 Loss 62549000 62712000 
 11 Loss 73284000 76605000 
 13 Loss 19464000 114143000 
 14 Loss 25073000 29208000 
 14 Loss 39388000 48557000 
 14 Loss 77705000 80457000 
 14 Loss 81665000 87099000 
 15 Loss 21446000 42460000 
 15 Loss 59978000 100339000 
 16 Loss 32057000 32802000 
 16 Loss 57971000 63546000 
 16 Loss 74148000 75652000 
 17 Loss 5331000 33073000 
 18 Loss 2799000 15325000 
 19 Loss 51694000 58276000 
 20 Loss 57837000 57960000 
 22 Loss 16415000 21718000 
 22 Loss 22972000 30190000 
 22 Loss 42594000 49691000 
WX1 NA NA NA NA 
WX11 NA NA NA NA 
WX12 10 Gain 46471632 46482772 
 3 Loss 70679388 72878326 
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 7 Loss 97572773 102016681 
 8 Loss 20238231 24748676 
 10 Loss 87533633 90320182 
 16 Loss 79991263 88815037 
 20 Loss 9305 20777252 
WX21 1 Loss 103719634 121274524 
 1 Loss 226729246 247249719 
 2 Loss 212300803 212472833 
 5 Loss 532800 960206 
 5 Loss 113739677 122978148 
 5 Loss 132269361 133955096 
 6 Loss 80505210 117354388 
 8 Loss 1 38349732 
 10 Loss 89266853 90942622 
 13 Loss 18932562 21828717 
 13 Loss 22199075 22286966 
 13 Loss 22461478 24879896 
 13 Loss 28984360 36614307 
 13 Loss 36937999 37107774 
 13 Loss 38360347 38639307 
 13 Loss 38710892 58886886 
 13 Loss 59861726 60475794 
 13 Loss 60870348 62340528 
 13 Loss 65064757 65124929 
 13 Loss 65403406 66567870 
 15 Loss 37761422 38224205 
 15 Loss 42726771 44743142 
 15 Loss 78477726 79133713 
 16 Loss 48213170 88815037 
 17 Loss 1 16560197 
 18 Loss 18797789 76117153 
 21 Loss 38781702 41795777 
WX33 3 Gain 396793 636336 
 8 Gain 1 63618424 
 8 Gain 63712624 146274826 
 9 Gain 1 140273252 
 11 Gain 1 3434916 
 11 Gain 61174200 76713100 
 2 Loss 117049439 139985547 
 3 Loss 146459695 146999714 
 4 Loss 138384193 138425384 
 4 Loss 145673587 146718005 
 4 Loss 155229215 155284830 
 4 Loss 155446377 155749839 
 4 Loss 168233424 172611491 
 6 Loss 73156714 96204363 
 6 Loss 104328938 104428260 
 6 Loss 122240077 122308873 
 6 Loss 127867196 128304359 
 6 Loss 128540740 129104430 
 6 Loss 129212530 129419904 
 6 Loss 129544326 129974959 
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 6 Loss 131011806 131056287 
 6 Loss 152084155 153118429 
 6 Loss 154079575 154156563 
 6 Loss 154325435 154365710 
 7 Loss 81200107 81558658 
 7 Loss 81774779 81848574 
 7 Loss 115402324 115954755 
 7 Loss 116699889 117147031 
 8 Loss 63618425 63712623 
 10 Loss 26348509 26464462 
 10 Loss 26781410 26882214 
 10 Loss 27016087 27076655 
 10 Loss 27124195 27342552 
 10 Loss 27620836 27853804 
 12 Loss 9688542 9760299 
 12 Loss 9955539 13113509 
 12 Loss 13230614 13889747 
 12 Loss 14036358 14541994 
 12 Loss 57025747 58758653 
 13 Loss 31005730 31114944 
 13 Loss 31305208 31344157 
 13 Loss 31515030 57465124 
 16 Loss 49924807 51329618 
 16 Loss 59218170 82019326 
 18 Loss 5107611 6762461 
 18 Loss 26124000 26508169 
 18 Loss 26649566 26693631 
 18 Loss 26737297 35406246 
 18 Loss 36234266 36397503 
 18 Loss 36457865 36654290 
 18 Loss 37247619 37627516 
 18 Loss 38044478 38267555 
 18 Loss 60550574 61602879 
 18 Loss 68451779 68599777 
 18 Loss 69167235 69664033 
WX34 3 Gain 158485028 179703855 
 3 Gain 180520125 199501827 
 3 Loss 35345 11603063 
 3 Loss 179703856 180520124 
 6 Loss 19020707 20681883 
 6 Loss 20761085 20937917 
 6 Loss 21416302 23929832 
 6 Loss 24026782 24104661 
 8 Loss 1 29235356 
 12 Loss 121919595 132349534 
 16 Loss 71069153 88827254 
 21 Loss 40658729 41706257 
WX39 6 Loss 161329012 161361759 
 14 Loss 90720368 92695404 
 21 Loss 38813713 41794266 
WX47 1 Loss 54335260 81077178 
 1 Loss 159034730 160009000 
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 1 Loss 162379945 163442247 
 1 Loss 166026508 167054802 
 1 Loss 204970848 205113350 
 1 Loss 233417026 234312641 
 2 Loss 38079787 38877532 
 2 Loss 193848381 195144908 
 6 Loss 64387092 170899992 
 8 Loss 11642275 23595033 
 10 Loss 74617549 95625273 
 12 Loss 44824605 46705196 
 12 Loss 64783290 66691888 
 13 Loss 34273944 72853255 
 16 Loss 67904043 88827254 
 17 Loss 4233792 21357124 
 20 Loss 1222507 2608014 
 22 Loss 17534130 18439584 
 22 Loss 20456013 20873061 
 22 Loss 22819541 27954161 
WX68 8 Gain 32518570 65119709 
 8 Gain 66913063 67499519 
 8 Gain 67657768 68058048 
 8 Gain 68216297 76550013 
 8 Gain 76929458 77131038 
 8 Gain 77261472 77712062 
 8 Gain 77822733 78004550 
 8 Gain 78666850 106933465 
 8 Gain 119363469 130105103 
 8 Gain 130483213 133756604 
 8 Gain 133874917 136481754 
 8 Gain 136552761 138471960 
 9 Gain 78306364 78315466 
 1 Loss 206894053 239464585 
 2 Loss 103065311 134983589 
 3 Loss 95032712 118773767 
 3 Loss 118773767 120464205 
 4 Loss 15736362 158101836 
 4 Loss 182369086 183006429 
 5 Loss 6715368 7804405 
 5 Loss 9142257 16377468 
 5 Loss 96888526 98353731 
 6 Loss 57608042 129684984 
 7 Loss 122548072 124231197 
 8 Loss 1 3710105 
 8 Loss 14278483 32518569 
 11 Loss 29225095 50021876 
 13 Loss 37724673 66890388 
 13 Loss 80989038 83727834 
 14 Loss 82511572 84382630 
 18 Loss 10278261 11064680 
 X Loss 27500735 31438286 
 X Loss 33736805 33800974 
WX7 7 Gain 61483915 61982787 
 257 
 16 Gain 32409159 32519575 
 19 Gain 8907610 8948574 
 1 Loss 51598 3730219 
 2 Loss 239602634 242738130 
 3 Loss 40466795 40504565 
 3 Loss 50090828 50463894 
 3 Loss 178387177 178424832 
 3 Loss 185707572 185773411 
 4 Loss 2281 3861574 
 4 Loss 5799924 9324707 
 4 Loss 133110182 133181035 
 5 Loss 68532 2019621 
 6 Loss 28691240 43868490 
 6 Loss 166377624 170899992 
 7 Loss 52911 2746427 
 7 Loss 27100155 27215851 
 8 Loss 1 43419779 
 8 Loss 142074606 146268960 
 9 Loss 21946628 21993990 
 9 Loss 129351734 140211216 
 10 Loss 62759 1775910 
 10 Loss 133628330 135356695 
 11 Loss 1 4185296 
 11 Loss 60574453 70661107 
 12 Loss 118035550 124060999 
 13 Loss 32584095 64576484 
 13 Loss 112370788 114126500 
 14 Loss 65320905 106356483 
 16 Loss 777 3193031 
 16 Loss 65782940 69401585 
 16 Loss 69501324 85890077 
 16 Loss 85890077 88815037 
 17 Loss 1 22045940 
 17 Loss 70533102 78774742 
 18 Loss 75183155 76116030 
 19 Loss 41910 8907610 
 20 Loss 59699747 62426598 
 21 Loss 41451916 46921386 
 22 Loss 44824438 44870605 
 X Loss 48898439 48947949 
 X Loss 152265691 153538137 
WX73 3 Gain 9064159 16561673 
 1 Loss 155711366 174483322 
 4 Loss 119672343 126337760 
 8 Loss 1 43948866 
 10 Loss 44454535 52135234 
 10 Loss 89747944 90345713 
 21 Loss 38686109 41796930 
WX76 6 Gain 79027120 79086762 
 7 Gain 1 6955684 
 7 Gain 109222681 109228672 
 8 Gain 140224529 146274826 
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 1 Loss 247062159 247191012 
 1 Loss 185267134 197650038 
 1 Loss 46189991 54596754 
 2 Loss 2784 160994 
 3 Loss 35345 208838 
 3 Loss 172804502 199501827 
 4 Loss 2281 129500 
 5 Loss 68532 176567 
 5 Loss 155189199 157376568 
 6 Loss 134241999 138920171 
 6 Loss 163621711 165577610 
 7 Loss 76141330 76147870 
 7 Loss 13556805 13603863 
 8 Loss 1 38259231 
 10 Loss 115460536 118582022 
 11 Loss 113216483 115726904 
 19 Loss 40927970 40995306 
 21 Loss 38785253 41784911 
WX8 9 Gain 107403235 109153734 
 9 Gain 119070378 119537695 
 1 Loss 154172285 177994740 
 3 Loss 57656072 61347774 
 3 Loss 65392668 73184410 
 3 Loss 123510645 126825050 
 5 Loss 56140687 59836517 
 5 Loss 130062557 132086114 
 5 Loss 156967926 159840212 
 5 Loss 167477493 169747571 
 8 Loss 21254 43455242 
 10 Loss 13957733 15454364 
 10 Loss 89542223 91297450 
 10 Loss 99939914 101262901 
 11 Loss 119309882 121191555 
 11 Loss 13450027 13607724 
 12 Loss 11402844 25720021 
 13 Loss 31082218 35506858 
 13 Loss 39638935 94520912 
 14 Loss 74246603 103360805 
 15 Loss 39672342 42589552 
 15 Loss 72813987 73388711 
 17 Loss 38976979 40254165 
 21 Loss 38844447 41811937 
WX80 1 Loss 186041798 198117691 
 3 Loss 73781698 98537399 
 5 Loss 18261805 31023065 
 7 Loss 8308178 19900982 
 7 Loss 77865005 95060999 
 7 Loss 117666968 120178742 
 12 Loss 34381530 34454003 
 12 Loss 70683024 91131188 
 20 Loss 6358544 6375175 
 21 Loss 19558915 19563668 
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 22 Loss 14387544 49691432 
WX83 12 Loss 17342896 23891537 
 12 Loss 24129367 27021347 
 21 Loss 9758742 15266430 
 21 Loss 15889240 23581864 
 21 Loss 38793972 41815828 
WX85 7 Gain 2744696 55677457 
 8 Gain 47332569 142070849 
 2 Loss 35935232 52721237 
 4 Loss 1 9232676 
 11 Loss 63446433 71180662 
 17 Loss 6988117 7656150 
 20 Loss 59614783 62426598 
 21 Loss 42032873 46944323 
 X Loss 1 154913754 
WX87 17 Gain 36413750 36697052 
 21 Gain 19246031 24271700 
 5 Loss 87568651 138115299 
 5 Loss 141582648 162156019 
 13 Loss 36797920 53044548 
 X Loss 38912084 39813113 
WX88 16 Loss 57921421 64080975 
WX9 2 Gain 212692916 214435363 
 4 Gain 31219833 31911965 
 8 Gain 63287366 99172005 
 8 Gain 100441890 144969049 
 13 Gain 93773674 94351847 
 14 Gain 37740281 38073332 
 16 Gain 25513759 33075363 
 1 Loss 1 13757231 
 1 Loss 20081111 21214051 
 1 Loss 46435842 48239003 
 1 Loss 110355200 111051516 
 1 Loss 227603814 227744613 
 1 Loss 245432373 247191012 
 2 Loss 135449312 138357640 
 2 Loss 138482121 139204172 
 2 Loss 168950319 169257939 
 3 Loss 9022084 10818764 
 4 Loss 86721508 90607210 
 5 Loss 3392236 3896952 
 5 Loss 55683443 56156229 
 5 Loss 66217086 73147260 
 6 Loss 20205471 27222185 
 6 Loss 90664331 91282826 
 8 Loss 59479715 61812252 
 9 Loss 1 17379969 
 10 Loss 88262202 106038979 
 12 Loss 16084277 17035815 
 12 Loss 18013939 19696626 
 12 Loss 29450184 30842551 
 16 Loss 44845877 67764873 
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 16 Loss 68643586 69401585 
 16 Loss 69760144 88827254 
 17 Loss 7150053 7585442 
 17 Loss 25898069 43465186 
 21 Loss 38819573 41795777 
WX92 3 Loss 50870534 50936172 
 10 Loss 50683999 51181268 
 16 Loss 74575644 75459731 
 17 Loss 72956442 73263644 
WX94 1 Gain 142273865 247249719 
 2 Loss 106569300 138232879 
 3 Loss 69338023 72981200 
 5 Loss 135213235 137282680 
 7 Loss 1 6933589 
 7 Loss 80250299 86790775 
 7 Loss 97673611 102259461 
 8 Loss 1 56942508 
 8 Loss 63668400 64278019 
 10 Loss 129138050 135356695 
 12 Loss 104163528 104692390 
 13 Loss 59218923 60300072 
 15 Loss 39343581 40234084 
 16 Loss 45062002 88827254 
 Y Loss 17082986 17275694 
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APPENDIX IV GENOMIC CHANGES IN CHINESE 
PROSTATE CANCER CLINICAL SAMPLES REVEALED 
BY SNP ARRAY ANALYSIS 
 
PatientID Chromosome Type Start (bp) End (bp) 
SH1 2 Loss 115187216 147289342 
 4 Loss 189625817 189807877 
 6 Loss 79861533 113130026 
 8 Loss 1 44039910 
 8 Gain 46960592 146274826 
 12 Gain 43012170 43527712 
 12 Gain 97092837 97696131 
 13 Loss 30104256 60613436 
SH2 10 Loss 46472155 46487769 
 13 Loss 45272996 50538801 
SH38 2 Loss 107204560 163452229 
 5 Loss 102185745 160634111 
 6 Loss 72532899 114436151 
 X Loss 77373324 79943657 
 X Loss 86405736 89522196 
 X Loss 103583939 105844257 
 X Loss 109970860 110035904 
 X Loss 135865973 136709358 
 X Loss 140157255 140606993 
 X Loss 143700365 144084633 
 X Loss 146566758 147347318 
SH10 1 Loss 96374420 96422722 
 1 Loss 98776717 98919794 
 1 Loss 104220245 108406965 
 1 Loss 207995257 237912942 
 3 Loss 1518281 1574465 
 3 Loss 27088775 27113033 
 3 Loss 33519217 37449374 
 3 Loss 67172555 67218274 
 3 Loss 69063367 70481668 
 3 Loss 75304112 76755398 
 3 Loss 82941791 83396229 
 3 Loss 85688432 86282247 
 3 Loss 88924737 90593590 
 3 Loss 95001146 95389510 
 3 Loss 99765589 110135707 
 3 Loss 116122372 116619718 
 3 Loss 137942032 140531350 
 3 Loss 163477405 168511242 
 4 Loss 52562621 53455033 
 4 Loss 59181529 61001341 
 4 Loss 130011686 134178874 
 4 Loss 136057149 138771436 
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 4 Loss 174175547 177718538 
 4 Loss 180457557 185738245 
 5 Loss 13495995 13823984 
 5 Loss 16654252 21861292 
 5 Loss 42680409 46384075 
 5 Loss 49467034 50474804 
 5 Loss 79538015 92066560 
 5 Loss 94606291 104294629 
 5 Loss 109281278 109892768 
 5 Loss 111374498 112334647 
 5 Loss 128776783 132100753 
 5 Loss 139366677 141567540 
 6 Loss 57636159 58214480 
 6 Loss 62080526 68164728 
 6 Loss 74947231 74981200 
 6 Loss 80540240 99520725 
 6 Loss 103657573 115774840 
 6 Loss 123981217 124841959 
 7 Loss 49680172 54102565 
 7 Loss 62140304 62790080 
 8 Loss 1 37929743 
 8 Loss 136476540 137735441 
 8 Loss 138510625 146274826 
 11 Loss 6716539 7786060 
 11 Loss 27023040 27226024 
 11 Loss 29029589 48660698 
 11 Loss 54540914 58386308 
 11 Loss 88762019 88903980 
 12 Loss 3795974 5346637 
 12 Loss 6284471 17812288 
 13 Loss 52142260 52172722 
 13 Loss 56030824 57908551 
 13 Loss 67263607 86893521 
 13 Loss 100047738 100114092 
 13 Loss 102206821 105443441 
 13 Loss 107065973 108300821 
 15 Loss 33835880 34896950 
 16 Loss 33211708 35153004 
 16 Loss 54395421 88827254 
 18 Loss 67847210 73645388 
 X Loss 78863912 80193677 
 X Loss 94642262 95705262 
 X Loss 96899124 97863156 
 Y Loss 11871131 27265149 
 7 Gain 1 49680172 
 7 Gain 53349037 53968241 
 7 Gain 54102565 62140304 
 7 Gain 62790080 158821424 
 8 Gain 37929743 136476540 
 8 Gain 137735441 138510625 
 13 Gain 92117048 93180895 
 16 Gain 45993149 54395421 
 263 
SH11 1 Loss 102186306 103174842 
 1 Loss 155357416 157641987 
 2 Loss 118444626 123269692 
 2 Loss 124797522 127635815 
 2 Loss 183413634 184033378 
 3 Loss 82540211 83609845 
 3 Loss 86935802 90593464 
 4 Loss 133870001 134454828 
 4 Loss 136607175 138031300 
 4 Loss 167234500 169103447 
 5 Loss 96915601 103407549 
 6 Loss 80777141 81377166 
 6 Loss 82510457 123601964 
 7 Loss 35141336 35443849 
 7 Loss 122142102 125972893 
 8 Loss 85745879 86410268 
 10 Loss 33708898 34908280 
 13 Loss 30440764 58650978 
 13 Loss 58879607 81412884 
 21 Loss 20363286 20737696 
 21 Loss 21450806 23615145 
 21 Loss 26051972 28863974 
 X Loss 26775292 26831745 
 4 Gain 1261125 2059837 
 4 Gain 72389508 72675276 
 7 Gain 1 35141336 
 7 Gain 35443849 122142102 
 7 Gain 125972893 158821424 
 14 Gain 36743291 37166918 
 15 Gain 23065281 23522363 
 16 Gain 45356215 45671726 
 20 Gain 60746078 61273890 
 21 Gain 16189193 16458068 
 X Gain 102623794 103049318 
SH4 3 Loss 74073414 75067256 
 5 Loss 64504797 64605716 
 6 Loss 20097982 24538401 
 6 Loss 27991442 29468663 
 8 Loss 1 39838266 
 11 Loss 84461352 84813864 
 12 Loss 21605002 34777980 
 12 Loss 53869123 54195059 
 12 Loss 76266242 78640246 
 12 Loss 79758496 84614235 
 13 Loss 30166084 114142980 
 16 Loss 74643742 80956581 
 21 Loss 36245600 39202530 
 17 Gain 43868789 78774742 
SH9 1 Loss 16404056 20105388 
 1 Loss 27974849 35201103 
 1 Loss 45901703 46880987 
 1 Loss 95108121 98897802 
 264 
 1 Loss 109843823 114060049 
 4 Loss 95361377 95809898 
 5 Loss 74174268 136979693 
 8 Loss 1 6924460 
 8 Loss 8179202 11903810 
 8 Loss 12605603 43947134 
 9 Loss 1 33896330 
 10 Loss 46466362 46487960 
 12 Loss 1 8259564 
 12 Loss 8582492 34747857 
 13 Loss 94174985 94771603 
 16 Loss 30221833 31616244 
 16 Loss 46951039 88827254 
 17 Loss 5298068 7862945 
 18 Loss 1 76117153 
 19 Loss 43804693 47685655 
 19 Loss 49766222 52884813 
 22 Loss 15409258 49691432 
 9 Gain 33896330 68776419 
 9 Gain 72326411 74549412 
 9 Gain 78725116 87304262 
 9 Gain 89138505 97756392 
 9 Gain 98721067 105600557 
 9 Gain 112386718 130722200 
 9 Gain 135438244 140273252 
 10 Gain 51874176 52609801 
 16 Gain 1 1914658 
 16 Gain 2814024 3849495 
 16 Gain 7576232 13527777 
 16 Gain 14177992 30221833 
 16 Gain 31616244 33426377 
 16 Gain 45017041 46951039 
 X Gain 28088179 28958286 
SH6 2 Loss 114017514 140320587 
 2 Loss 142494565 144013720 
 2 Loss 146191595 146444008 
 2 Loss 192548015 193787318 
 2 Loss 240036996 240514577 
 5 Loss 107262831 110175875 
 8 Loss 1 43951508 
 10 Loss 43526904 44121951 
 10 Loss 72391784 73161152 
 10 Loss 84102404 89726394 
 11 Loss 34886211 35391014 
 11 Loss 59544253 61655806 
 15 Loss 51170050 78180672 
 16 Loss 46240302 50795091 
 16 Loss 51060119 88827254 
 17 Loss 1 15561208 
 17 Loss 66463256 68960340 
 X Loss 104938958 105480951 
 8 Gain 46962974 146274826 
 265 
 9 Gain 79552451 140273252 
 11 Gain 54691469 55747305 
 11 Gain 59324997 59544253 
 16 Gain 1 46240302 
 16 Gain 50795091 51060119 
 17 Gain 15561208 22361738 
SH15 1 Loss 59009810 59936332 
 2 Loss 216509672 217145246 
 4 Loss 90346225 95565128 
 6 Loss 76060989 116734954 
 8 Loss 5301253 7368996 
 8 Loss 8088440 34086688 
 8 Loss 39115430 41695488 
 8 Loss 42909281 43901208 
 8 Loss 47864530 55125245 
 8 Loss 78183361 79469903 
 8 Loss 82055178 82774199 
 8 Loss 85733565 88677650 
 10 Loss 88152913 88363476 
 10 Loss 89060956 96670052 
 12 Loss 6433512 14808599 
 13 Loss 68758269 70032773 
 13 Loss 72109121 73370174 
 13 Loss 102203432 106143829 
 17 Loss 53342555 55311617 
 3 Gain 116826927 199501827 
 6 Gain 62170171 62301188 
 10 Gain 46475550 46488126 
 14 Gain 35890055 36191994 
 14 Gain 23546171 23570709 
SH34 1 Loss 1 121191458 
 2 Loss 23032186 23790145 
 2 Loss 127213732 127458445 
 2 Loss 138980562 139235948 
 2 Loss 141700589 141898808 
 3 Loss 80669502 82860324 
 3 Loss 193229632 195698869 
 4 Loss 116868146 138744902 
 5 Loss 87380214 128749921 
 6 Loss 85981604 97466652 
 6 Loss 123525403 126516287 
 10 Loss 85006609 91373800 
 11 Loss 100629158 102499438 
 12 Loss 12697787 14089282 
 13 Loss 38652766 70606800 
 13 Loss 71183188 77995778 
 13 Loss 79887113 80243892 
 16 Loss 58299640 60337049 
 X Loss 61842934 62809993 
 X Loss 63892375 64604028 
 1 Gain 141829267 247249719 
 7 Gain 1 78209358 
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 7 Gain 83062023 158821424 
 18 Gain 1 76117153 
SH17 2 Loss 133428118 133559326 
 2 Loss 136957790 143225391 
 2 Loss 153991843 155969170 
 2 Loss 166258856 166359254 
 3 Loss 16848979 29506958 
 4 Loss 18876321 19905100 
 4 Loss 24919303 31923018 
 4 Loss 41959850 44000152 
 4 Loss 122820051 125543792 
 4 Loss 173033061 174965724 
 4 Loss 175986641 177621948 
 5 Loss 49463938 82936466 
 5 Loss 84704111 87023345 
 5 Loss 90059490 94538233 
 5 Loss 97658316 112169108 
 5 Loss 151131636 151335232 
 5 Loss 153051623 153670424 
 6 Loss 75959621 90354793 
 6 Loss 96547251 126425467 
 6 Loss 153270240 153293777 
 8 Loss 1 6949789 
 8 Loss 8115556 43886069 
 8 Loss 89457714 90498629 
 8 Loss 106226625 106328167 
 8 Loss 107958648 112711727 
 13 Loss 38411508 56212314 
 13 Loss 95833696 96239517 
 16 Loss 45018093 88827254 
 15 Gain 21982273 24830372 
SH12 1 Loss 33209480 35348139 
 3 Loss 178256165 179428639 
 5 Loss 118577261 119255796 
 5 Loss 122445575 127552852 
 6 Loss 612089 1242873 
 6 Loss 3916351 13747697 
 11 Loss 58489068 60255277 
 16 Loss 70481632 71715541 
 16 Loss 83240089 83565853 
 X Gain 2704235 154913754 
 Y Gain 1 27210317 
SH28 1 Loss 80840633 106292342 
 2 Loss 25305182 46188107 
 2 Loss 234879284 242951149 
 6 Loss 4208047 4731185 
 6 Loss 71105393 95225698 
 6 Loss 107581642 108222986 
 6 Loss 158308746 170899992 
 7 Loss 125046702 126943092 
 7 Loss 149984933 158821424 
 8 Loss 19054085 42660136 
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 11 Loss 91239555 134452384 
 12 Loss 107314362 132349534 
 15 Loss 27254577 65790445 
 15 Loss 94192807 100338915 
 16 Loss 45543155 88827254 
 17 Loss 1127588 19264452 
 17 Loss 35312236 40210696 
 18 Loss 30324920 76117153 
 19 Loss 52131207 54366834 
 1 Gain 141503959 242805359 
 3 Gain 142762574 178887628 
 7 Gain 1 4240321 
 8 Gain 67970583 146274826 
 11 Gain 66244788 91239555 
 X Gain 1 38466517 
SH27 2 Loss 58935953 75177395 
 2 Loss 138574868 152327511 
 3 Loss 149122363 149285546 
 4 Loss 1 10256669 
 5 Loss 98133001 102910692 
 5 Loss 106601912 111339667 
 6 Loss 79383305 101683100 
 8 Loss 15266181 16144997 
 8 Loss 21539606 42957777 
 9 Loss 1 3859214 
 10 Loss 42217449 57253499 
 12 Loss 9374592 17574264 
 13 Loss 29777917 86557835 
 15 Loss 93174303 95268836 
 16 Loss 68673231 88827254 
 3 Gain 149285346 171253207 
 4 Gain 58828924 64425870 
 4 Gain 86202912 98274834 
 4 Gain 99839444 167742784 
 5 Gain 128868025 180857866 
 7 Gain 72968503 153309671 
 8 Gain 48934546 133049691 
 9 Gain 99772033 120694449 
 14 Gain 33594537 73756395 
 20 Gain 43321624 59925461 
SH14 2 Loss 123387013 163835519 
 3 Loss 111322412 116434641 
 3 Loss 145807785 146725450 
 3 Loss 164491188 168856298 
 5 Loss 97458387 132485205 
 5 Loss 162407625 166711700 
 6 Loss 74573549 129640970 
 11 Loss 22607321 51423435 
 13 Loss 52968024 55978955 
 X Loss 111804662 115091700 
SH18 1 Loss 1 63938873 
 1 Loss 102008434 102122510 
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 1 Loss 180998536 194471929 
 1 Loss 205161982 215099713 
 1 Loss 215651163 233888540 
 1 Loss 239327213 241728953 
 2 Loss 106769411 107236309 
 2 Loss 111360090 116148261 
 2 Loss 122671220 123131531 
 2 Loss 122671220 125097873 
 2 Loss 181743444 186019117 
 2 Loss 187145250 189343603 
 3 Loss 75869760 76266281 
 3 Loss 96552479 96659329 
 4 Loss 95783851 95834526 
 4 Loss 147523722 148619113 
 5 Loss 96328708 108422309 
 5 Loss 135600618 143134031 
 6 Loss 73024961 76120243 
 6 Loss 76732638 77326562 
 6 Loss 77524864 85773288 
 6 Loss 87219812 88198677 
 8 Loss 1 13817944 
 8 Loss 28998909 31579832 
 8 Loss 31814963 43943659 
 11 Loss 1 36792711 
 11 Loss 44141304 57526344 
 11 Loss 80858757 134452384 
 12 Loss 12285820 14553398 
 12 Loss 123330475 123666265 
 13 Loss 38398021 57632771 
 14 Loss 40703595 40774908 
 15 Loss 18272154 100338915 
 16 Loss 48166703 88827254 
 X Loss 137478358 146554647 
 X Loss 152238523 153471973 
 1 Gain 102122510 180998536 
 1 Gain 194471270 205161982 
 1 Gain 215099713 215651163 
 1 Gain 233888540 239327213 
 1 Gain 241738953 247249719 
 2 Gain 56165904 56735148 
 2 Gain 116912323 122671219 
 2 Gain 125097874 167237891 
 3 Gain 95460209 101405203 
 4 Gain 168604915 181408398 
 6 Gain 69482850 73024960 
 6 Gain 76120244 76732637 
 6 Gain 85773289 86572720 
 6 Gain 96705771 170899992 
 7 Gain 136121904 136537947 
 8 Gain 46962324 146274826 
 10 Gain 1 8182271 
 11 Gain 57526345 78364892 
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 13 Gain 29896459 38398020 
 13 Gain 57632772 58225955 
 14 Gain 74591694 106368585 
 22 Gain 14423580 49691432 
SH19 1 Loss 155189525 155339784 
 1 Loss 155824680 155984580 
 1 Loss 181117178 199085560 
 2 Loss 154875197 155082633 
 2 Loss 185376550 187020796 
 3 Loss 25055172 25486439 
 4 Loss 134021685 137113000 
 4 Loss 164633564 180657452 
 6 Loss 70436744 71034982 
 6 Loss 71819089 103842776 
 6 Loss 103870444 113583606 
 8 Loss 16896730 43874648 
 12 Loss 11558595 18178956 
 12 Loss 18280145 22457331 
 18 Loss 61060312 61251370 
 3 Gain 163992863 164109445 
 12 Gain 30839231 31062054 
 12 Gain 123288949 123666204 
 18 Gain 33037227 33359412 
 X Gain 152380311 153481094 
SH35 1 Loss 70002883 72854240 
 1 Loss 154567458 156170645 
 1 Loss 187058726 189000174 
 1 Loss 207177205 235099942 
 2 Loss 55337894 58270824 
 2 Loss 106123133 107665492 
 2 Loss 110507457 116475207 
 2 Loss 128238037 129343138 
 2 Loss 132920579 134089610 
 3 Loss 4112172 4429477 
 3 Loss 15935133 16453556 
 3 Loss 17725457 36357075 
 3 Loss 42957605 43754956 
 3 Loss 56166553 56217852 
 3 Loss 60213494 61090189 
 3 Loss 78679128 90585565 
 3 Loss 110536153 112435459 
 3 Loss 135851857 136650965 
 3 Loss 138934354 139313325 
 3 Loss 144726439 147558845 
 3 Loss 165316995 166052296 
 3 Loss 168586230 168836823 
 4 Loss 57364653 60814559 
 4 Loss 107303067 107790829 
 4 Loss 109438155 116482411 
 4 Loss 134117051 134776535 
 4 Loss 165393906 166353103 
 5 Loss 1 632358 
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 5 Loss 12597956 12785579 
 5 Loss 84119956 121216278 
 5 Loss 154821699 155492916 
 6 Loss 51992028 53744868 
 6 Loss 54603799 56713211 
 6 Loss 63897802 65062338 
 6 Loss 71551551 97772305 
 6 Loss 159933675 160343140 
 7 Loss 124884027 125703463 
 8 Loss 1502323 31632787 
 8 Loss 79806380 80425124 
 8 Loss 112486425 113231478 
 9 Loss 21948396 23757290 
 10 Loss 54553751 55628170 
 10 Loss 117183864 119014144 
 11 Loss 111208339 113212175 
 11 Loss 125745795 126806089 
 12 Loss 18004643 18255941 
 13 Loss 38393335 38472278 
 14 Loss 39482293 45877018 
 16 Loss 3714874 4513116 
 17 Loss 21364935 22209011 
 18 Loss 10417826 11690349 
 X Loss 26816041 26882640 
 X Loss 37213584 38068710 
 X Loss 44722362 45809932 
 5 Gain 639723 1467474 
 5 Gain 59666152 60365781 
SH29 NA    
SH30 4 Loss 117041642 127668219 
 4 Loss 140055679 140557884 
 8 Loss 1 43944056 
 13 Loss 31937048 85778429 
 8 Gain 46980076 146274826 
SH31 NA    
SH25 2 Loss 133615010 133649829 
 2 Loss 137822119 142859206 
 2 Loss 145733198 146969451 
 4 Loss 93647992 95383153 
 4 Loss 114227636 116456479 
 4 Loss 127095277 127398888 
 5 Loss 97447911 101868377 
 5 Loss 102691889 105393922 
 5 Loss 110092446 110432105 
 5 Loss 151910630 152271119 
 6 Loss 83054180 98577492 
 6 Loss 113659241 125019455 
 8 Loss 1 43944034 
 9 Loss 70248787 70839820 
 9 Loss 103636022 103737914 
 11 Loss 104510323 109469435 
 12 Loss 36143458 41651675 
 271 
 12 Loss 81038492 81263046 
 12 Loss 82795547 82984970 
 12 Loss 86015298 86695012 
 12 Loss 129390414 132349534 
 13 Loss 36371422 76001483 
 13 Loss 76909402 77623433 
 16 Loss 68007504 88827254 
 X Loss 1978976 2717200 
 Y Loss 2675195 3991630 
 7 Gain 1 158821424 
 8 Gain 46966435 112277700 
 8 Gain 112312127 146274826 
 11 Gain 65014982 104510322 
 11 Gain 109469436 134452384 
SH36 1 Loss 90845605 104178552 
 3 Loss 67240765 73211774 
 6 Loss 82936137 119479947 
 8 Loss 1 40197065 
 13 Loss 24484478 25889628 
 13 Loss 69086852 75289546 
 14 Loss 28661537 29131923 
 15 Loss 40235628 41632887 
 15 Loss 66647586 76661602 
 16 Loss 51480249 88827254 
 17 Loss 6701317 7942642 
 17 Loss 62875191 69810126 
 18 Loss 1 76117153 
 21 Loss 13372194 13874821 
 21 Loss 22937891 23588350 
 21 Loss 38790931 38978331 
 21 Loss 40761832 41000858 
 13 Gain 24354286 24484477 
 16 Gain 1 51480248 
SH21 1 Gain 144451120 148909761 
 1 Gain 193328508 196241674 
 1 Gain 215593949 219457641 
 1 Gain 241410738 247249719 
 3 Gain 37297279 42845063 
 3 Gain 125770914 130443094 
 3 Gain 167344572 173308502 
 4 Gain 72470911 74488709 
 4 Gain 160984438 162453375 
 5 Gain 103158074 105678420 
 6 Gain 50118868 52045175 
 7 Gain 29307647 33348353 
 7 Gain 94790923 97845434 
 7 Gain 134225698 139385377 
 8 Gain 82897165 86641906 
 10 Gain 52081139 55060776 
 10 Gain 104447980 110344744 
 11 Gain 24319027 29045348 
 11 Gain 40674784 44587415 
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 12 Gain 111695702 120345537 
 14 Gain 34998566 37262267 
 14 Gain 78143169 80791349 
 15 Gain 50639905 52559413 
 16 Gain 69378660 69766320 
 18 Gain 6404717 7194521 
 18 Gain 58889508 62572215 
 21 Gain 15189353 19419028 
 21 Gain 22953424 26880777 
 X Gain 133164251 137376323 
 Y Gain 19678965 20027660 
 8 Loss 1 15317220 
SH24 3 Loss 165240030 166357454 
 4 Loss 127849791 128290879 
 4 Loss 130912115 133949786 
 5 Loss 86812347 90169890 
 6 Loss 82431319 82471709 
 6 Loss 85833862 116207073 
 6 Loss 122103342 122434866 
 6 Loss 123159810 123313112 
 6 Loss 130543009 131281689 
 6 Loss 132593745 135415977 
 8 Loss 1 43943522 
 11 Loss 105849067 131809644 
 11 Loss 132124856 133619846 
 13 Loss 36417342 85342820 
 8 Gain 46966327 146274826 
SH33 2 Loss 138888864 145249539 
 3 Loss 22110155 28563404 
 3 Loss 88855293 90586522 
 4 Loss 147034886 148057348 
 6 Loss 86584697 106624901 
 8 Loss 1 24976605 
 8 Loss 36760180 42380679 
 8 Loss 95757586 96943917 
 8 Loss 104553523 105461390 
 13 Loss 43956629 80399983 
 16 Loss 21270457 22958797 
 16 Loss 25214997 28397421 
 16 Loss 88629090 88827254 
 17 Loss 37227281 42150204 
 18 Loss 15168480 64879440 
SH20 2 Loss 115224599 132605258 
 6 Loss 72870915 128026677 
 7 Loss 84970181 87301435 
 13 Loss 38452642 56888371 
 13 Loss 63297219 64472742 
 13 Loss 67836237 69548370 
 18 Loss 43640371 43717650 
 22 Loss 20832142 20835250 
 X Loss 33809110 34263540 
 X Gain 152234969 153563815 
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SH16 1 Loss 73837896 75289501 
 1 Loss 86815311 88023665 
 1 Loss 102077543 102292433 
 2 Loss 122242851 144907019 
 3 Loss 88184163 90586131 
 3 Loss 114818098 121467007 
 3 Loss 162614223 163838573 
 4 Loss 120440539 130715102 
 4 Loss 160658158 160780914 
 4 Loss 163097506 163247999 
 5 Loss 2074318 2119192 
 5 Loss 43208969 44092901 
 5 Loss 88896544 88923364 
 5 Loss 91049541 91803190 
 5 Loss 97161916 99853388 
 5 Loss 108967993 110753406 
 5 Loss 128600780 128852150 
 5 Loss 152920419 153346427 
 5 Loss 161962702 164441313 
 6 Loss 65401167 99380722 
 7 Loss 14504169 17636091 
 7 Loss 78353613 80692233 
 7 Loss 81765081 83775805 
 7 Loss 85933740 85953539 
 7 Loss 113649757 113810633 
 7 Loss 115557745 115624082 
 8 Loss 1 43944241 
 8 Loss 84669258 85826285 
 8 Loss 110386665 110613490 
 8 Loss 111004695 112037043 
 11 Loss 50020206 59926975 
 11 Loss 89908198 89949976 
 11 Loss 90686335 90811383 
 11 Loss 102837815 134452384 
 13 Loss 20917095 22788932 
 13 Loss 36071841 75250138 
 16 Loss 59739937 64115819 
 3 Gain 95001525 114727097 
 3 Gain 121467008 162614222 
 3 Gain 163951308 199501827 
 8 Gain 59611133 84669257 
 8 Gain 85826286 110386664 
 8 Gain 110613491 110004694 
 8 Gain 112037044 114912043 
 8 Gain 123383022 146274826 
 9 Gain 70127077 140273252 
 11 Gain 1 50020205 
 11 Gain 59926976 89908197 
 11 Gain 89949977 90686334 
 11 Gain 92501531 98332585 
 X Gain 1 154913754 
SH37 1 Loss 165735622 165823543 
 274 
 2 Loss 10323063 23804009 
 2 Loss 220841638 242951149 
 3 Loss 180602618 199501827 
 4 Loss 137415548 138370295 
 4 Loss 162611643 162725548 
 4 Loss 165023543 166774509 
 4 Loss 168386699 168633383 
 4 Loss 169930022 175162165 
 4 Loss 178109770 179978935 
 5 Loss 44943306 45971729 
 5 Loss 50072653 51513985 
 5 Loss 82800754 91279328 
 5 Loss 98081995 98209091 
 5 Loss 100221605 103326566 
 5 Loss 105959930 107846001 
 5 Loss 112386669 112886362 
 5 Loss 116373957 116637057 
 6 Loss 62372617 66452945 
 6 Loss 71579296 75025380 
 6 Loss 90881437 91538386 
 6 Loss 92699514 92863302 
 6 Loss 93889745 98031290 
 7 Loss 120438073 127749638 
 8 Loss 1 40919614 
 10 Loss 49017366 53961043 
 10 Loss 83341214 92381000 
 11 Loss 101843219 132385505 
 13 Loss 28105067 82560760 
 14 Loss 57284907 98099161 
 15 Loss 18275409 100338915 
 16 Loss 56214953 88827254 
 1 Gain 148089578 164051254 
 1 Gain 165823544 247249719 
 3 Gain 121864637 176731645 
 7 Gain 17163916 35356387 
 8 Gain 40919615 146274826 
 9 Gain 87428200 140273252 
 12 Gain 15103732 130751195 
 18 Gain 1 76117153 
SH40 1 Loss 59015383 60009332 
 1 Loss 120116687 120488836 
 2 Loss 216503517 217182763 
 3 Loss 52997923 53014626 
 4 Loss 90353375 95559228 
 6 Loss 76060313 116734707 
 8 Loss 5305188 5682392 
 8 Loss 5953084 34083490 
 8 Loss 39113855 39349896 
 8 Loss 39506749 41695292 
 8 Loss 42871380 43900809 
 8 Loss 47868094 55124307 
 8 Loss 78226882 79442567 
 275 
 8 Loss 82045319 82776232 
 8 Loss 85734859 88540449 
 10 Loss 88890528 96672636 
 12 Loss 6492416 14825775 
 13 Loss 68751099 70036146 
 13 Loss 72114422 73372814 
 13 Loss 102203678 106146387 
 15 Loss 19107169 20231015 
 15 Loss 28178722 28726687 
 15 Loss 30237820 30654807 
 15 Loss 41632039 41814267 
 15 Loss 74661227 74689283 
 17 Loss 53288172 55312000 
 19 Loss 48978867 48484167 
 Y Loss 23058086 23950736 
 Y Loss 23987246 26781957 
 1 Gain 16733113 17155775 
 3 Gain 116282410 199501827 
 8 Gain 5682393 5953083 
 9 Gain 43017181 44806502 
 14 Gain 35976663 36252069 
 14 Gain 105596895 106063498 
 16 Gain 21242798 21887051 
 16 Gain 22338277 22632596 
 16 Gain 32014590 33013707 
 19 Gain 40541099 40562250 
SH39 2 Loss 118222257 140607069 
 2 Loss 163497581 165504232 
 3 Loss 82919186 90587056 
 5 Loss 98239792 101380804 
 6 Loss 72572974 95977149 
 7 Loss 49405506 49789066 
 8 Loss 1 33845833 
 8 Loss 34522283 43834346 
 12 Loss 7724915 9173998 
 12 Loss 12656908 14841606 
 12 Loss 15819941 18464901 
 13 Loss 71086502 100138936 
 14 Loss 18535839 19528394 
 15 Loss 22120088 22337055 
 16 Loss 33078912 33537386 
 19 Loss 48061502 48232155 
 X Loss 78097299 78389721 
 X Loss 98869014 99273280 
 7 Gain 1 49405505 
 7 Gain 49789067 158821424 
 8 Gain 33845834 34522282 
 8 Gain 47044155 133689181 
SH5 1 Loss 74078385 96454714 
 1 Loss 146348245 147801020 
 2 Loss 75779457 161903093 
 2 Loss 219235404 242951149 
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 3 Loss 80567164 81425109 
 3 Loss 143500040 144702060 
 3 Loss 145049738 147021233 
 4 Loss 18174268 19335900 
 4 Loss 35175253 44465087 
 4 Loss 46460819 47544050 
 4 Loss 116579994 116911354 
 4 Loss 123835779 124203060 
 4 Loss 126661202 128452081 
 4 Loss 136353719 137318880 
 4 Loss 179302148 182364678 
 5 Loss 63356790 105777814 
 6 Loss 80627671 122436179 
 7 Loss 55893940 57669465 
 8 Loss 133945111 134648458 
 8 Loss 135094736 135894794 
 9 Loss 9813750 16740414 
 10 Loss 119106948 120128904 
 11 Loss 37744602 49280945 
 12 Loss 8949624 15593601 
 12 Loss 21342489 21755733 
 13 Loss 39523462 58835914 
 13 Loss 63081067 63130502 
 13 Loss 65269318 67883902 
 13 Loss 78611863 79947252 
 13 Loss 81508690 87387389 
 16 Loss 61947665 88827254 
 22 Loss 23992589 24253443 
 X Loss 86014294 86448378 
 X Loss 89228899 90024146 
 X Loss 91402725 93762640 
 15 Gain 19536630 20333925 
SH23 1 Loss 101302130 140188384 
 1 Loss 147216782 147692739 
 1 Loss 226896323 239097277 
 2 Loss 106158042 117616023 
 2 Loss 126443301 152744398 
 2 Loss 184330111 187580923 
 3 Loss 162504686 164859081 
 4 Loss 129881778 137553512 
 4 Loss 167559313 191273063 
 5 Loss 83259758 86075507 
 5 Loss 98302525 99822049 
 5 Loss 101657603 109169160 
 6 Loss 68486816 125102672 
 7 Loss 9762263 9874896 
 7 Loss 64195651 64693275 
 8 Loss 18007213 36606352 
 11 Loss 30130741 31471802 
 11 Loss 37829528 40854467 
 12 Loss 1 16000196 
 12 Loss 37695372 39273394 
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 13 Loss 38482228 83013292 
 14 Loss 82735271 83248843 
 16 Loss 57805103 88827254 
 17 Loss 41711730 42140592 
 X Loss 143454117 144672353 
 Y Loss 23036368 27214383 
 15 Gain 18397182 20312838 
SH22 6 Loss 82222624 99215397 
 8 Loss 9745650 11923293 
 8 Loss 15011958 17848793 
 18 Loss 59480256 60545151 
 7 Gain 1 158821424 
 19 Gain 20383570 20519847 
SH32 1 Loss 231650561 233125963 
 3 Loss 69517002 74025590 
 3 Loss 125443029 127597681 
 5 Loss 125918852 126681739 
 6 Loss 1 170899992 
 8 Loss 41946842 42912460 
 9 Loss 125629848 126335694 
 10 Loss 101926106 104369082 
 11 Loss 62372500 63380966 
 11 Loss 114280666 114910220 
 11 Loss 129606253 131043251 
 12 Loss 1 68291588 
 13 Loss 17924099 114142980 
 16 Loss 45018224 88827254 
 17 Loss 5036918 9761734 
 17 Loss 12140016 12517751 
 21 Loss 38802482 41790486 
 5 Gain 120504492 121008430 
 7 Gain 109532260 110058779 
 8 Gain 6923162 7973960 
 15 Gain 18430900 20304419 
 Y Gain 23374703 26878013 
SH13 1 Loss 1 86639715 
 2 Loss 1 242951149 
 5 Loss 51170745 118599746 
 7 Loss 32533595 33578595 
 10 Loss 1 135374737 
 12 Loss 9822344 18068873 
 12 Loss 18450521 28602045 
 13 Loss 17922748 114142980 
 15 Loss 18274530 100338915 
 16 Loss 51153259 88827254 
 17 Loss 1 69966253 
 18 Loss 1 76117153 
 21 Loss 22475880 24649601 
 Y Loss 2673164 27210364 
 1 Gain 119383041 247249719 
 3 Gain 1 141880249 
 3 Gain 163581790 168039021 
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 7 Gain 51392888 158821424 
 8 Gain 7013219 7868764 
 8 Gain 41238447 146274826 
 9 Gain 28731267 140273252 
 12 Gain 18068874 18450520 
 12 Gain 31054059 33271310 
 16 Gain 45020314 51153259 
 17 Gain 69966254 78774742 
 19 Gain 3811886 4918346 
 21 Gain 24649602 26056823 
 X Gain 2715928 154913754 
SH3 6 Loss 62382884 127696200 
 13 Loss 34434765 95463766 
 8 Gain 39904943 146274826 
SH26 3 Loss 67037946 67792959 
 3 Loss 70650812 71037987 
 3 Loss 71766262 73059329 
 6 Loss 52365384 53142921 
 6 Loss 55034433 57473326 
 14 Loss 57647500 68670795 
 3 Gain 73922241 199501827 
 6 Gain 1 52365383 
 6 Gain 53142922 55034432 
 11 Gain 1 134452384 
SH7 1 Loss 99400289 100124233 
 1 Loss 100336236 102970722 
 1 Loss 161714940 165556951 
 2 Loss 117163309 146427468 
 2 Loss 147982274 161333134 
 2 Loss 163489648 164905188 
 5 Loss 87458797 97119841 
 5 Loss 98094836 99730072 
 5 Loss 101869556 103247314 
 5 Loss 110805161 112078702 
 6 Loss 64383604 103570569 
 7 Loss 83283556 84951896 
 9 Loss 13299391 19376728 
 11 Loss 31782217 50313883 
 12 Loss 75803585 81970119 
 13 Loss 39376348 66089286 
 16 Loss 47427139 61598454 
 X Loss 7467872 7625760 
 Y Loss 2673106 27211134 
 7 Gain 1 83283556 
 7 Gain 84951896 117899435 
 7 Gain 127012432 158821424 
 9 Gain 33611364 140273252 
 16 Gain 1 32779440 
 19 Gain 20384137 20573206 
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